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Abstract 
Amal Abdallah Mahammad Elsharif 
Title: Functional investigation of dual αvβ3 and αllbβ3 integrin inhibition in 
haematological and solid tumour models.    
Keywords: RGD binding integrins, K562, adhesion, metastasis, integrin 
antagonists. 
Invasion and metastasis of cancer is the leading cause of increased 
mortality. In addition, haematological malignancies (leukaemia and 
lymphoma) are a significant cause of morbidity and mortality in both 
children and adults. Therefore, new treatments which will inhibit cancer 
progression are required. Integrin adhesion receptors, particularly the RGD-
binding integrin subfamily comprising αvβ3, αvβ5, αvβ6, αvβ8, αllbβ3, α5β1, 
α8β1 and αvβ1 are related to progress and spread of cancer and poor 
prognosis. Because of the importance of integrin biology in the regulation of 
cancer dissemination, the integrin receptors are being utilised as targets to 
regulate cancer progression. The goal of this study was to develop a dual 
αvβ3/ αIIbβ3 expressing model for testing integrin antagonists. Expression 
of αv, αIIb, and β3 integrin subunits was characterised using 
immunofluorescence and flow cytometry in a panel of cell lines.  After 
characterising the expression of αv, αIIb and β3 integrin subunits in 
inducible and natural expression models (K562 and MCF-7 cells 
respectively), functional tests for cellular adhesion, detachment and 
migration were determined. Phorbol 12-myristate 13-acetate (PMA)-treated 
K562 cells showed increased adhesion on fibrinogen compared to 
untreated cells. Adhesion of cancer cells (K562 ± PMA and MCF-7) to 
  
ii 
 
fibrinogen was inhibited and detachment was induced by the known β3 
antagonists, cRGDfV and GR104453. 
Migration of cancer cells (K562 without PMA and MCF-7) was inhibited by 
combination of the known β3 antagonists. A panel of 12 novel small 
molecules developed in the ICT was investigated for cytotoxicity and activity 
in the validated function assays. ICT9055 was the most potent antagonist in 
inhibition of cell adhesion, migration, and inducing cell detachment. The 
data presented in this thesis had selected models and assays for evaluating 
small molecule integrin antagonists and identified ICT9055 as a promising 
molecule to develop for further preclinical evaluation. 
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Chapter 1: Introduction 
 
 
1.1 Metastasis 
 
Cancer metastasis is the transition of tumour cells from a primary host site to 
another site. This transition is comparatively common, either as polyclonal 
metastasis or as monoclonal metastasis (Gundem et al., 2015). The invasion of 
tumour and progress to metastasis are the signatures of malignancy that lead to 
the death of most cancer patients (Hanahan and Weinberg, 2011). As will be 
discussed below, the metastases produced by carcinomas are the result of a 
complex process of cellular biological events collectively called the invasion-
metastasis cascade (Figure 1) (Huang et al., 2011; Valastyan and Weinberg, 
2011).  
1.1.1 Events of the invasion–metastasis cascade 
 
Typically, the metastatic cascade involves tumour growth, lymphangiogenesis 
and angiogenesis, entrance of malignant cells into the circulation by 
intravasation, anchorage and/or attachment in the target organ, and infestation 
of the target organ by proliferation and extravasation within the parenchyma of 
the organ (Valastyan and Weinberg, 2011). These multiple steps depend on the 
loss of cell adhesion, which leads to the detachment of the cell from the primary 
tumour, and consequently the capability of the cell to achieve a motile 
phenotype by changes in cell interactions with extracellular matrix (Martin et al., 
2013), and re-adhesion at the target site. Some cancer cells are able to form 
specific adhesive interactions in certain tissues that favour their trapping. For 
instance, the expression of αv integrin in circulating tumour cells causes 
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adherence within the hepatic micro-vessels. In contrast, migration of attached 
cells into the parenchyma of liver is not influenced by inhibiting αv-integrin. 
These data support the hypothesis that particular interactions between host 
organs and circulating tumour cells are required for the arrest of organ-specific 
tumour cells (Enns et al., 2005). Since cell-cell interactions enabling adhesion of 
tumour cells in the vasculature of specific organs are crucial stages in the 
metastatic cascade, blocking of these interactions represents a potentially 
valuable target for reduction of metastasis (Bendas and Borsig, 2012; Witz, 
2008). 
 
Moreover, the ubiquitous existence of integrins on tumour cells, stromal cells, 
vasculature, and blood components suggest that integrins may be involved in 
many steps of the metastatic cascade. As most human tumours originate from 
epithelial cells, integrins expressed on epithelial cells are normally present also 
in tumour cells (Bendas and Borsig, 2012).  
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Figure 1: The invasion–metastasis cascade. 
Tumour cells leave their primary sites of growth, intravasate (following local invasion), need to 
survive in the circulation, arrest at a distant organ site, extravasate (translocate systemically), and 
adapt to survive in distant tissues (micro-metastasis formation, metastatic colonisation). Adapted 
from (Valastyan and Weinberg, 2011).           
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1.1.1.1 Invasion from the primary tumour site (local invasion) 
  
Carcinoma cells need first to penetrate the basement membrane in order to 
invade the stroma (Bissell and Hines, 2011).  Invasion involve the secretion of 
proteolytic enzymes to damage  the extracellular matrix and the basement 
membrane and the suppression/expression of proteins participating in the 
control of cell movement and migration (Brooks, 1996). Additionally, the 
basement membrane also participates in transducing signal events into 
carcinoma cells through pathways originated by integrin-mediated cell-matrix 
adhesions which are the interaction of a cell with the extracellular matrix, 
resulting in changes in proliferation, cell polarity, survival, and invasiveness 
(Bissell and Hines, 2011). Most types of carcinomas have the ability to invade 
as coherent multicellular units at a cellular level by a process of collective 
invasion. Individual tumour cells can invade through two distinctive processes: 
the protease, stress-fibre, and integrin-independent, Rho-associated protein 
kinase (ROCK) dependent “amoeboid invasion” programme; or the protease, 
stress-fibre, and integrin-dependent “mesenchymal invasion” programme 
(Ganguly et al., 2013). Indeed, distinctive expression of molecules that allow 
either amoeboid or mesenchymal invasion can be shown in signs of local 
invasion obtained from mammary cancer models (Wang et al., 2004). Tumour 
cells are able to switch between these different invasion strategies in response 
to changes in microenvironmental conditions. This has led to the suggestion 
that strong suppression of single cell invasion needs associated inhibition of the 
amoeboid and mesenchymal invasion programmes (Friedl and Wolf, 2003). 
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1.1.1.2 Intravasation 
 
To intravasate, invading carcinoma cells must first enter into lymphatic or blood 
vessels derived from the tumour neovasculature or located next to the tumour 
(Reymond et al., 2013). Whereas lymphatic spread of cancer cells is usually 
investigated in human tumours and represents a significant prognostic marker 
for cancer progression, spread through the haematogenous circulation 
represents the main mechanism by which metastatic cancer cells disseminate 
(Gupta and Massague, 2006). Intravasation is facilitated by molecular 
alterations that enhance the ability of cancer cells to pass barriers of endothelial 
cell that form the micro-vessels walls (Sonoshita et al., 2011). The mechanisms 
of intravasation are likely to be strongly impacted by the structural 
characteristics of tumour associated blood vessels through the mechanisms 
shown in Figure 2, many of which converge on the actions of vascular 
endothelial growth factor (VEGF). Cancer cells develop and form new blood 
vessels in their local microenvironment by the process of neoangiogenesis 
(Carmeliet and Jain, 2011).  
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Figure 2: Mechanisms of tumour angiogenesis. 
Angiogenic factors such as VEGF, vascular endothelial growth factor; PDGF, platelet-derived 
growth factor and FGF, fibroblast growth factor are secreted from the tumour and surrounding 
cells to regulate and enhance main stages in angiogenesis. Endostatin directly interacts with 
VEGFR-2 to inhibit VEGF and bFGF, binding, and inhibits integrin function and MMP-2 activity in 
endothelial cells. Angiopoietin (Ang-1) and Ang-2, angiostatin and platelets factor 4 are also 
involved. Adapted from (Zhao and Adjei, 2015).  
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1.1.1.3  Cancer cells in the circulation 
 
After cancer cells have intravasated into the blood vessels, they can spread via 
the arterial and venous systems. Recent diagnostic tools for circulating tumour 
cells such as the herringbone-chip and microfluidic mixing device have 
facilitated detection and characterisation of circulating tumour cells in the 
bloodstream of cancer patients (Stott et al., 2010). Circulating tumour cells 
apparently represent cancer cells that are en route between primary cancer 
cells and dissemination sites and consequently might represent “metastatic 
intermediates”. In order to reach distant organ sites, circulating tumour cells in 
the bloodstream must survive a variation of stresses. For instance, they must be 
able to survive loss of the integrin-dependent adhesion to the ECM that is 
typically important for cell survival; epithelial cells normally undergo  
programmed cell death in the absence of such anchorage (Guo and Giancotti, 
2004). 
In addition to stresses forced by matrix separation, tumour cells in the 
bloodstream must survive hemodynamic shear forces, and evade cells of the 
innate immune system, particularly NK cells (natural killer cells). Cancer cells 
appear to evade both of these threats via exploiting a mechanism of normal 
blood coagulation (Joyce and Pollard, 2009); triggering platelet aggregation to 
form a tumour cell-platelet complex. Consequently, platelet-coated tumour cells 
have more ability to continue in the circulation until they arrest at distant sites, 
an event whose probability may be further increased because of the larger 
effective diameter of these micro-emboli (Valastyan and Weinberg, 2011). 
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1.1.1.4 Extravasation 
 
Cancer cells in the blood stream may begin growth and form a microcolony 
that ultimately breaches the walls of surrounding vessels and extravasates into 
the tissue parenchyma (Al-Mehdi et al., 2000). Otherwise, tumour cells may 
pass from the lumina of vessels into the tissue parenchyma by crossing 
pericyte layers and the endothelial cells that separate the lumina of vessels 
from the stromal microenvironment (Wyckoff et al., 2007). 
Primary tumours are able to secrete factors that disrupt these 
microenvironments and enhance vascular hyperpermeability in order to 
conquer physical barriers to extravasation that work in tissues with low 
microvascular permeability (Padua et al., 2008). For instance, the secreted 
protein angiopoietin-like-4, in addition to the pleiotropically acting factors such 
as EREG, COX-2, MMP-1, and MMP-2, perturb pulmonary vascular 
endothelial cells junctions in order to promote the extravasation of breast 
cancer cells in the lungs (Gupta et al., 2007). In addition, MMP-3, MMP-10, 
angiopoietin-2, VEGF and placental growth factor secreted by different types 
of primary tumours are able to induce pulmonary hyperpermeability prior to the 
arrival of cancer cells in the lungs, thereby facilitating the subsequent 
extravasation of cancer cells in the bloodstream (Hiratsuka et al., 2011; Huang 
et al., 2009; Weis et al., 2004). Lastly, inflammation monocytes recruited to 
pulmonary metastases by CCL2-dependent mechanisms induce the 
extravasation of breast cancer cells in the lungs by releasing VEGF (Qian et 
al., 2011). 
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1.1.1.5 Micro-metastasis formation 
 
Extravasated cancer cells need to survive in the foreign microenvironment that 
they encounter in distant tissues. The micro-environment of the metastatic site 
typically varies significantly from that in the existing site of primary tumour 
formation. These micro-environmental variations may include the ECM 
components, stromal cells, cytokines and growth factors, in addition to 
hematopoietic progenitor cells that adapt to the local microenvironments by 
producing MMP-9.  Activation of MMP-9 at the new locus of metastasis may 
lead to stimulation of many integrins, as well as the release of molecules  such 
as the chemoattractant stromal cell-derived factor-1 (SDF-1), that have been 
isolated in the ECM (Psaila and Lyden, 2009). Significantly, it is believed that all 
of these events occur prior to tumour cells arriving in metastatic sites. In order 
to survive in these foreign locations and produce small micro-metastases, it has 
become clear that tumour cells organise complex mechanisms to adapt distant 
microenvironments (Zhang et al., 2009). 
 
1.1.1.6 Metastatic colonisation 
 
Most of the disseminated tumour cells persist as micro-colonies over periods of 
weeks or months. The metastatic tumour cells could proliferate continually. Due 
to the counterbalancing effects of a high apoptotic rate, a net increase in their 
overall number may not occur, however. The underlying mechanisms of high 
tumour cell attrition rate remain unclear.  A failure of the spreading tumour cells 
to trigger formation of new blood vessels is suggested as one explanation for 
this phenomenon, however (Chambers et al., 2002).  
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Furthermore, the capacity of spreading tumour cells to escape and to start 
effective proliferation may rely on cell non-autonomous mechanisms which are 
required to switch foreign microenvironments into most hospitable niches. For 
instance, the outgrowth of tumour cells may rely on the activation and 
mobilisation into the bone marrow-derived cell circulation and the sequential 
recruitment of these cells to a metastatic site. In some conditions, these 
processes might be activated by systemic signals secreted by cancer cells, 
such as SDF-1 (Hiratsuka et al., 2011; McAllister et al., 2008). 
Investigating blood samples of cancer patients has shown the number of cancer 
cells (circulating tumour cells) far exceeds the number of overt metastatic 
lesions that develop. Tumour cells that survive after infiltrating certain organs, 
known as disseminated tumour cells, can be found in the bone marrow of 
tumour patients for a long time and yet only almost half of these patients 
progress overt metastasis. These clinical observation indicate that metastatic 
colonisation is a very ineffective process in which the majority of cells die and 
only small numbers survive and form macro-metastases (Massague and 
Obenauf, 2016). 
Findings using experimental mouse models are in agreement with clinical data. 
For instance, intravenous injection of cancer cells in mouse models leads to the 
death of the majority of cells within two days after they are filtered by the lungs 
(Wong et al., 2001), also happens when arterially injected cancer cells  reach 
the liver and brain (Minn et al., 2005).  
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1.2 Basic processes of leukaemia  
 
Leukaemia is an uncontrolled proliferation of white blood cells leading to 
increased numbers in the bone marrow and blood. Leukaemias are categorised 
as acute or chronic, and on cell type, such as myelogenous or lymphocytic. The 
key classes of leukaemia are acute myeloid leukaemia (AML), chronic myeloid 
leukaemia (CML), acute lymphoblastic leukaemia (ALL), and chronic 
lymphocytic leukaemia (CLL) (Ball and Kagan, 2007).   
The process of leukaemia transformation is based not only on increased 
proliferation but also, at least to some extent, on decreased apoptosis. 
Dysregulation of the processes controlling programmed cell death lead to 
prolong the life span of cells, leading to spread of leukaemia cells (Schnerch et 
al., 2012). 
Moreover, the formation of new blood vessels and angiogenic factors are 
involved in the dissemination of some leukaemias. Increased vascularity has 
been reported in paediatric ALL (Perez-Atayde et al., 1997), AML (Hussong et 
al., 2000) and myelodysplastic syndrome (MDS). VEGF expression is a 
prognostic factor in AML (Aguayo et al., 1999). This suggests that  angiogenic 
factors might have a direct impact on vascularity of bone marrow as well as on 
leukaemia cells (Aguayo et al., 2000).  
Spreading in ALL involves migration of leukaemia cells within the bone marrow 
microenvironment and into the peripheral circulation. This migration is promoted 
at least partly because of VEGF/placental-derived growth factor (PDGF) 
stimulation of leukaemia cells within the bone marrow (Fragoso et al., 2006).  
Also, PLGF or VEGF stimulation of AML cell lines leads to an increase in cell 
migration over non-stimulated cells (Casalou et al., 2007). The 
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microenvironment through stromal cells, growth factors, and cytokines providing 
a permissive environment is also involved in initiation of leukaemia, 
development and metastasis, whereas leukaemia cells impact on stromal cells 
through secreted factors and cell–cell interactions (Ayala et al., 2009). The 
stromal cells also regulate migration and leukaemia blast cell (immature white 
blood cells) growth. The influence of stromal cells on leukaemia blasts, differing 
to the other, seems to be recapping normal physiological cell to cell adhesion 
through adhesive receptors such as integrins in normal hematopoietic 
progenitors. Stromal ligands such as fibronectin interact with leukaemic blast 
integrins (Bendall et al., 1994; Bradstock and Gottlieb, 1995) and the adhesive 
interaction is required for leukaemic blast proliferation and survival. In 
leukaemic blasts and stromal cells, reciprocal activation of ILK/Akt pathway 
seems to be important for this adhesion-driven AML blast survival (Ayala et al., 
2009).  
Leukaemia cells have an inherent mobility to move throughout the circulation, 
suggesting that no mutations are necessary for anchorage independent growth. 
Trendowski argues that leukaemia is inherently metastatic, endowed with the 
deadly phenotype of malignant cells simply because of their cell of origin.  If 
leukaemia cells were inherently metastatic, they should have distinctive 
migratory patterns as found in other cancers. For example, in several tumour 
conditions, it seems that leukaemia cells behave similarly to cancers arising 
from other tissues such as the skin, breast, and  other muscles (Trendowski, 
2015).  
Blocking the interactions of stromal cells or stroma-derived growth factors with 
leukaemic cells represent some of the main processes that should be targeted 
as a promising strategy to treat leukaemia.  Inhibition of proangiogenic 
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pathways and developed of integrin inhibitors are among the most interesting 
areas for  cancer therapy (Aguayo et al., 2000). 
 
1.3 Integrins   
 
Integrins are family I transmembrane heterodimeric glycoprotein receptors that 
are present in organisms ranging from echinoderms to corals, sponges, 
nematodes and mammals. They serve as the major metazoan receptors for cell 
adhesion and are associated with the extracellular and intracellular 
environments (Zent, 2010). Integrins mediate cell to cell, cell to ECM, and cell to 
pathogen interactions. They transfer bidirectional signals across the plasma 
membrane and regulate multiple biological functions, including cell 
differentiation, cell migration and wound healing (Luo and Springer, 2006). A 
characteristic of integrins is the individual family members’ ability to bind 
multiple ligands. The major extracellular ligands of integrins include a large 
number of ECM proteins such as bone matrix proteins, fibronectins, collagens, 
fibrinogen, thrombospondins, laminins, von Willebrand factor (VWF) and 
vitronectin, reflecting the primary role of integrins in the adhesion of cells to 
extracellular matrices (Plow et al., 2000). 
Structurally, integrins are non-covalent heterodimers containing an α and a β 
glycoprotein subunit (Figure 3) (Arnaout et al., 2005; Hynes, 2002b; Sheldrake 
and Patterson, 2009).  There are 8 β and 18 α subunits which combine to form 
24 human αβ integrin dimers (Figure 4) (Chen et al., 2012; Humphries, 2000; 
Hynes, 1992; Sheldrake and Patterson, 2009). Both subunits comprise a single 
transmembrane domain, short intracellular domains (except for β4 with long 
cytoplasmic domain) and a multi-domain extracellular portion (large extracellular 
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domain) (Humphries, 2000; Shimaoka et al., 2002).  Each α and β integrin 
subunit has a large N-terminal globular domain (Liddington, 2014).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Basic integrin structure 
Each integrin has one α chain and one β chain spanning the membrane into both the extracellular 
space and intracellular space, where a short cytosolic domain binds the cytoskeleton through 
effector proteins. Both α and β integrin subunits contribute to the distinct ligand-binding site which 
recognises the extracellular matrix. 
  
  
15 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: The integrin family of matrix receptors that form 24 human αβ integrin dimers. 
The integrin family can be considered in several subfamilies including RGD binding integrins (red) 
which recognise the tripeptide sequences arginine-glycine-aspartate existing in several ECM 
proteins, the collagen receptors (dark blue), laminin binding integrins (light blue) and leukocyte- 
integrins (green). Some integrin subunits have an inserted I-domain (underline) (Sheldrake and 
Patterson, 2014). 
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These integrins are divided into subfamilies (Figure 4) dependent on the identity 
of subunits and bound ligands. The 24 recognised integrin heterodimers are 
characterised as arginine–glycine–aspartate acid binding (RGD), leukocyte 
adhesion integrins, collagen-binding and laminin-binding integrins (Goodman 
and Picard, 2012).  
The RGD-recognising integrins consist of 8 types (Table 1), which recognise the 
common sequence of RGD tripeptide at a binding site formed at the α and β 
subunit headpiece junction (Plow et al., 2000). This family of 8 integrins 
includes two β1 integrins (α5, α8), αIIbβ3 and five αv integrins (Humphries et 
al., 2006). Specifically the αv subunit pairs with β1, 3, 5, 6, and 8. The β3 
integrin subunit is able to associate with not only αv but also the αIIb subunit 
(CD41) (Wilder, 2002). While some integrin pairs preferentially bind a single 
ligand, others recognise a number of ligands; for example, αvβ3 binds 
vitronectin, VWF, fibronectin, tenascin, fibrillin, osteopontin (OPN), fibrinogen, 
and thrombospondin (Calderwood, 1999; Weis and Cheresh, 2011). These 
integrins can readily differentiate between different RGD-containing ECM 
proteins and respond variously to the interaction with each one of them despite 
their obvious similarity (Kapp et al., 2017). 
Integrins modulate signal transduction pathways that control cellular and 
biological functions including migration, cell adhesion, cell differentiation, 
proliferation and apoptosis (Zent, 2010).  Also, integrins link the ECM to the 
actin cytoskeleton and transfer mechanical force and biochemical signals via 
the plasma membrane. This allows cells to produce traction through migration 
and uses tension through matrix remodelling. Linkages with  the cytoskeleton 
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also permit integrins to regulate gene expression and cell shape, and mediate 
cell adhesion (Calderwood, 1999). 
Table 1 : Ligands and functions of the RGD-recognising integrin subfamily  
 (Sutherland et al., 2012). 
Integrin  Ligands/ recognition sequences Main function  
α5β1 Fibronectin, Osteopontin Angiogenesis 
α8β1 Fibronectin, Vitronectin, Nephronectin 
Development of lung 
and kidney   
Differentiation and 
function of hair cells  
αIIβ3 
Fibronectin, Fibrinogen, Von Willebrand 
factor, Vitronectin 
Platelet aggregation 
αvβ3 
Fibronectin, Vitronectin, Fibrinogen, Von 
Willebrand factor, Bone sialoprotein, 
Osteopontin, LAP-TGF-β 
Resorption of bone 
Angiogenesis 
αvβ5 
Vitronectin, Fibronectin, Bone 
Sialoprotein, 
Angiogenesis  
αvβ6 
Fibronectin, Vitronectin, Osteopontin, 
LAP-TGF-β 
Activation of TGF-β 
Fibrosis 
αvβ8 Vitronectin, LAP-TGF-β 
Activation of TGF-β, 
Brain development   
 Angiogenesis 
αvβ1 
Fibronectin, Fibrinogen, Vitronectin, 
Osteopontin, LAP-TGF-β 
Fibrosis 
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1.3.1 Activation of integrin and ligand binding 
 
Both subunits αIIb and αv do not have an I domain. The I domain is responsible 
for ligand binding if present. If it is not present, ligand binding occurs on the I-
like domain in the β subunit and the β-propeller headpiece of the α-subunit, and 
is supported by interactions between binding site residues, the ligand and one 
or more divalent cations bound in the integrin subunits (Figure 5) (Takagi, 2007; 
Xiong, 2002; Zhang and Chen, 2012).  
 
 
 
 
 
 
 
Figure 5 : Characteristics of the RGD binding site. 
The α subunit links the basic chain of arginine side via interactions with different subunit specific 
acidic residues. Ligand binding to the β subunit is basically through an electrostatic interaction 
between a positively charged metal ion (usually Mg2+) conncected with the integrin subunit and a 
carboxylate group on the ligand (Sheldrake and Patterson, 2014). 
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A specific characteristic of integrins is their increasing ligand binding through 
affinity maturation which progresses from low affinity (inactive) to a high affinity 
(active) state (Figure 6) and which can be induced by high affinity ligands or by 
inside-out signalling (intracellular signalling events). Ligand binding enhances 
allosteric alterations in the receptor conformation, resulting in the activation of 
intracellular signalling pathways, including PI3K-PKB-mTOR, Ras-MAPK and 
small GTPases such as Rho, Rac pathways (outside-in signalling) (Alghisi et 
al., 2009; Hynes, 2002b).  Integrin activation involves binding the cytoplasmic 
tail to talin. Talin is a high molecular weight cytoskeletal protein capable of 
linking integrins (Burridge and Connell, 1983). This leads the headpiece of the 
extracellular domain to extend to a vertical position above the cell surface, 
exposing the ligand binding site. This, in turn, permits the instigation of several 
signalling pathways (inside-out and outside-in signalling pathways) by enlisting 
intracellular molecules to bind to the cytoplasmic tail (Kim et al., 2011).  
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Figure 6: The conformational changes of integrin activation states. 
The various conformations of an integrin are linked with distinct affinities: low affinity shows the 
bent conformation, and intermediate affinity and high affinity show the two extended 
conformations. Intracellular signalling activation increases ligand binding by inducing a transition 
between these affinity states, known as affinity regulation.  
 
 
Figure 7 shows bidirectional signalling utilizing integrin αIIbβ3 as an example. 
αIIbβ3 has already been recognised as a target for antithrombotic therapy  
(Bakewell et al., 2003; Cohen et al., 2000; Goodman et al., 2012). Defects in 
structure or expression of αIIbβ3 lead to a variety of bleeding diseases identified 
as Glanzmann’s thrombaesthenia (Tomiyama, 2000). 
 
  
  
21 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: Bidirectional signalling of αIIbβ3 integrin. 
αIIbβ3 equilibrates between activated and resting states; the activated state in stimulated 
platelets and the resting state is dominant in unstimulated platelets. (A) Inside-out signalling; 
agonist-dependent intracellular signals enhance the interaction of main regulatory ligands (talin) 
with integrin cytoplasmic tails (in this example the β3 tail). This results in conformational 
transitions in the extracellular domain that lead to high affinity for adhesive ligands (fibrinogen). 
(B) Outside-in signaling; binding of extracellular ligand, initially reversible, becomes increasingly 
irreversible and induces clustering of integrin and further conformational alterations.This results in 
the activation of enzymes, effectors and adaptors to form integrin-based signaling complexes. 
Adapted from (Shattil and Newman, 2004). 
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Integrins rely on intracellular effector proteins to transduce signals because they 
lack catalytic activity (Figure 8). Focal adhesion kinase (FAK) is a non-receptor 
tyrosine kinase (TK), which begins to be activated upon integrin-extracellular 
matrix interactions and integrin clustering. FAK reacts with several signalling 
proteins, including Cas, paxillin, phosphoinositide 3-kinase (PI3-K) and Src 
kinases (Mitra and Schlaepfer, 2006; Tilghman and Parsons, 2008). Through 
Src, integrin signalling is able to be FAK independent as Src also associates 
directly with β3, and β3 integrin clustering enhances activation of Src and auto-
phosphorylation (Arias-Salgado, 2003; Taherian et al., 2011) (Taherian et al., 
2011). 
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Figure 8: Integrin mediated signalling pathways. The composition of the ECM, its mechanical 
properties, and the environment of growth factors regulate the outside-in signalling by integrins in 
interacting with growth factor receptors. Growth factor signalling co-operates with integrin-
mediated signalling on different levels: by regulating the affinity of the integrin for ECM ligands (I), 
by regulating the activity of integrin-intracellular effector proteins such as FAK, PI3K, and Src (II), 
and by regulating the downstream effectors activity such as, Akt, JNK, ERK and Rho GTPases 
(III). The essential signalling module downstream from integrins is the Src/FAK complex, which 
stimulates ERK and JNK and ERK to regulate proliferation, differentiation and cell survival. Also, 
through activation of Crk/Dock180 or alternatively PIX/GIT pathways, the Src/FAK complex 
regulates activity of Rho GTPase, leading to cytoskeletal reorganization and regulation of 
adhesion, migration and polarity. Integrins also activate PI3K, which in collaboration with integrin 
linked kinase (ILK) and mTOR, controls cell survival by Akt. Cross-talk between the several 
pathways. Adapted from (Legate et al., 2009).  
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Specific integrin signals allow tumour cells to detach from neighbouring cells, 
proliferate and survive in distant microenvironments during progression from the 
growth of the tumour to metastasis. There is further evidence that certain 
integrins bind to receptor tyrosine kinases to activate signalling pathways that 
are required for tumour invasion and metastasis (Guo and Giancotti, 2004). For 
example, αvβ3 integrin connects with IGFR-1 (insulin-like growth factor 
receptor), PDGFR (platelet-derived growth factor receptor) (Borges et al., 2000; 
Schneller et al., 1997), and VEGFR2 (vascular endothelial growth factor 
receptor-2) (Soldi et al., 1999). These connections suggest that the signalling 
relationship between integrins and receptor tyrosine kinases may be due to 
receptor co-clustering upon cell attachment or stimulation of growth factor 
ligand production. Growth factor stimulation of RTKs or ECM-integrin 
interactions promotes an increase in receptor tyrosine kinases and the local 
concentration of integrins at focal adhesions. This cross-talk can occur at the 
main edges of tumour cells, although it can even occur directly through changes 
of the intracellular localisation of integrins (Lipscomb and Mercurio, 2005). 
 
1.3.2 Integrins in angiogenesis 
 
Angiogenesis is the growth of new blood vessels that occurs in normal 
development and some pathophysiological conditions. Angiogenesis is the 
process of sprouting, cell migration, division and endothelial cell assembly from 
pre-existing vessels (Carmeliet and Jain, 2000; Fouad and Aanei, 2017). 
Therefore, angiogenesis has many roles in normal physiology involving in 
embryogenesis, wound healing, the female reproductive cycle and bone 
formation (Carmeliet, 2003). Moreover, angiogenesis has an important function 
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in the development of tumours.  Primary cancer cells are supplied by nutrient 
and oxygen taken from adjacent vascular tissues, and the supply of local blood 
becomes insufficient when these cells proliferate, resulting in a nutrient-
deprived tumour environment and inadequate oxygen supply. Angiogenesis in 
tumours can occur by recruitment of rare and circulating bone marrow-derived 
endothelial progenitor cells (Avraamides et al., 2008).    
Angiogenesis supports tumour invasion, survival and metastasis. Endothelial 
cells that are in the microenvironment of the tumour are in an inactive state but 
when tumour cells begin producing pro-angiogenic factors this can result in an 
angiogenic switch (Bergers and Benjamin, 2003). Some endothelial integrins 
(αvβ3,αvβ5, αllbβ3and α5β1) are involved in angiogenesis (Avraamides et al., 
2008)  and will be discussed in this section.   
αvβ3 is one of the most investigated integrins because of its function in 
regulation of angiogenesis (Nussenbaum and Herman, 2010). It is expressed 
on angiogenic endothelial cells at high levels in remodelling and pathological 
tissues, while inactive endothelial cells express αvβ3 at low levels (Weis and 
Cheresh 2011). Through the function of pro-angiogenic and anti-angiogenic 
molecules, the interaction between the ECM and αvβ3 has the ability to control 
angiogenesis (Atkinson et al., 2014). The pro-angiogenic function for αvβ3 is 
supported by its cooperation with vascular endothelial growth factor receptor 2 
(VEGFR2) in endothelial cells that enhance angiogenesis. Also, its function 
during angiogenesis is to activate MMP-2 at the migration tip of endothelial cells 
to disrupt elements of the ECM and facilitate cell infiltration and migration. 
These roles support αvβ3 as an essential tumour angiogenic promotor (Brooks 
et al., 1994; Brooks et al., 1995). Therefore, αvβ3 integrin has been considered 
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an attractive antiangiogenic target for the development of small molecule 
antagonists. β3 integrin subunit blocking utilising antibodies, signalling-defective 
mutants or RGD peptide antagonists lead to a reduction in tumour progression 
and angiogenesis (Brooks et al., 1994; Mahabeleshwar et al., 2006). 
The expression of αvβ3 is also associated with tumour angiogenesis and the 
metastasis of cancer cells (Shan et al., 2015) such as the MDA-MB-435 human 
breast cancer cell line, where αvβ3-mediated interactions with platelets support 
the arrest of cancer cells within  the bloodstream and results in haematogenous 
metastasis (Felding-Habermann et al., 2001). In addition, the interaction 
between αllbβ3 on platelets and αvβ3 on endothelial cells through fibrinogen, 
acting as bridges among the cells, induces angiogenesis and inflammation 
(Katrancha and Gonzalez, 2014). 
αvβ5 is needed for transforming growth factor α (TGF-α) or vascular endothelial 
growth factor (VEGF) prompted angiogenesis. Anti-αvβ3 antibodies inhibited 
angiogenesis promoted by basic fibroblast growth factor (bFGF), whereas anti 
αvβ5 antibodies inhibited angiogenesis promoted by VEGF in both the chick 
chorioallantoic membrane (CAM) and the rabbit corneal eye pocket assay 
(Friedlander et al., 1995). Angiogenic assays indicate that αvβ5 is required for 
VEGF and TGF-α mediated angiogenesis in vivo, whereas TNF-α and bFGF 
depend on αvβ3 to initiate angiogenesis. The pathway of VEGF/αvβ5 signalling 
is dependent on protein kinase C and Src kinase (Eliceiri et al., 2002).  
α5β1 is abundantly expressed on the vasculature of human tumours while it is 
poorly expressed on inactive endothelial cells. The expression of α5β1 is 
induced by several angiogenic factors such as TNF-α, FGF and IL-8 (Kim et al., 
2000). Notably, novel non-peptide antagonists of α5β1 had little effect on 
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angiogenesis induced by VEGF but inhibited angiogenesis induced by 
fibronectin in both murine and chick embryo models and led to regression of 
human tumour models in vivo. Therefore, integrin α5β1 and fibronectin, like 
integrin αvβ3, are involved in a pathway of angiogenesis that is distinct from 
VEGF-mediated angiogenesis (Kim et al., 2000).  
   
The expression of RGD binding integrins is shown to correlate with cancer 
metastasis and poor prognosis (Nieberler et al., 2017; Pontes-Junior et al., 
2010; Sutherland et al., 2012; Zheng et al., 1999). αvβ3, αllbβ3 and α5β1 
integrins are among the most prominent integrins in cancer progression and 
widely expressed in metastases in both haematological malignancies and solid 
tumours. 
 
1.3.3 RGD binding integrins in haematological malignancies  
 
1.3.3.1 αvβ3 in haematological malignancies 
 
Interaction of the bone marrow microenvironment with immature haematopoietic 
cells is significant for several processes, including differentiation and 
proliferation of haematopoietic progenitor cells, mobilisation of progenitors in 
blood cell donors, and persistence of residual disease in leukaemia which is 
related to defensive effects of the bone marrow on leukaemia blasts during 
chemotherapy (Roselova et al., 2017). For example, acute myeloid leukaemia 
cells are dependent on integrins and chemokine receptors for marrow homing 
and migration (Bönig and Kim, 2015).  
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ECM signalling of integrins is important for the viability of cancer cells of the 
hematopoietic origin (Hehlgans et al., 2007).  
Furthermore, adhesion within the marrow microenvironment leads to 
chemotherapy resistance in acute myeloid leukaemia and other hematologic 
malignancies by interfering with apoptosis or activating survival pathways 
(Becker and Appelbaum, 2015). Yi et al (2016) established that the expression 
level of integrin β3 is crucial for osteopontin-enhanced chemotherapy 
insensitivity in acute myeloid leukaemia cells. Miller et al.(2013) also found that 
loss of integrin β3 weakens leukaemia cell homing and prompts differentiation 
of myeloid cells via spleen tyrosine kinase (SYK), thereby inhibiting integrin β3–
SYK signalling that might repress leukaemia growth with reduced toxicity. 
Therefore, RGD-binding integrins, particularly β3, represent potential 
therapeutic targets in leukaemia cells. 
Lymphoma cells express αvβ3 integrin (Goodman and Picard, 2012). Lymphoid 
tumour cells (CEM T-cell lymphoblastic leukaemia, Burkitt's lymphoma, and 
U266 multiple myeloma) have been shown to interact with the ECM 
components vitronectin and fibronectin via αvβ3 integrin. This adhesion was 
inhibited by a neutralising monoclonal anti-αvβ3 integrin antibody. Vitronectin 
and fibronectin promote the formation of activated Src/FAK complex and 
activation of ERK-2 by engaging αvβ3 integrin. Engagement of αvβ3 integrin 
also may be of importance in the spread of human lymphoid tumours by 
modulating cell adhesion, proliferation, and interacting with the extracellular 
matrix components. The interaction of vitronectin and fibronectin allows cells to 
attach to the substratum and increases their proliferation and protease secretion 
(Vacca et al., 2001). 
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Although there are variable levels of integrin expression between different 
cases of chronic lymphocytic leukaemia, the integrin is still able to mediate 
change functional cellular responses to adhesion in vitro (Vincent et al., 1996). 
ITGB3 (integrin β3 gene) was identified as an essential gene for human 
leukaemia cells in xenotransplantation studies and murine leukaemia cells in 
vivo. Knockdown of integrin β3 impaired homing of primary leukaemia cell, 
induced differentiation via the intracellular kinase Syk and downregulated 
leukaemia stem cell transcriptional programmes. In contrast, loss of integrin β3 
in normal hematopoietic cells did not impair progenitor or stem cell 
differentiation or function in the primary transplant. In this context of malignant 
cells, using an integrin β3 knockout mouse model, β3 integrin is not necessary 
for normal haematopoiesis but is essential for leukaemogenesis such as mixed 
lineage leukaemia, demonstrating the importance of the integrin β3 signalling 
pathway as a promising target in acute myeloid leukaemia. Systemically, the 
data provided by Miller et al. indicate a significant role of β3 gene in both 
leukemic cells and interaction with stromal cells (Miller et al., 2013). 
In addition, β3 integrin is required for mixed-lineage leukaemia cells (MLL-AF9) 
in mouse cells; mice transplanted bone marrow not encoding β3 survived longer 
than those transplanted with encoding β3 cells, showing the importance of the 
β3 gene in  mediating  leukaemic proliferation (Feliciano, 2013; Zeisig and So, 
2013).  AML cells such as transformed cells (MLL-AF9) interact with the 
microenvironment of bone marrow, most probably in the endosteal region 
(Ishikawa et al., 2007). This interaction is considered to be important for cell 
survival and impacted on the lineage fate of MLL-AF9 leukaemia (Wei et al., 
2008).  
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A large set of integrin-associated proteins is required for the assembly of 
adhesion complexes by different cells types, including the leukaemia cell line, 
K562 (Horton et al., 2015; Roselova et al., 2017). K562 is a useful model to 
study the differentiation of blood cells induced by phorbol myristate acetate 
(PMA) (Huang et al., 2014). The expression of β3 integrin is controlled at the 
level of transcription, as confirmed by its response to phorbol ester treatment. 
High levels of β3 mRNA have been demonstrated by northern blot analysis and 
high expression of β3 was also shown in cell-free translation of mRNA from 
K562 cells stimulated with PMA (Huo et al., 2006).   
Al-Asadi et al., (2017) found that the expression of αv and β3 subunits was 
significantly upregulated in dormant leukaemia-initiating cells and increased 
adhesion to vitronectin. Quantitative PCR confirmed adhesion-related protein 
upregulation (Al-Asadi et al., 2017). 
αvβ3 is important for chemosensitivity and disease development in human AML 
cells. The interactome of the integrin consists of several intracellular mediators, 
including the Syk kinase, β-catenin, and a large number of HoxA genes and the 
FGF2 receptor that work together for downstream signalling of β3 integrins. 
Thus, inhibition of Syk as well as blocking of β3 by a specific antibody may be a 
potential strategy for inhibition of AML-supporting signalling circuits (Becker et 
al., 2015; Becker and Appelbaum, 2015; Tavernier-Tardy et al., 2009).   
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1.3.3.2 αllbβ3 in haematological malignancies 
 
αIIbβ3 (gpIIbIIIa) binds fibrinogen and regulates the accumulation of platelets 
into thromboses (Coller and Shattil, 2008). αIIbβ3 is the main membrane protein 
on the platelet surface (Quinn et al., 2003) and its primary adhesion receptor of 
blood platelet (Lau et al., 2009). Fibrinogen has six potential linking sites for 
αIIbβ3. Platelets binding fibrinogen leads to a crosslink between platelets which 
causes platelets aggregation as a central response for thrombosis and 
haemostasis (Katrancha and Gonzalez, 2014).  
Plasma fibrinogen levels have a prognostic effect with an adverse outcome in 
acute myeloid leukaemia patients (AML) at the time of diagnosis without 
increased early mortality. Both solid-phase and soluble fibrinogen promote Syk 
signalling in human megakaryoblastic cell lines (Berger et al., 2017). 
Thrombopoietin enhances the adhesion of leukemic cells to fibrinogen and the 
activation of αllb integrin is thereby increased (Tohyama et al., 1998). 
Recognition of the RGD sequence on the fibrinogen ligand leads to increased 
binding. The impact is only seen with αllbβ3, but not with αvβ3 integrins, and 
signalling through PI3K is significant for high integrin expression/binding. The 
level of β3 integrin expression per AML cell is comparable with the expression 
in endothelial carcinoma cells (Johansen et al., 2018; Zhai et al., 2015). 
Chronic myelogenic leukemic cells such as K562 undergo megakaryocytic 
differentiation in response to PMA induction. Megakaryocytic cell surface 
markers CD41 and CD61 (αIIb and β3) are often utilised as differentiation 
markers of the megakaryocyte cell lineage expressed in K562 cells treated with 
PMA (Shelly et al., 2000). PMA-stimulated K562 cell adhesion mediated by β-
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integrin agonists was partially inhibited by the selective αIIbβ3 antagonist 
(tirofiban) and α5β1 integrin agonists. These findings demonstrated that both 
α5β1 and αIIbβ3 integrins may participate in mediating cell K562 cell adhesion 
(Galletti et al., 2014). So far, no further published studies revealed the 
expression and suggested a role of αIIbβ3 in haematological malignancies. 
 
1.3.3.3 α5β1 in haematological malignancies 
 
α5β1 is a specific receptor for fibronectin. Both α5β1 and fibronectin play a 
significant role in the development of the vascular system during 
embryogenesis (Li et al., 2009; Serini et al., 2006). Expression of α5β1 integrin 
is upregulated in endothelial cells within new blood vessels and also on the 
surface of tumour cells. α5β1 integrin ligation stimulates cell growth and 
migration during Akt and MAPK activation mediated signalling pathways (Millard 
et al., 2011).  
α5β1 is one of the integrins constitutively expressed in malignant T lymphocytes 
(Bachsais et al., 2016). Integrins expressed in lymphocytes participate in 
mediating interactions with ECM proteins during the transmigration process (Jin 
and Varner, 2004). For example, blocking of α5 with anti-α5 mAb represses the 
activity of pro-MMP-9 appreciably, showing the significant role of α5β1 integrin 
in the fibronectin-induced MMP activity and expression which promotes K562 
cell migration (Dutta et al., 2010).  
Integrins and tyrosine kinases contribute to mediating signals for cell survival 
and suppressing programmed cell death in acute lymphoblastic leukaemia 
bearing the Philadelphia chromosome (Ph+ leukaemia). An α5 inhibitory 
antibody prevented adhesion of Ph+ leukaemia cells to fibronectin and acted 
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synergistically with the BCR-ABL fusion protein inhibitor imatinib to enhance 
apoptosis. In immune-deficient mice, the α5 inhibitory antibody delayed and 
impaired the engraftment of Ph+ leukaemia cells (Hu and Slayton, 2014). 
 
1.3.4 RGD binding integrins in solid tumours 
1.3.4.1 αvβ3 in solid tumours 
 
Different types of tumours express αvβ3 integrin including prostate cancer, 
breast cancer, melanoma, pancreatic cancer, ovarian cancer, pancreatic 
cancer, cervical cancer and glioblastoma (Desgrosellier and Cheresh, 2010). 
αvβ3 plays a vital role in multiple cellular processes that result in the 
development of cancer including tumour growth, malignant transformation, 
invasion and metastasis (Byzova et al., 2000; Enns et al., 2005). Furthermore, 
previous studies have demonstrated that there is a positive relationship 
between the expression of the αv subunit on tumours and their ability to migrate 
and adhere (Li et al., 2009). αvβ3 is implicated in regulating cancer cell survival 
and programmed cell death. αvβ3 signalling suppresses the expression of the 
pro-apoptotic protein Bax by p53 downregulation and regulates the expression 
and activity of bcl-2. αvβ3 integrin raises the BaX:bcl-2 ratio, which results in an 
increase in cancer cell survival by inhibiting the mitochondrial pathway of 
apoptosis that comprises caspase activation and the release of cytochrome c 
(Martin and Vuori, 2004). 
In addition, tumour progression is induced by αvβ3 integrin through the 
activation of Src, which results in activation of the focal adhesion kinase FAK-
independent survival pathway and induction of tumour growth (Albelda et al., 
1990; Gruber et al., 2005). 
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High expression of αvβ3 permits cancer cells to link to ECM proteins such as 
fibrinogen, fibronectin vitronectin, osteopontin and von Willebrand factor which 
are present in the microenvironment of the tumour. These adherent interactions 
supply cell survival signals for invading endothelial cells (Davis, 1992; 
Desgrosellier and Cheresh, 2010). 
αvβ3 is expressed in activated macrophages, cytokine-stimulated endothelial 
cells, leukocytes, osteoclasts, and certain invasive cancers, although it is not 
typically expressed in normal epithelial cells (Cooper et al., 2002; Suyin et al., 
2013). αvβ3 is implicated in different cellular activities including cell adhesion, 
angiogenesis, and migration on components of extracellular matrices (Cooper 
et al., 2002).  αvβ3 is significant in vascular angiogenesis in the early stages 
(Brooks et al., 1994), and in osteoclast-mediated resorption of bone which is 
mediated by αvβ3-expressing osteoclast attachment to the surface of the bone 
(Ross et al., 1993; Teti et al., 2002). 
In different cancer types (breast cancer, prostate cancer, and melanoma), the 
αvβ3 and αvβ5 integrins are extensively expressed (Schittenhelm et al., 2013). 
The  matching ligands exert a significant role in regulating the sprouting ability 
of endothelial cells through angiogenesis, and localisation of inflammatory cells 
recruited to the invasive tumour cells or wound repair sites (Weis and Cheresh, 
2011). 
In human breast cancer cells, αvβ3 mediates cell adhesion to vitronectin which 
is crucial for supplying strong binding to the underlying ECM and the necessary 
cytoskeletal rearrangements (Hamidi et al., 2016; Nieberler et al., 2017). Zhao 
et al., (2007) found that αvβ3 integrin overexpression in breast cancer cells 
such as MDA-MB-231 associated with increased incidence of bone metastasis 
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in vivo. αvβ3 expression was higher in tissue with metastatic tumours than in 
primary tissue. Tumour cell expression of αvβ3 stimulates osteoclast-mediated 
bone resorption and bone destruction once infiltrated into the bone marrow. A 
selective αvβ3 non-peptide antagonist not only blocks bone colonisation by 
αvβ3-expressing cancer cells, but also inhibits osteoclast-mediated bone 
resorption in animal models of bone metastasis (Zhao et al., 2007). 
In a mouse model, transfection of cells from bone metastasis with αvβ3 or 
utilising MDA-MB-231 breast cancer cells leads to an elevated number and 
areas of osteolytic bone metastases associated with active αvβ3 expression on 
the cell surface. The anti-αvβ3 antibody LM609 inhibited tumour cell adhesion 
and invasion to cortical bone (Pecheur et al., 2002) and inhibited the metastasis 
of breast cancer cells (Felding-Habermann et al., 2001).   
Other studies showed that MDA-MB-435 and 21NT human breast cancer cells 
both responded to exogenous or endogenous osteopontin with highly migratory 
and invasive characterisation in vitro, showing that osteopontin could contribute 
functionally to the malignant behaviour of breast cancer (Tuck et al., 1999; Tuck 
et al., 2000; Tuck et al., 2001). These effects can be inhibited functionally in 
MDA-MB-435 cells with αvβ3 antibodies but not with antibodies raised to αvβ1 
or αvβ5. In contrast to this, antibodies to αvβ3 had no effect in 21NT cells, but 
migration and invasion were inhibited by anti αvβ1 or αvβ5 antibodies (Tuck et 
al., 2000). Both MDA-MB-435 and 21 NT cells expressed αvβ1 and αvβ5 
integrins but only MDA-MB-435 cells have high levels of αvβ3. These data 
demonstrate that different levels of integrin expression may control how cells 
respond to a ligand in the tumour microenvironment. Additionally, 21NT cells 
stably transfected with osteopontin and β3 and injected in nude mice, 
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expression of αvβ3 alone is insufficient to induce colonisation in the mammary 
fat pad in vivo. The injected mice showed increased tumour take, a reduced 
tumour doubling time, and a reduced tumour latency period relative to controls 
(Furger et al., 2003).  
It is likely that αvβ3 may have various roles at different stages of metastatic 
progression. Activated αvβ3 expressed in breast cancer cells increases 
migration and metastasis to the lung following intravenous injection of cancer 
cells in mice (Felding-Habermann, 2001; Felding-Habermann et al., 2002; 
Felding-Habermann et al., 2001). Enhanced metastasis of breast tumour cells 
was suggested to be mediated through aggregation of tumour-induced platelets 
and their capture in blood vessels. These events are blocked by antibodies 
targeting human αvβ3 on tumour cells or αIIbβ3 on platelets (Felding-
Habermann et al., 2001).  
Additionally, prostate adenocarcinomas isolated from bone metastases express 
αvβ3 receptors, which regulate adhesion to and migration by bone ECM 
proteins including osteopontin and vitronectin (Zheng et al., 2000). The αv 
subunit mediates prostate epithelial cell interactions with osteopontin, which 
stimulates cell proliferation and subpopulation growth (Elgavish et al., 1998). It 
has also been shown that bone sialoprotein promotes integrin-mediated 
migration, increases expression of MMPs, and upregulates integrin survival 
signalling pathways in prostate cancer cells (Gordon et al., 2009).  
αvβ3 is expressed in the active conformation on prostate cancer cells and 
comparing matched samples of bone metastasis with primary tumour showed 
that integrin activation is elevated in bone metastases in comparison to the 
primary tumour (Marthick and Dickinson, 2012; Maruyama et al., 2002). The 
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subunits αv and β3 are found at all stages of prostate cancer; however, the 
αvβ3 heterodimer is associated with increased metastatic potential in cell lines 
(Edlund et al., 2001). Prostate cancer cells began to express integrin β3 upon 
oncogenic transformation, which is further increased in metastatic prostate 
cancer, leading to induced tumour metastasis and invasion. Notably, 
overexpression of αvβ3 in prostate cancer cells is associated with increased 
bone metastasis (McCabe et al., 2007). Overexpression of αvβ3 has been 
identified as a significant factor for prostate cancer progression and metastasis 
because it was expressed by tumour associated blood vessels. Therefore, αvβ3 
integrin could be involved in prostate cancer metastasis even though no 
significant expression was found in prostate cancer cells (Heß et al., 2014). 
The progression of malignant melanoma is also related to the expression of 
αvβ3 integrin (Pickarski et al., 2015). In vivo and in vitro studies in melanoma 
cells overexpressing αvβ3 showed that it can increase metastasis by enhancing 
adhesion to vitronectin (Li et al., 2001). Overexpression of αvβ3 is inversely 
related to the survival of melanoma patients (Trikha et al., 2002b). The 
expression of β3 integrin was not detected in benign melanocytes but only 
detected in metastatic melanoma cells. These data showed that the expression 
of β3 integrin might be a biomarker for the aggressive phase of melanoma 
(Albelda, 1990). Mouse models showed reduced metastasis of haematogenous 
B16 murine melanoma cells to the lung on blocking αv (Lonsdorf et al., 2012) or 
ανβ3 integrin (Ramos et al., 2008). Also, no alterations in the proliferation rate 
were shown in siRNA-transfected B16 cells; however, they had weak ability to 
connect to fibronectin. Furthermore, suppression of integrin β3 expression led to 
almost complete impairment of the capacity of B16 cells to migrate through 
matrigel and metastasise. Mice inoculated to form B16 metastasis in the lung 
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showed decreased number of colonies compared the control group 
(Nasulewicz-Goldeman et al., 2012). 
 
 
1.3.4.2 αIIbβ3 integrin in solid tumours 
 
αIIbβ3 integrin is not only expressed on the surface of platelets but is also on 
cancer cells (Millard et al., 2011). αIIbβ3 is aberrantly expressed in breast 
(Kononczuk et al., 2015), melanoma and prostate cancers and is related to 
increased tumour growth, metastasis, and recurrence (Trikha et al., 2002a). It 
also been established that the capability of breast cancer cells to aggregate 
platelets is associated with metastatic potential of the tumours, and blockade of 
tumour cell induced platelet aggregation (TCIPA) is related to the suppression 
of metastasis in vivo (Oleksowicz et al., 1995). 
Prostate cancer cells, particularly those grown orthotopically, express αIIbβ3. 
αIIbβ3 expression is localised in focal contacts on the cells of prostate 
carcinoma. αIIbβ3 expression plays a partial role in the invasion of prostate 
tumour cells through a reconstituted basement membrane; αllbβ3 antibodies 
inhibited cell invasion by approximately 40%, and the invasion of prostate 
tumour cells specifically requires the active αIIbβ3 integrin conformation (Trikha 
et al., 1996).  
Association analysis between cancer integrin expression and biochemical 
recurrence probability following the surgical removal of localised prostate 
cancers found αllbβ3 integrin expression in recurrent prostate tumours to be 
stronger than in non-recurrent tumours and was marginally significant for 
recurrence (Pontes-Junior et al., 2010). Moreover, the existence of αIIbβ3 on 
the surface of DU-145 prostate cells is related to high tumourigenicity, 
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development of lymph node metastases and local invasion. PC-3 cells, which 
have intracellular localisation of αIIbβ3, were less invasive. For example, PC-3 
cells injected into mice led to the development of intraprostatic tumours while 
DU-145 cells injected in mice caused tumours that were able to metastasise to 
new sites, notably lymph nodes (Trikha et al., 1998).  
 
Expression of αIIbβ3 was found to be high in later stages of melanoma but low 
in early stages, in contrast to the expression of αvβ3 integrin which was high in 
early stages of melanoma. Using isogenic cell lines, the importance of αIIbβ3 
integrin in human melanoma cell growth was demonstrated. No differences 
were shown in the growth between mock-transfected cells and αIIbβ3 
expressing cells in vitro, but, αIIbβ3 expressing cells expanded into larger 
tumours concomitant with a decrease their rate of programmed cell death in 
vivo (Trikha et al., 2002a). αIIbβ3 expressing cells in the exponential growth 
stage upregulate expression of basic fibroblast growth factor, thus providing an 
angiogenic growth factor for melanoma cells and stimulating tumour growth 
(Dome et al., 2005).  
 
The interaction between tumour cells and platelets is related to increased 
metastases. Through the bridge of fibrinogen, the interaction of cancer cells 
with platelet αIIbβ3 and endothelial cells αvβ3 facilitated tumour cell metastasis 
(Bakewell et al., 2003; Gay and Felding-Habermann, 2011) In the presence of 
fibrinogen, the adhesion of melanoma cells to αIIbβ3 integrin-expressing 
Chinese Hamster Ovary (CHO) cells was increased. Inhibition of αIIbβ3 or αvβ3 
on melanoma cells led to a significant reduction in adhesion of melanoma cells 
to other αIIbβ3 integrin expressing melanoma cells (Schwarz et al., 2006).  
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Exposure of B16 melanoma cells to RGD peptide significantly decreased the 
platelet-mediated adhesion of fluorescently-labelled melanoma cells to 
endothelial cell monolayers under flow conditions, compared with untreated B16 
melanoma cells or a control peptide. Additionally, depletion of platelets caused 
a significant reduction in adhesion of melanoma cells to the injured vascular wall 
in vivo (Lonsdorf et al., 2012). Therefore, inhibition of αIIbβ3 integrin may be a 
therapeutic strategy against tumour metastasis by disrupting the engagement 
between platelet αIIbβ3 and tumour cells (Bakewell et al., 2003).  
 
 
1.3.4.3 α5β1 integrin in solid tumours 
  
α5β1 integrin controls fibronectin matrix assembly that leads to the stability and 
organisation of the ECM. Cellular α5β1 expression is associated with the 
capability of prostate cancer cells to accumulate a fibronectin matrix forming 
cohesive aggregates. Fibronectin matrix assembly and high α5β1 levels are 
inversely related to invasiveness; absence of integrin α5β1 allows detaching of 
cells, resulting in metastasis and intravasation (Jia et al., 2012). α5 is highly 
expressed in oesophageal squamous cell carcinoma (SCC) patient samples 
compared to normal oesophageal epithelial cell lines. α5 expression is 
significantly associated with tumour size, lymph node metastasis, and poor 
overall survival of oesophageal SCC patients (Xie et al., 2016). Inhibiting α5β1 
integrin leads to a decrease in the dynamics of cell shape changes and cell 
spreading in the early stage of adhesion, and a decrease in the number of 
adherent cells. Re-organization of cytoskeletal proteins is also weaker than in 
control cells. In the spreading and adhesion of prostate cancer cells, α5β1 
interacted with fibronectin, whereas inhibition of αvβ3 did not affect spreading 
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on, and adhesion to fibronectin (Stachurska et al., 2012). It has previously been 
observed that integrins α5β1 and αvβ3 support fibronectin-dependent platelet 
adhesion and promote formation of filopodia but, in contrast to αllbβ3, are 
unable to induce formation of lamellipodia. These data highlight a possible role 
for fibronectin in supporting thrombus adhesion in cancer (McCarty et al., 2004). 
Fibroblasts display continued migration on fibronectin coated substrates, as a 
role of fibronectin surface density. Characterisation of fibroblast dynamics and 
adhesion identified alterations in focal adhesion dynamics, adhesion plaque 
formation, cytoskeleton organisation, and intracellular signalling between 
fibronectin and vitronectin. Inhibition of α5β1 and αvβ3 showed that αvβ3-
mediated reduction of the directional persistence of cell migration involved 
changed α5β1 trafficking rather than remodelling of actin cytoskeleton and 
adhesion structures. The results demonstrated that fibroblasts show increased 
directional persistence in migration on fibronectin but not vitronectin coated 
substrates. Hence the engagement of both integrins α5β1 and αvβ3 is essential 
for directional continuation in fibroblast migration on fibronectin but not on 
vitronectin (Missirlis et al., 2016).  
 
1.4 Integrins as therapeutic targets 
 
Integrins are widely recognized as targets for antitumor therapy (Ray et al., 
2014; Sheldrake and Patterson, 2014). Integrin antagonists are generally 
designed to inhibit the interaction between integrins and their associated 
extracellular ligands. Some of the integrin antagonists are still under undergoing 
research in preclinical or clinical trials and some have reached the 
pharmaceutical market. Extensive details regarding integrin antagonists have 
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been reviewed (Cox et al., 2010; Galletti et al., 2014; Millard et al., 2011; Stupp 
et al., 2014). 
Given the importance of αvβ3/αvβ5, αllbβ3 and α5β1 integrins in the 
progression of a number of cancers, there is significant therapeutic potential for 
development of integrin antagonists. 
 
1.4.1 αvβ3/αvβ5 integrin antagonists 
 
A large number of non-peptidic and peptidic antagonist ligands for the αvβ3 
receptor have been developed which are mostly associated with the minimal 
recognition motif RGD (Morgan et al., 2009). Pharmacological inhibitors of αvβ3 
repress the development of new blood vessels in many models  (Al-Husein et 
al., 2012; Kumar, 2003b), and antagonists of αvβ3 such as antibodies (MEDI-
522), small molecules and peptides (cilengitide) have been investigated as 
antiangiogenic agents (Alghisi et al., 2009; Stupp et al., 2014), albeit without 
clinical success. 
Cilengitide, an RGD cyclic peptide antagonising αvβ3 and αvβ5 entered into 
clinical trials in patients with recurrent glioblastoma. The phase I and phase II 
clinical trials showed responses that provided evidence for drug targeting to 
tumours, and evidence of dose-dependent effects (Reardon et al., 2008). 
However, the phase III trial in glioblastoma patients with a methylated MGMT 
promoter investigating cilengitide combined with standard chemo-radiotherapy 
showed no clinical response due to failure in meeting the primary endpoint for 
prolonging overall survival (Stupp et al., 2014). Becker et al.,(2015) 
demonstrated that the failure of cilengitide was because of its distribution from 
plasma to other body fluids, and was excreted by the kidney. The short half-life 
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of cilengitide also means tumours are not exposed to curative concentrations for 
much of the time and might unfortunately enhance tumour growth.  
Normalization of blood vessels is a strategy to promote the antitumor impacts of 
chemotherapies, but this depends on dose and exposure time and is therefore 
difficult to achieve clinically. Wong et al.(2015) demonstrated that combining a 
low dose of cilengitide with a chemotherapy drug (gemcitabine) decreased 
tumour growth, and metastasis, and increased overall survival. This has been 
interpreted as the αvβ3/αvβ5 integrin inhibitor enhancing chemotherapy 
efficiency through vascular promotion by increased tumour blood flow and 
vascular leakiness, and tumour blood vessel density, resulting in increased 
chemotherapy delivery whilst also reducing tumour hypoxia.  
Furthermore, Zhao et al. found also that combining cilengitide nanotherapy with 
ultrasound-targeted microbubble destruction could potentially be used in 
glioblastoma to overcome clinical issues such as fast blood clearance (including 
high kidney and liver uptake) and poor blood-brain barrier penetration. 
Cilengitide nanotherapy showed significant apoptotic and cytotoxic impacts in 
C6 glioblastoma cells. A bio-distribution study in a rat glioblastoma model 
showed build-up of high cilengitide level in tumours exposed to combined 
therapy. The tumour cilengitide level in rats was elevated over three-fold, renal 
clearance significantly reduced and tumour retention of cilengitide prolonged 
when compared with free cilengitide with or without ultrasound-targeted 
microbubble destruction (Zhao et al., 2016). 
 
A recent study demonstrated that colony formation of epithelial cells on laminin 
was significantly decreased by single agent cilengitide and cetuximab an EGF-R 
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inhibitor, or cilengitide with cetuximab combined. Cytokine measurements also 
showed significant decreases in monocyte chemo-attractant protein 1, 
interleukin-6 and vascular endothelial growth factor. The largest decreases in 
colony formation of epithelial cells and release of monocyte chemoattractant 
protein 1 and vascular endothelial growth factor was observed by combining 
cilengitide and cetuximab. Efficacy of the combined drugs surpassed that of the 
individually applied agents, but the combination was not synergistic. Cetuximab 
could not significantly enhance the effects of cilengitide. In contrast, interleukin-
6 (IL-6) release was significantly blocked by cetuximab but not by cilengitide, 
whereas their combination strongly decreased IL-6 release (Wichmann et al., 
2017). 
A range of αvβ3 inhibitory antibodies have been under investigation, such as 
LM609, CNTO95, MEDI-522, DI17E6, and c7E3 (Liu et al., 2008). DI17E6 is a 
humanised monoclonal antibody specific for the αv subunit (Wirth et al., 2014). 
DI17E6 was selected for clinical trial because in preclinical studies it induced 
detachment and blocked adhesion of prostate cancer cells to different 
extracellular matrix proteins and cells found in the bone microenvironment 
without effect on cell cycle or activity of caspase 3, and 7 or cell viability.  In 
addition, DI7E6 inhibited invasion and migration of prostate cancer cells as well 
as reduced phosphorylation of downstream targets FAK, ERK and Akt. These 
results demonstrated that blocking of αv with DI17E6 prevents several pro-
metastatic phenotypes of prostate cancer cells. In a phase 1 study in patients 
with progressive metastatic prostate cancer after chemotherapy it decreased 
PSA values in 2 patients (Jiang et al., 2017).  
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MEDI-522 (Etaracizumab) is a humanised monoclonal antibody specific for 
αvβ3 integrin. A phase I dose escalation trial in 25 patients with diverse 
metastatic solid tumours (prostate, colorectal, breast, melanoma, ocular 
melanoma, non-small cell lung cancer, sarcoma, and renal cancers) showed 
some evidence that treatment with MEDI-522 decreased the size of tumours as 
estimated by imaging with dynamic computer tomography. Treatment with 
MEDI-522 (Etaracizumab) was without severe toxicity, and no maximum 
tolerated dose or dose limiting toxicities were observed. Three patients with 
metastatic renal cell cancer had prolonged stable disease (McNeel et al., 2005). 
However, further investigations in patients with metastatic melanoma (phase 2) 
using Etaracizumab alone or in combination with dacarbazine show that both 
treatments failed to improve overall survival (Hersey et al., 2010). 
There are many small molecule integrin antagonists such as GLPG0187 that 
was developed as a pan-antagonist for RGD-integrin receptors, targeting αvβ1, 
αvβ3, αvβ5, αvβ6, and α5β1 with nanomolar affinity. GLPG0187 inhibited of 
osteoclast-mediated bone resorption, angiogenesis, and the formation of new 
bone metastasis and the progression of bone metastasis during cancer 
treatment (van der Horst et al., 2011). GLPG0187 decreased cell number and 
reduced proliferation and migration in PC-3 prostate cancer cells implanted 
within the metatarsal in vivo but did not affect cell survival in vitro (Reeves et al., 
2015). The effect of GLPG0187 was also investigated in breast carcinoma 
progression. It showed a reduction of tumour invasion in a zebrafish embryo 
model, inhibition of the progression of bone metastases in a mouse model, and 
maximum activity when in combination with paclitaxel (Li et al., 2015). 
GLPG0187 was withdrawn from development following a phase I clinical trial, 
having shown no response even with continuous dosing (Cirkel et al., 2016). 
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MK-0429 is a specific oral αvβ3 inhibitor. MK-0429 was shown to be selective 
for αvβ3 vs α5β1 or αIIbβ3 by measuring adhesion of transfected HEK293 cells 
and has been shown to reduce the development of B16F10 melanoma lung 
metastases following tail vein injection. This suggests αvβ3 is more important 
than α5β1 or αIIbβ3 in the growth and colonisation of B16F10 melanoma cells 
in the lungs, although the expression levels of αvβ3 appear to be lower than 
those of αvβ5 in these cells (Pickarski et al., 2015). MK-0429 has been used in 
clinical trials for prostate cancer and significantly reduces the bone resorption 
marker urinary N-telopeptide but did not reduce PSA levels (Rosenthal et al., 
2010). 
 
1.4.2 αIIbβ3 antagonists 
 
The platelet αIIbβ3 integrin was the first integrin to be effectively targeted 
therapeutically. In the 1990s, three inhibitors of αIIbβ3 integrins were approved 
for use in heart disease: Abciximab (antibody), Eptifibatide (cyclic peptide) and 
Tirofiban (small molecule inhibitor), all of which are intravenously administered; 
decreasing the risk of ischaemic events in those undergoing percutaneous 
coronary intervention and patients with acute coronary syndromes (Cox et al., 
2010). These three αIIbβ3 antagonists are quite discrete in design from one 
another, and all three are mechanistically distinct from other platelet inhibitors 
such as P2Y12 inhibitors or aspirin (Bledzka et al., 2013). 
Both Abciximab and c have been investigated in programmed cell death in 
breast cancer cells such as MCF-7.  Eptifibatide produced a stronger pro-
apoptotic effect in MCF-7 cells than abciximab and could therefore be 
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considered as a novel candidate for anticancer therapy (Kononczuk et al., 
2015).  
Abciximab and related murine antibodies have dual β3 antagonist activity and 
are effective in blocking angiogenesis and tumour growth through targeting of 
the interaction of tumour cells with endothelial cells and platelets. This is in 
addition to the immediate impact of abciximab on tumour size and growth. 
However, the associated bleeding and immunogenicity of abciximab suggests 
that there is a need for additional development of a non-immunogenic small 
molecule as a more attractive clinical candidate for long term anticancer therapy 
(Trikha et al., 2002a). 
 
 
1.4.3 α5β1 integrin antagonists 
   
α5β1 is currently being targeted both for cancer therapy and retinal 
neovascularisation in age-related macular degeneration (AMD). An example 
α5β1 antagonist is Volociximab, a chimeric human-mouse monoclonal antibody 
with high affinity for the α5β1 integrin (Ramakrishnan et al., 2006). Volociximab 
has been well tolerated in Phase I trials without severe side effects (Ricart et al., 
2008). In preclinical studies using a rabbit VX2 carcinoma model, Volociximab 
was effective in inhibiting tumours growing intramuscularly or subcutaneously 
and this effect was shown to be related to reduced blood vessel density within 
these tumours (Bhaskar et al., 2008). However, despite being safe, Volociximab 
was not effective in ovarian cancer (Bell-McGuinn et al., 2011), but did show 
some evidence of clinical activity in non-small cell lung cancer in combination 
with paclitaxel and carboplatin (Besse et al., 2013). 
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1.5 Aims and objectives 
Targeted drugs for cancer therapy which will control the process of tumour 
progression and metastasis are required. The RGD-binding integrin subfamily 
including αvβ3, αvβ5, αllbβ3 and α5β1 plays an important role in these 
processes and as has been described previously there is a need to develop 
new small molecule antagonists. The hypothesis underlying this work is that 
dual β3 integrin antagonists will have an enhanced effect on cancer progression 
and metastasis through targeting tumour cell interaction with αvβ3 on 
endothelial cells and αllbβ3 on platelets resulting in inhibition of both 
angiogenesis and metastasis. The overarching aim in this work is that of 
characterising a dual β3-expressing model cell system which will be used to 
identify dual hit β3 integrin antagonists.  
These aims will be addressed by the following means:  
 Evaluation of the expression of αIIb, αv, α5, β3 and β5 integrin subunits in a 
panel of human tumour cell lines to use in cell-based assays to investigate the 
effects of β3 integrin antagonists. 
 Evaluation of the effect of phorbol 12-myristate 13-acetate (a protein kinase 
C stimulator) on the expression of the αIIb integrin subunit in K562 cells. 
  Development and validation of cell-based adhesion, detachment and 
migration assays to investigate the effect of β3 inhibition on cellular function in 
dual β3 expressing models. 
 Evaluation of the effect of ICT compounds in the developed models to 
characterise and identify new integrin antagonists. 
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2 Chapter 2: Characterisation of αIIb, αv, α5, 
β3 and β5 integrin subunit expression in a 
panel of human cancer cell lines 
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2.1 Introduction 
 
Integrin adhesion receptors, particularly the RGD-binding integrin subfamily are 
related to the spread of cancer and poor prognosis. Dual β3 antagonists are 
expected to have a direct anti-proliferative effect on dual β3 expressing models 
and inhibit angiogenesis and metastasis through targeting cancer cell 
interactions with platelet αIIbβ3 and endothelial cell αvβ3 integrin. The 
expression of αvβ3, αIIbβ3 and α5β1 is widely demonstrated in literature in 
many human tumour cell lines and tissues (see Chapter 1). The expression of 
integrins in many studies to date is not the same in vivo as in vitro (Goodman 
and Picard, 2012; Stachurska et al., 2012; Taylor et al., 2012; Terry et al., 
2014). 
Most cancer cells can express αvβ3 in different states of activation, and cells 
from metastatic lesions express the integrin in the high affinity/constitutively 
activated form (Felding-Habermann, 2001), targeting of the activated conformer 
of αvβ3 inhibited metastasis from the blood stream (Weber et al., 2016). 
Therefore, αvβ3 is considered to be important as a cancer drug target for its 
high expression in endothelial cells and many tumours in addition to its vital role 
in enhancing metastasis (Kumar, 2003a; Liu et al., 2008). Furthermore, αvβ3 
may also become a valuable tumour marker to identify specific cells, which 
distinguish between healthy and tumour patients. 
αIIbβ3 integrin is expressed mainly on platelets and its presence has also been 
detected on some tumour cells (Kononczuk et al., 2015; Millard et al., 2011; 
Trikha et al., 1998). For example, the expression of αIIbβ3 integrin in prostate 
cancer cells is involved in the process of tumour cell invasion (Gay and Felding-
Habermann, 2011).  
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This section has been designed to characterise the expression of integrins in a 
panel of cancer cell lines (leukaemia cells; K562, prostate cells; LNCap, DU145, 
and PC-3, breast cells; MCF-7, melanoma; M14, MeWo, and UACC-62 and 
colon cells; HT-29), to determine the models to be utilised in screening novel 
integrin antagonists. 
 
2.2 Aim and objectives 
 
The aim of the work described in this chapter was to investigate a panel of 
cancer cell lines that may be used for screening novel integrin antagonists. This 
was achieved by the following means: 
  Measuring growth rates of designated cell lines to optimise their seeding 
density for subsequent experiments. 
 
  Characterising the expression of αv, αIIb, α5, β3 and β5 integrin subunits in a 
panel of cell lines using immunofluorescence and flow cytometry. 
 
 Confirming the expression of αIIb and β3 in 3D cell culture for a selected 
model. 
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2.3 Materials and methods 
2.3.1 Materials 
 
All reagents such as media and their supplements, if not specified otherwise, 
were obtained from Sigma-Aldrich (Poole, U.K.). Primary antibodies and 
secondary antibodies were utilized to identify the expression of αllb, αv, α5, β3, 
and β5 as shown in Table 2. The washing solution used was phosphate-
buffered saline (PBS); pH 7.4 at 37 ºC. The blocking reagent used in all 
antibody dilutions was bovine serum albumin (BSA). Normal goat serum was 
obtained from Vector Laboratories Ltd (Peterborough, U.K.). VECTASHIELD® 
Mounting Media with DAPI (4', 6-diamidino-2-phenylindole) and Vectastain 
Avidin Biotin Complex (ABC) were obtained from Vector Laboratories Ltd 
(Peterborough, U.K.). 3, 3-diaminobenzidine tetra- hydrochloride (DAB) 
chromogen was from Sigma-Aldrich, Poole, U.K. Anti-αvβ5 adhirons C3 and A8 
were generated and provided by Dr. Darren Tomlinson, University of Leeds.  
 
2.3.2 Cancer cell lines and cell culture 
  
The panel of cancer cell lines that were cultured were: K562 derived from 
chronic myelogenous leukaemia (CML); LNCap, a human prostate carcinoma 
derived from lymph node; DU-145, human prostate adenocarcinoma derived 
from dural metastasis; PC-3, human prostate adenocarcinoma derived from 
grade IV cancer metastasized to bone; MCF-7, breast adenocarcinoma derived 
from a metastatic site pleural effusion; HT-29, human colorectal 
adenocarcinoma derived from colon cancer; M14, MeWo, UACC-62, human 
melanoma  derived from human skin tissue. All cell lines were obtained from the 
American Type Culture Collection (ATCC). 
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Primary antibodies Type Company Secondary antibody Company 
Anti-β3 (B-7) Monoclonal mouse antibody 
Santa Cruz 
Biotechnology(Santa Cruz, 
USA) 
Goat Anti-Mouse IgG H&L 
(Alexa Fluor® 488) 
Abcam 
(Cambridge, 
U.K.) 
Anti-α5 (C-9) Monoclonal mouse antibody Santa Cruz Biotechnology 
Goat Anti-Mouse IgG H&L 
(Alexa Fluor® 488) 
 
Abcam 
(Cambridge, 
U.K.) 
Anti-αv (Q-20) Polyclonal rabbit antibody 
Santa Cruz Biotechnology  
(Santa Cruz, USA) 
 
Donkey Anti-Rabbit IgG 
H&L 
 (Alexa Fluor® 488) 
 
Abcam 
(Cambridge, 
U.K.) 
Anti-αllb (EPR4330) Monoclonal rabbit antibody Abcam (Cambridge, U.K.) 
Donkey Anti-Rabbit IgG 
(H&L) Antibody, Alexa 
Fluor® 546 
Molecular 
Probes 
(Invitrogen, 
USA) 
Anti-αllb (C-20) Polyclonal goat antibody 
Santa Cruz Biotechnology 
(Santa Cruz, USA) 
Donkey Anti-Goat IgG 
H&L(Alexa Fluor® 790) 
Abcam 
(Cambridge, 
U.K.) 
Anti-β5 (ab15459) Polyclonal rabbit antibody Abcam (Cambridge, U.K.) 
Donkey Anti-Rabbit IgG 
H+L (Alexa Fluor® 488) 
Abcam 
(Cambridge, 
U.K.) 
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Table 2: Primary antibodies (PAbs) and secondary antibodies (2Abs) used in immunofluorescence studies and flow cytometry. 
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2.3.3 Methods 
2.3.3.1 Cell maintenance 
 
To prepare one 500-ml portion of basic media (RPMI Medium 1640 I X), the 
RPMI medium was supplemented with 10% foetal bovine serum (FBS) (50 ml) 
200 mM L-glutamine (5 ml) and 100 mM sodium pyruvate (5 ml). The RPMI 
medium was used for all cell lines except MCF-7, which was used with 
complete Dulbecco's Modified Eagle Medium (DMEM). 
The cells were grown and maintained at 37 ºC, 5% humidity in an incubator. 
Cells were allowed to reach 70 - 80% confluence. Following this, the 
suspension cells (non-adherent cells) were removed directly and placed into a 
sterile tube. The cells were centrifuged at 1000 rpm for 5 minutes. Adherent 
cells were passaged by discarding the medium and washing the flask contents 
with 5 - 10 ml of PBS, depending on the size of the flask, before trypsinisation 
using 1 - 2 ml of a 0.25% trypsin/EDTA solution, and incubating for 2–5 minutes 
at 37 ºC. When cells were released in the flask, 10 ml of the complete medium 
was added to inhibit the trypsin/EDTA action. Then the trypsinised cells were 
placed into the sterile tube and centrifuged at 1000 rpm for 5 minutes (Heraeus 
Megafuge 1.0 centrifuge, DJB Labcare Ltd., U.K.). The cell pellet was re-
suspended in the required volume of fresh media that was dependent upon the 
required split ratio. A portion of this was transferred into the new flasks.  
 
To count cells, a Neubauer haemocytometer (7201004, VWR International Ltd. 
Poole, U.K.) was used. 10 µl of cell suspension pipetted on the edge of the 
coverslip allowed cells to be drawn under the coverslip to cover the counting 
grid. The cells were counted using an inverted microscope (Olympus, CK2, X20 
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objective lens magnification). The number of cells on the counting grid was 
multiplied by 1 X 104 to give the number of cells per ml.  
 
2.3.3.2 Cell lines growth curve 
 
Growth curves were characterised to assess whether cells utilised in 
experiments were within the log phase (exponential growth phase). 
 
2.3.3.3 Growth curve for K562 cells growing in suspension culture 
When cell lines reached 70 – 80% of confluency, cell suspension were poured 
into 20 ml tubes and centrifuged for 5 minutes at 1000 rpm. The supernatant 
was removed, and 10 ml of fresh medium was added to re-suspend cells by 
vortex shaking. 10 µl of suspension cells was placed in the chamber of the 
haemocytometer to count the number of cells for different concentrations: 1 
X104, 2 X104, 5 X104 and 1 X105 cell/ml. Five flasks (T25) each containing 10 ml 
were prepared on days 1, 2, 3, 4, and 7. Every day, the flask was counted for 
each cell concentration, and the growth curves plotted. The growth curves of 
cells were measured in triplicate. 
  
2.3.3.4. Growth curve by MTT assay 
The number of proliferating cells was determined by MTT (3-(4, 5-
Dimethylthiazol-2-yl)-2, 5-DiphenyltetrazoliumBromide) conversion to formazan, 
which indicates metabolic activity and consequently, cell viability. Briefly, cells 
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were counted as described above. 200 μl/well of cells was seeded at different 
concentrations: 1X102, 5 X102, 1 X103, 5 X103 ,1 X10
4, 5 X104, 1 X105, 2 X105 
cells/ml into five 96 well plates and were permitted to adhere (in case of 
adherent cells) to the bottom of the plate by incubating at 37 ºC for 24 hours. 
Every day, cell proliferation was measured by adding 20 μl of filter sterilised 
MTT per well (5 mg/ml in distilled water filtered through a 0.2 µm filter and 
stored for a maximum of 4 – 6 weeks at 4 ºC) and incubated 4 hours with MTT. 
Following this, the media was gently removed with a validate pipette, and 150 μl 
of DMSO was added and mixed with the blue formazan crystals to dissolve 
them. Finally, the absorbance of formazan solution was read 
spectrophotometrically at 540 nm. The mean absorbance was calculated and 
plotted versus time (days). This experiment was repeated three times. 
 
2.3.3.5 Immunofluorescence/Immunocytochemistry 
2.3.3.5.1 General protocol for αv, αllb, α5, β3 and β5 antibody labelling  
 
Dilution of 1 to 10 ml of poly-L-lysine solution (0.1 %) in distilled water was 
prepared and 300 μL (enough to cover the surface of the coverslip) was added 
onto autoclaved coverslips. The coverslips were incubated for 25 minutes. The 
poly-L-lysine solution was aspirated from the coverslips and allowed to air dry 
for 25 minutes. Coated coverslips were used either immediately or stored in a 
dark and dry place for up to one week before use. 
Cell suspension were prepared and counted 5 X105 cells/ml were seeded on 
poly-L-lysine coated coverslips in 6-well plates and were incubated in 5% CO2 
at 37 ºC overnight.  
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The supernatant was removed from each well and the coverslips were rinsed 
with 1 ml of PBS. Cells were then fixed with 1 ml of fixative solutions 4% 
paraformaldehyde (PFA) for 5 – 15 minutes at room temperature, 100% 
methanol for 10 –15 minutes at -20 ºC, or 100% acetone for 5 seconds at room 
temperature. The plates were then left to dry and were used immediately or 
stored at -20 ºC until used. The cells were rinsed with 1 ml PBS to rehydrate 
them and were blocked by adding 300 µl of blocking solutions 5% BSA/PBS or 
10% normal goat serum for one hour at room temperature. 
 
The blocking solution was aspirated and 100 µl of the selected diluted primary 
antibody was added and incubated at 4 ºC overnight or for one hour at room 
temperature (this depends on the type of antibody, Table 3). The primary 
antibody was omitted for negative controls. Cells were washed three times for 5 
to 10 minutes with PBS and then 100 µl of the diluted secondary antibody 
(concentration of secondary antibody depends on primary antibody, Table 3) 
was added and incubated for one hour in a dark place at room temperature. 
The cells were washed with PBS for 3 X 5 minutes. The PBS was then removed 
and the coverslips were mounted on each slide with a drop of mounting medium 
with DAPI stain and the slides were left for at least one hour at 4 ºC to be 
examined by immunofluorescence microscopy. 
 
2.3.3.5.2 Preparation of adherent cells 
 
A suspension of adherent cells was prepared and counted. 3 X 105 cells/ml 
were seeded immediately on coverslips in 6-well plates without a coating agent. 
The plates were incubated at 37 ºC overnight until cells were seen adhering to 
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coverslips. They were then labelled with antibodies or anti-αvβ5 adhiron as 
described in Table 3. 
 
 
 
 
 
 
 
 57 
 
 
 
Table 3: Optimised concentrations of antibodies used for immunofluorescence.
 Anti-αv (Q-20) Anti-β3 (B7) Anti-β5 (C-9) Anti-α5 
Anti-αllb 
(EPR4330) 
Anti-αllb      
(C-20) 
Anti-αvβ5 
(adhiron 
A8) 
Anti-αv β5 
(adhiron 
C3) 
Cell seeding 
concentration 
5x105 Cell/ml for all experiments 
 
Fixation 4% PFA 4% PFA 100%Acetone 4% PFA 4% PFA 4% PFA 4% PFA 4% PFA 
Blocking 5% BSA/PBS 5% BSA/PBS 5% BSA/PBS 
5% BSA/PBS 
& 10% 
normal goat 
serum 
5% BSA/PBS 5% BSA/PBS 
1.5% normal 
goat serum 
/PBS 
1.5% 
normal goat 
serum /PBS 
Dilution of primary Abs 1:50 1:50 1:200 1:100 1:50 1:50 
1:50 &1:200 
(anti-HIS) 
1:100 
&1:200 
(anti-HIS) 
Incubation of primary 
Abs 
Overnight at 
4 °C 
Overnight at 
4 °C 
1 hour at room 
temperature 
Overnight at 
4 °C 
Overnight at 
4 °C 
Overnight at   
4 °C 
1 hour at room 
temperature 
for each Ab 
without 
washing 
1 hour at 
room 
temperatur
e for each 
Ab without 
washing 
Dilution of secondary 
Abs 
1:200 1:50 1:200 1:200 1:200 1:200 1:200 1:200 
Incubation of 
secondary Abs 
One hour in a dark place at room temperature 
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2.3.3.6  Flow cytometry 
 
2.3.3.6.1  General protocol for indirect flow cytometry procedure 
 
Indirect labelling requires two incubation steps: first with primary antibody then 
with a suitable secondary antibody. The secondary antibodies had fluorescent 
dyes (FITC, TRITC) and were used to detect integrin expression by the FACS 
machine (FACSCaliburTM, Becton Dickinson).  
 
2.3.3.6.2 General procedure for integrin subunit labelling by FACS 
analysis 
  
Cells were harvested and washed with PBS and the cell number determined. 
1ml of cell suspension (approximately 5X105 cells/ml) was added to each FACS 
tube and spun down for 5 min at 1000 rpm, following which the supernatant was 
removed and 100 μl of 4% PFA was added. The solution was kept for 5 –10 
minutes at room temperature. Fixed cells were obtained after the supernatant 
was removed. Dilution of primary antibodies was made in 1% BSA/PBS. 100μl 
of diluted primary antibodies were added to each tube according to their optimal 
concentrations in Table 3 and incubated for 30 – 60 minutes at 4°C in the dark. 
The cells were centrifuged with cold PBS three times at 1000 rpm for 5 minutes.  
 
A fluorochrome-labelled secondary antibody was diluted (1:500) in 1% 
BSA/PBS. 100 μl of diluted secondary antibodies was added to each tube and 
incubated for at least 20 – 30 minutes at 4°C in the dark. The cells were 
centrifuged again with cold PBS three times at 1000 rpm for 5 minutes, and 
then 1 ml of 1% BSA/PBS was added to the cell suspension and the 
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suspension cells were immediately stored at 4°C in the dark until their analysis. 
For analysis on FACSCaliburTM, cells were distinguished from debris by forward 
scatter and side scatter parameters. Positive and negative antibody staining 
was measured by log fluorescence in the FL1 channel as secondary antibodies 
were used conjugated to FITC.  
 
2.3.3.6.3 Data analysis 
 
Data analyses were performed using Cell Quest software and calculated their 
mean by Excel software. 
 
2.3.3.7 MCF-7 spheroid preparation  
 
100 μl/well of MCF-7 cells was seeded at 5X104 cell/ml into non-treated 96 well 
plates. The 96 well plates were centrifuged for 20 minutes/1000 rpm to 
aggregate the cells then incubated at 37°C. Media was refreshed every 2 - 3 
days. The diameter of spheroids was measured using calibrated graticule fixed 
to the light microscope at X10 objective lens. 
 
2.3.3.6.4 Preparation of methylcellulose 
 
Methylcellulose (6 g) in 500 ml glass bottle was autoclaved then mixed with 250 
ml medium preheated to 60°C for 30 min. After that, 250 ml medium was added 
and stirred for 30 - 45 minutes at RT. The solution was left in the fridge for 1 - 2 
h at 4°C to ensure complete solubilization then centrifuged for 2 hours then 
divided in 50 ml tubes and kept at 4°C.    
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2.3.3.6.5  Fixation and paraffin embedding of spheroids  
 
Spheroids were collected using a micropipette into 20 ml universal tube and 
they were left to settle as sediment. Media was removed, and PBS added for 
washing. The cell pellets were then fixed with 2 ml Bouin's solution (composed 
of 70% acetic acid, 5% picric acid and 25% formaldehyde in an aqueous 
solution) for 75-100 minutes at room temperature. 
Bouin's solution was drained off, and spheroids were washed with 70% ethanol 
3 times until the solution became colourless as much as possible (removing 
yellow colour of Bouin's solution) and then left in 70% ethanol at room 
temperature until the embedding processing.  
Spheroids were then immersed in 90% ethanol/water for 1hr., followed by two 
changes of absolute (100%) ethanol after 30 minutes for each change and 
replaced with 100% xylene twice for 30 minutes. Afterwards, spheroids were 
transferred for embedding moulds with a small amount of xylene, then covered 
with liguid paraffin and left in an oven at 68 °C for 30 min. The paraffin/xylene 
mixture was removed, and the melted paraffin was added and left again in the 
oven for 5 minutes. This step was repeated two times. In the final stage 
spheroids were centered in the middle of the mould covered with fresh paraffin. 
Transfer moulds were stood on a cold plate for 2 - 3 hours then stored in the 
freezer at -20 °C. 
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2.3.3.6.6 Immunohistochemistry 
 
2.3.3.6.6.1 APES coating slides 
 
Slides coated with 4% 3-aminopropyltriethoxysilane (APES) in acetone before 
using for paraffin-embedded (PE) spheroids sections. The slides were 
sequentially immersed in 100% acetone and 4% APES, then washed in running 
tap water twice for 2 minutes each.  
 
2.3.3.6.6.2 Paraffin-embedded spheroids 
 
Sections (5 µm thick) of paraffin embedded spheroid blocks were cut using a 
microtome and mounted on super frost plus slides (BDH, Poole, UK). The slides 
were dried on a hot plate at 40°C for 2 - 3 hrs. Then the sections were 
subjected to H&E staining and immuno-detection. 
 
2.3.3.6.6.3 H&E staining for Formalin Fixed Paraffin Embedding (FFPE) 
sections 
 
Sections on APES slides were dewaxed by incubating for 5 min in 100% xylene 
(two times) and 50% xylene-ethanol and then rehydrated by incubating 
consecutively for 5 min in absolute ethanol (twice), 90% ethanol and finally 70% 
ethanol. Slides were stained first with Harris haematoxylin for 10 minutes 
followed by washing in running tap water, and then incubated in acid alcohol 
(0.5% HCl in 70% ethanol) for 5 seconds. Then excess haematoxylin was 
removed from the cells leaving the nuclei, but not cytoplasm strongly stained 
red. Again, the slides were briefly washed in tap water. Excess stain was 
removed from the section by washing with tap water for 5 minutes and 
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immersing in Scott’s Tap Water (sodium bicarbonate 2 g. magnesium sulphate 
20 g. dissolved in deionised water 1 litre) for 2 min to allow the colour to 
develop.  
Sections were counterstained in 1% aqueous eosin for 1 - 2 minutes followed 
by washing briefly in tap water, then drained for 1 minute to let excess water 
runoff. Finally, sections were dehydrated by incubating for 3 minutes each in the 
following sequence of solution: 100% ethanol (twice), 50% xylene/ethanol (one 
time), and 100% xylene for 2 minutes. Slides were then immersed in clean 
xylene for 5 minutes. Finally, slides were mounted using DPX medium 
(distyrene-plasticiser-xylene) (VWR International Ltd. Poole, UK), a coverslip 
was applied, and the sections were left to dry. 
 
2.3.3.6.6.4 Immuno-detection of αIIb and β3 integrin subunits expression 
in MCF-7 spheroids 
 
Sections were deparaffinised and dehydrated by sequential immersion in 
xylene, 50% (xylene/ethanol), 100% ethanol two times, 90% ethanol, 70% 
ethanol and distilled water for 5 minutes for each step. 
 
2.3.3.6.6.4.1 Antigen retrieval 
 
Slides were placed in a plastic microwavable container filled with citrate buffer 
(sodium salt of citric acid; 10 mM and pH 6.0). For heating induced epitope 
retrieval, the microwavable container was wrapped with pierced cling film and 
heated at 600W (medium-high power (NN-E201W, Panasonic) for 20 min with 
topping up of citrate buffer when necessary. Slides were then left to cool down 
for 30 min and washed twice in TBS solution (pH 7.55) for 5 minutes. 
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2.3.3.6.6.4.2 Endogenous peroxidase and nonspecific staining block  
 
The quenching of endogenous peroxidase activates was performed by 
incubation of slides for 15 minutes in freshly prepared 3% hydrogen peroxide 
(H2O2) in distilled water. Following this, nonspecific blocking was done with 
1.5% normal serum (horse or goat) for 30 minutes at room temperature, then 
excess serum was removed by pipette and covered with αllb or β3 primary 
antibodies at dilution given in Table 3 and incubated overnight at 4ºC in a 
humidity chamber. Negative controls were incubated with 1.5% normal serum 
(horse or goat) without primary antibody for the same period of time. The 
following day, slides were washed 3 times with TBS buffer for 3 minutes. The 
slides were then covered with 1:200 biotinylated secondary antibody (anti-rabbit 
or anti-mouse IgG (H+L) incubation for 30 minutes at RT. Meanwhile, ABC 
reagent (Avidin-Biotin Complex) working solution of peroxidase–labelled 
streptavidin was prepared by mixing 10µl solution A with10µl solution B in 1 ml 
of TBS buffer. Excess secondary antibody was removed by washing three times 
with Tris buffered Saline (TBS) solution for 3 minutes.  
 
The sections were then incubated with ABC reagent for 30 minutes, then 
washed twice with TBS solution for 5 minutes. The colour was developed by 
using DAB detection kit (Vector Laboratories). DAB solution was prepared by 
mixing1 drop of buffer stock solution, 2 drops of DAB and 1 drop of H2O2 in 2.5 
ml of distilled water. Sections were then counterstained with Harris' hematoxylin 
for 10 minutes followed by washing with tap water and stained in Scott's tap 
water for 2 minutes. Sections were dehydrated and cleared by immersing 
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sequentially in 70% ethanol, 90% ethanol, absolute 100% ethanol, 50% xylene-
ethanol, 100% xylene and 100% fresh xylene (5 minutes each). Slides were 
mounted with coverslips by using DPX slide mount medium. 
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2.4 Results 
2.4.1 Characterisation of growth curves of cancer cell lines 
 
Growth curves were measured to identify the lag phase, log phase and 
saturation phase, in order to analyse the cellular growth and determine the best 
time for using the cells in subsequent assays. Figure 9 shows growth curves of 
K562 and prostate cell lines. K562 cell lines began exponential growth from day 
1 which continued until day 7 for most concentrations except 1X105 cells/ml. 
Prostate cells lines also began exponential growth from day 1. LNCaP cells 
(2X105cells/ml) showed diminution in cells number from day 5 whereas PC-3 
numbers began to decline from day 4 at 5 X104cells/ml and 1X105 cells /ml. 
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Figure 9 : Cellular growth curves. (A) K562 were assessed using a haemocytometer method and growth curves of prostate cell lines, (B) PC-3, (C) DU-145 and (D) 
LNCap, were assessed by the MTT assay (see sections 2.3.3.3 and 2.3.3.3 for details). Data are shown as mean ± SE of 3 independent experiments.
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2.4.2 Investigation of the expression of integrin subunits using 
immunofluorescence  
 
2.4.2.1 Screening of αv, α5, αIIb, β3 and β5 in K562, LNCap, DU-145, PC-3 
and MCF-7 
 
The human erythromyeloblastoid leukaemia cell line K562, and prostate cancer 
cell lines DU-145, LNCap and PC-3, were investigated for the expression of αv, 
α5,  αIIb, β3 and β5 integrin subunits using protocols previously optimised in our 
research group (Table 3) (Ahmedah, 2015). The expression of these integrin 
subunits is shown in Figures 10 -14. In K562 cells, high cytoplasmic expression 
of αv and α5, moderate cytoplasmic expression of β3 and moderate cytoplasmic 
expression of β5 were detected, but no expression of αllb was detected. In 
LNCap cells, high cytoplasmic expression of αv and α5 was detected, moderate 
cytoplasmic expression of β5 was detected, low expression of β3 was detected, 
but no expression of αllb was detected. In DU-145 cells, high membrane 
expression of αv and αllb and high cytoplasmic expression of β5 were detected, 
and moderate membrane expression of α5 and moderate cytoplasmic 
expression of β3 were detected. In PC-3 cells, high cellular membrane 
expression of αv and αllb was detected, moderate cytoplasmic expression of α5 
and β3 was detected, and moderate cellular membrane expression of β5 was 
detected. In MCF-7 cells, high cellular membrane expression of αv, αllb and β3 
was detected, moderate cellular membrane and cytoplasm expression of β5 
was detected, and no expression of α5 was detected.  
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Figure 10: Expression of αv, α5, αIIb, β3 and β5 integrin subunits in K562 cells. Integrins 
were detected using immunofluorescence with Q20 anti-αv, C9 anti-α5, EPR4330 anti-αIIb,  B7 
anti-β3, and ab15459 anti-β5 integrin antibodies. Bar Length = 50 μm. Blue-fluorescent DAPI is 
nuclear staining and colours (green and red) represent integrin expression detected by a 
fluorophor. White arrows point to positive labelling of αv, α5, αIIb, β3 and β5 integrin subunits in 
K562 cells. 
K562 
cells
            TRITC/FITC                 DAPI              Overlay 
αv
α5
αIIb
β3
β5
  
70 
 
 
Figure 11: Expression of αv, α5, αIIb, β3 and β5 integrin subunits in LNCap cells. Integrins 
were detected using immunofluorescence with Q20 anti-αv, C9 anti-α5, EPR4330 anti-αIIb, B7 
anti-β3, and ab15459 anti-β5 integrin antibodies. Bar Length = 50 μm. Blue-fluorescent DAPI is 
nuclear staining and colours (green and red) represent integrin expression detected by a 
fluorophore. White arrows point to the positive labelling of αv, α5, αIIb, β3 and β5 integrin 
subunits in LNCap cells. 
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Figure 12: Expression of αv, α5, αIIb, β3 and β5 integrin subunits in DU-145 cells. Integrins 
were detected using immunofluorescence with Q20 anti-αv, C9 anti-α5, EPR4330 anti-αIIb, B7 
anti-β3, and ab15459 anti-β5 integrin antibodies. Bar Length = 50 μm. Blue-fluorescent DAPI is 
nuclear staining, and green colour represents integrin expression detected by a fluorophore. 
White arrows point to the positive labelling of αv, α5, αIIb, β3 and β5 integrin subunits in DU-145 
cells.  
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Figure 13 : Expression of αv, α5, αIIb, β3 and β5 integrin subunits in PC-3 cells. Integrins 
were detected using immunofluorescence with Q20 anti-αv, C9 anti-α5, EPR4330 anti-αIIb,  B7 
anti-β3, and ab15459 anti-β5 integrin antibodies. Bar Length = 50 μm. Blue-fluorescent DAPI is 
nuclear staining, and green colour represents integrin expression detected by a fluorophore. 
PC3 cells FITC DAPI overlay
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White arrows point to the positive labelling of αv, α5, αIIb, β3 and β5 integrin subunits in PC-3 
cells. 
 
 
Figure 14: Expression of αv, α5, αIIb, β3 and β5 integrin subunits in MCF-7 cells. Integrins 
were detected using immunofluorescence with Q20 anti-αv, C9 anti-α5, EPR4330 anti-αIIb, B7 
anti-β3, and ab15459 anti-β5 integrin antibodies. Bar Length = 50 μm. Blue-fluorescent DAPI is 
nuclear staining, and green colour represents integrins expression detected by a fluorophore. 
MCF-7 cells FITC DAPI overlay
αv
α5
αllb
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White arrows point to the positive labelling of αv, α5, αIIb, β3 and β5 integrin subunits in MCF-7 
cells.   
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2.4.2.2 Use of Adhirons to detect αvβ5 integrin in MCF-7 
 
Adhirons A8 and C3 are novel reagents, artificical binding proteins (ABPs) 
developed to bind to αvβ5 by Dr. Darren Tomlinson. Their performance was 
compared to the commercially available antibodies used to detect αvβ5 
expression on MCF-7 cells using the protocol detailed in Table 3. High 
membrane and cytoplasm expression of αvβ5 were observed with Adhiron A8 
and Adhiron C3, whereas high membrane expression of αv and moderate 
membrane and cytoplasm expression of β5 were observed uisng antibodies. 
These data showed similar performance between adhirons and antibodies 
(Figure 15) suggesting the adhirons have similar sensitivity and specificity.   
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Figure 15 : Expression of αvβ5 integrin in MCF-7 cells. 
αvβ5 was detected using immunofluorescence with adhiron A8 and C3 (anti αvβ5). Bar Length = 
50 μm. Blue-fluorescent DAPI is nuclear staining, and green colour represents integrin expression 
detected by a fluorophore. White arrows point to the positive labelling of αvβ5 integrin in MCF-7 
cells. 
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2.4.2.3 Expression of αIIb and β3 in HT-29, M14, MeWo and UACC-62 
 
The melanoma cell lines, MEWO, M14 and UACC-62 were selected as known 
models of melanoma expressing β3 (Hieken et al., 1996), and HT-29 as a non-
β3 expressing line. They were investigated for the expression of αIIb and β3 
integrin subunits according to the optimised protocols (Table 3). 
 
The αllb integrin subunit screening results showed that the majority of these cell 
lines did not express the αllb integrin subunit on cell membranes or 
cytoplasmically. The exception was UACC-62 cells, where moderate membrane 
expression of αllb was detected. Whereas high expression of β3 integrin subunit 
was detected in the membrane of UACC-62 cells and the cytoplasm of M14 
cells but no expression was detected in HT-29 and  MEWO cells as shown in 
Figures 16 and 17. 
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Figure 16: Expression of the αIIb integrin subunit in HT-29, MEWO, M14 and UACC-62 
cells.  αIIb was detected using immunofluorescence with EPR4330 anti-αIIb integrin antibody. 
Bar Length = 50μm. Blue-fluorescent DAPI is nuclear staining, and green colour represents 
integrin expression detected by a fluorophore. White arrows point to the positive labelling of αIIb 
integrin subunits in the selected cell lines. 
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Figure 17: Expression of the β3 integrin subunit in HT-29, MEWO, M14 and UACC-62 cells. 
β3 was detected using immunofluorescence with B7 anti-β3 integrin antibody. Bar Length = 
50μm. Blue-fluorescent DAPI is nuclear staining, and green colour represents integrin expression 
detected by a fluorophore. White arrows point to the positive labelling of integrin subunits in the 
selected cell cells. 
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2.4.3 Quantification of the expression of αv, α5, αIIb, β3 and β5 integrin  
subunits 
2.4.3.1 Quantification of αv, α5, αIIb, β3 and β5 in K562, DU145, PC-3, 
LNCap and MCF-7 cells using FACS 
 
The cell lines were harvested and incubated with anti αv, αIIb, α5, β3 and β5 
antibodies and their expression determined by FACS analysis of mean 
fluorescence intensity (Figure 18).  For histograms, see Appendix III. Very high 
levels of αv expression were observed in all cells lines, whereas moderate αllb 
expression was observed on MCF-7 cells; low levels on PC-3 cells, weak 
staining on K562 cells and DU145 cells and no expression on LNCap cells. High 
levels of α5 expression were seen in K562 cells, moderate on LNCap cells and 
low levels on DU145 cells and PC-3 cells, and no expression on MCF-7 cells. 
High levels of β3 were observed in K562 and MCF-7 cells, moderate levels on 
DU145 and low levels were observed in LNCap and PC3 cells. The expression 
of β5 was cells moderate in all cell lines except PC3, which expressed a low 
level. 
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Figure 18: Expression of αv, α5, αIIb, β3 and β5 integrin subunits in K562, DU145, PC-3, LNcap and MCF-7 cells. The mean fluorescence intensity 
of αv, α5, αIIb, β3 and β5 subunits. Values are the average of 3 independent experiments and error bars are SE.  
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2.4.3.2 Quantification of αIIb and β3 integrin subunits in M14, MeWo, 
UACC-62 and HT-29 cells using FACS 
 
The cell lines were harvested and incubated with anti αIIb and β3 antibodies 
and their expression determined by FACS analysis of mean fluorescence 
intensity (Figure 19). For histograms, see Appendix IV. No expression of αIIb 
and β3 was detected in any of these cell lines except M14 had low expression 
of β3. 
The comparison of αIIb and β3 integrin expression in all cell lines tested using 
the two detection techniques is shown in Table 4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19: Expression of αIIb and β3 integrin subunits in M14, MeWo, UACC-62 and HT-29 
cells using FACS analysis. The mean fluorescence intensity of αIIb and β3 integrin subunits. 
Values are the average of 3 independent experiments and error bars are SE.  
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Table 4: Comparison of integrin expression in different tumour cell lines 
with specific antibodies for αllb and β3 integrin subunits using IF and 
FACS. Keys for IF and FACS -: no expression. ±: Weak expression, +: Low 
expression, ++: Moderate expression, +++: High expression. 
Types of 
cells 
Human 
cancer 
cell lines 
αllb β3 
IF FACS IF FACS 
Leukaemia K562 - ± +++ +++ 
Prostate 
cancer 
DU145 +++ + ++ ++ 
PC3 +++ + ++ + 
LNCap - - + + 
Colon 
cancer 
HT-29 - - - - 
Melanoma 
MEWO - - + - 
M14 - - ++ + 
UACC-62 + - ++ - 
Breast 
cancer 
MCF-7 +++ ++ +++ +++ 
 
 
 
2.4.4 Expression of αllb and β3 integrin subunits in spheroids  
2.4.4.1 Spheroid generation. 
 
Since integrin expression was seen for MCF-7 and K562 cells by IF and FACS, 
both was selected as 3D models for use in vitro under conditions more similar to 
those in vivo. 104 cells/100 μl of MCF-7 and K562 cells was used to optimise 
spheroid formation to obtain regular and large (>500 µm) diameter of spheroids 
(Figure 20 B). Spheroid growth was monitored every day and the optimal 
parameters were determined to control their morphology.  MCF-7 cells formed a 
compact spherical shape which grew over time, but K562 cells were not a 
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successful model for spheroids due to increasing in their size without coherent 
compacting together (Figure 20 A). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20: Formation of spheroids in 96 well plates. (A) Transmission microscope images of 
MCF-7 and K562 spheroids. Scale bar = 100 µm at 20X objective lens. (B) Effect of time of 
incubation on spheroid diameter. Values are the average of 3 independent experiments and error 
bars are SE. 
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2.4.4.2 Spheroid histology  
 
Haematoxylin and Eosin (H&E) staining was carried out on MCF-7 spheroid 
sections at day 3. Microscopic examination revealed the spheroid to be clearly 
differentiated with the presence of mitotic nuclear and cytoplasmic regions and 
absence of necrotic or hypoxic regions (Figure 21). 
  
   
Figure 21: Histology of MCF-7 cell spheroids. Spheroids were processed and stained with 
H&E staining at day 3. Scale bar = 25 µm and 100 µm at 10X and 40X objective lens 
respectively. 
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2.4.4.3 Immuno-detection of αllb and β3 integrin subunits in spheroids.
  
 
Expression of αllb and β3 integrin subunits in MCF-7 spheroids was assessed 
using IHC staining as previously described in Materials and Methods, section 
2.3.3.7.3.4. 
Moderate expression of αllb and high expression of β3 were observed in MCF-7 
spheroids (Figure 22), the level of β3 was consistent with that observed for 
monolayer (2D) cultures (Figure 14 and 18). But the level of αllb expression was 
changed from high to moderate level in 3 dimensional. 
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Figure 22: Expression of αllb and β3 integrin subunits in MCF-7 spheroids. Subunits were 
detected using IHC with EPR4330 anti-αIIb and B7 anti-β3. Brown colour indicates positive 
staining (αllb and β3 expression). Scale bar = 25 µm and 100 µm at 10X and 40X objective lens 
respectively. 
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2.5 Discussion  
  
Integrins as heterodimeric receptors are vital molecules which function in cell 
adhesion, growth and migration because of serving as cell-cell adhesion 
receptors which bind to other cells and respond to the ECM. As described 
previously in chapter 1, the expression and function of integrins are involved in 
cancer progression, angiogenesis and metastasis. Consequently, there are 
many extensive research studies about integrin expression in in vitro and in vivo 
(Goodman and Picard, 2012; Stachurska et al., 2012). 
The aim of this chapter was to characterise the expression of integrins 
in a panel of human cancer cell lines, in order to determine which could 
be utilised as models for screening novel integrin antagonists. Growth 
curves of cancer several cell types were measured to determine the log 
phase (exponential growth), where cells are dividing rapidly.  
Immunofluorescence and flow cytometry showed the expression of αv, 
αIIb, α5, β3 and β5 integrin subunits in the panel of cancer cell lines, 
was either in the cytoplasm or on the cell membrane. The selectivity 
and specificity of the primary antibodies for integrin subunit detection 
had previously been determined in-house using Western blotting 
(Ahmedah, 2015). 
Zheng et al. have demonstrated the absence of the expression of αvβ3 and 
αllbβ3 integrin in normal prostate cells. For instance, human prostate 
adenocarcinoma tissue expressed the β3 subunit, whereas normal human 
prostate tissue did not (Zheng et al., 1999).   
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Previous studies have also revealed the expression of αv and β3 integrin 
subunits as well as αvβ3 integrin in the MCF-7 breast tumour cell line (Beauvais 
et al., 2004). 
The expression of αv and β3 integrin subunits on DU145 and PC-3 cells has 
been detected, although it was not confirmed on LNCap cells (Cooper et al., 
2002; Witkowski et al., 1993). Although the expression of these subunits has 
been detected in LNCap cells (Cooper et al., 2002), Zheng et al. found that αv 
and β3 integrin subunits were not expressed in LNCap (Zheng et al., 2000). 
Another study has also demonstrated low αvβ3 expression in PC-3 compared to 
LNCaP (Chatterjee et al., 2001). 
In the present study, the results of immunofluorescence show that the prostate 
cancer cells DU145, PC-3 and LNCap express a relatively high level of αv 
integrin subunit but only moderate expression of β3 was detected on DU145 
and PC-3 cells, and low expression was detected on LNCap cells. These results 
were generally consistent with previous studies which found moderate 
expression of αv in PC3 cells by flow cytometry (Goodman and Picard, 2012; 
Zheng et al., 2000).   
LNCap cells expressed a moderate level of α5 and β5; no expression of αllb 
was detected. In DU145 cells, high expression of αllb and β5 were detected and 
moderate expression of α5 was detected. In PC-3 cells, high expression of αllb 
was detected and moderate expression of α5 and β5 was detected. In previous 
studies, the intracellular expression of αllbβ3 has been detected in PC-3 cells 
whereas it is localised to the cell membrane in DU-145 as measured by 
immunofluorescence (Trikha et al., 1998). The expression of β5 in DU145 and 
PC3 cells  found by Trikha et al., 1998 is contrary to that of Bauer et al. who 
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found very low expression of β5 in DU145 and PC3 (Bauer et al., 2007). These 
conflicting data might be a result of the types of antibodies utilised in each of the 
research studies and cell lines being derived from various laboratories.  
In MCF-7 cells, high membrane expression of αv, αllb and β3 was detected, 
moderate expression of β5 was detected, and no expression of α5 was 
detected. These data match those observed in earlier studies (Meyer et al., 
1998; Taherian et al., 2011). 
A high level of αllb was detected in MCF-7 cells by the EPR4330 antibody, in 
contrast with other in-house results using the C20 antibody (Alshammari, 2013). 
The EPR4330 antibody is a rabbit monoclonal CD41 antibody, but the C20 is 
goat polyclonal IgG antibody, the homogeneity of monoclonal antibodies is very 
high relative to polyclonal.  
Adhirons are new artificial binding protein scaffolds depend on a designed 
consensus phytocystatin protein. Adhirons are well expressed and highly stable 
permitting highly specific binding reagents to be developed for molecular 
recognition applications (Tiede et al., 2014). Adhirons are proposed as an 
alternative to antibodies, and are one of a number of non-antibody binding 
reagents which have been developed, usually through adaptation of a naturally 
occurring protein or protein domain (Bedford et al., 2017).  
Adhirons A8 and C3 were compared in performance to anti-αvβ5 antibodies in 
MCF-7 cells. High expression of αvβ5 was shown with both A8 and C3 
adhirons; Q20 anti-αv antibody showed high expression, and ab15459 anti-β5 
antibody gave moderate expression. Similar staining patterns were obtained 
with both the anti-αv and β5 antibody and adhiron A8 and C3. This indicates 
that these adhirons are effective for detecting αvβ5, providing a good 
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fluorescent signal. The selectivity appears comparable at this stage, but further 
studies will be required in αvβ5-negative cells to confirm the adhirons do not 
recognise any unexpected targets. 
M14, MeWo, UACC-62 and HT-29 cells were further screened using 
immunofluorescence anti αllb EPR4330, anti β3 B7 antibodies. There was no 
detectable expression of αllb on these cells except the low level of expression, 
in UACC-62 cells whereas high expression of β3 was observed in M14 and 
UACC-62 but no expression in other cell types. These data agree with Li et 
al.(2001) who found that high level of β3 integrin subunits was expressed in 
melanoma human tumour cell lines (M14 and UACC-62), and confirms previous 
results in the group, as well as the observation in clinical tissues that 
overexpression of β3 is a hallmark of melanoma. 
Using immunofluorescence, the expression gives only the localisation of 
antibodies as there is a component of intensity. Therefore, the flow cytometry 
was used to evaluate the sensitivity of the antibodies as well as quantify the 
level of integrin expression. FACS analysis may be more sensitive than 
immunofluorescence for detecting very low levels of protein (Jenson et al., 
1998). 
Flow cytometry data generally confirmed the results of immunofluorescence in 
the panel of cancer cells, except for the expression of αllb and β3 in UACC-62 
cells, which was positive by IF but negative by FACS. The expression of αv, αllb 
and β3 subunits was fluorescence shifted more than control in MCF-7, in 
contrast with other in-house results for expressing of αllb and β3 subunits, 
where weak expression of β3 and no expression of αllb were observed 
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(Alshammari, 2013). This suggests that integrin expression is dependent on the 
batch of cells used as well as the identity of the cell line. 
Stachurska et al.(2012) suggested that there are many reasons for differing in 
integrin expression found in different studies researchers, including different 
specificity of the antibody, methods of integrin detection, heterogeneity of cell 
subpopulations and different cell culture conditions. In this current work, 
different specificity of the antibody and FACS were used whereas western blot 
was used in other in-house work. 
A high level of αv was expressed in all tested cell lines, which was to be 
expected; as mentioned in the literature review; αv can associate with not only 
β3 but also β1, β5, β6, and β8. This result is consistent with data obtained in 
earlier studies (Goodman et al., 2012; Trikha et al., 2002a).  
MCF-7 was identified as a suitable αv, αllb and β3 integrin-expressing cell line 
by flow cytometry and immunofluorescence. This result is in agreement with the 
finding of other studies which showed that MCF-7 cells express αvβ3 and αllbβ3 
integrins using both flow cytometry and immunofluorescence (Kononczuk et al., 
2015; Oleksowicz et al., 1995). 
The expression of αIIb and β3 integrin subunits was determined in MCF-7 3D 
model.  Spheroids are used as they are a surrogate for the tumour environment, 
allowing cells to interact in 3 dimensions (Li et al., 2008). According to previous 
studies, spheroids also show zones reminiscent of tumours and proliferation 
gradients. Thus, expression of proteins in multicellular tumour spheroids is more 
similar to expression profiles in vivo than those in 2D cell culture (Friedrich et 
al., 2009; Katt et al., 2016), which confers a high degree of biological and 
clinical relevance on them (Fennema et al., 2013). Hauptmann et al. also found 
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that the expression of integrins in tumour cells depends on the system of culture 
and its expression in spheroids is much closer to the situation in nude mouse 
tumours (Hauptmann et al., 1995). The contrast of protein expression levels 
between cell lines, comprising breast cancer, and their tissue origins showed 
that almost 30% of proteins are differently expressed in in vitro cell lines. 3D 
cultures differ in cellular responses due to both the 3D organisation of the cell 
surface receptors involved in interactions with surrounding cells, but it also 
encouraged physical constraints to cells (Edmondson et al., 2014). K562 cells 
were not suitable for use in model of spheroids because of the inability of cells 
to compact together. Usually, in 2D, K562 cells grow fast and tend to aggregate 
when reaching a high density without compacting. A high level of β3 membrane 
expression was observed in 2D and 3D MCF-7 models but αllb was moderately 
expressed in 3D compared to 2D. This may suggest αllb is less important in 
cancer cell-cancer cell interactions than it is with soluble proteins found in cell 
culture medium. It is also noteworthy that these spheroids did not contain 
necrotic or hypoxic regions because spheroid formation at day three was 
chosen to confirm the integrin expression in MCF-7, not to investigate changes 
in integrin expression as part of tumour progress in 3D. 
In this part of the study, MCF-7 cells were chosen as a useful native dual β3-
expressing model to investigate novel dual αvβ3 and αllbβ3 antagonists in the 
functional assays. In the next chapter, the effect of PMA treatment on integrin 
expression in K562 will be described to develop an inducible model as a known 
αllb-expressing model.   
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3.1  Introduction 
 
In normal human tissues, the expression of αllbβ3 is mainly on platelets but it is 
also expressed in some types of tumours including melanoma and prostate. 
αllbβ3 is considered an essential part of the metastatic process (Hynes, 2002a; 
Jin et al., 2011; Trikha et al., 1998). For example, some prostate cancer cells 
express αllbβ3 integrin, which is involved in the invasion of tumours (Gay and 
Felding-Habermann, 2011; Hynes, 2002). αllbβ3 integrin makes an interaction 
between platelets and cancer cells, leading to metastasis and making it a 
promising cancer target (Bakewell et al., 2003).  
Additionally, αvβ3 is involved in the migration of endothelial cells which results 
in angiogenesis. αvβ3 also contributes to the tumorigenesis of several cancer 
types (Borsig et al., 2002; Liu et al., 2009). For example, no expression of β3 
integrin was found in normal breast tissue compared to breast carcinoma tissue 
(Havaki et al., 2007). 
Phorbol 12-myristate 13-acetate (PMA) is a Protein Kinase C activator that 
participates in the regulation of megakaryocyte differentiation and activates the 
downstream mitogen-activated protein kinase (MEK/MAPK) pathway. PMA 
treatment of K562 cells upregulates proto-oncogene transcription factors 
notably jun/Fos. The change in cell adhesion ability is correlated to integrin 
expression and cytoskeleton changes (Huang et al., 2014). PMA has been 
extensively utilised in studying megakaryocyte biology. PMA is a potent 
activator of immediate early response genes and enhances megakaryocytic 
phenotype in leukemic cell lines including K562. PMA promotes early growth 
response protein 1 (EGR-1) expression in K562 and HEL cells, and this is 
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related to upregulation of megakaryocyte specific αllb (Cheng et al., 1994; 
Jalagadugula et al., 2008). Phorbol esters are known to enhance transcription 
of the C-sis gene which results in expression of αIIb in K562 cells (Zanyk et al., 
1988). Phorbol esters induce expression of integrins in K562 cells including αv 
and β3, but αIIb was not detected (Jarvinen et al., 1993). Other studies showed 
that PMA induced several integrins in leukaemia cell lines and also enhanced 
the secretion of thrombospondin, which may be utilised as a binding ligand for 
αvβ3 integrin (Ylanne et al., 1990). 
 
3.2 Aims and objectives 
 
The main aim of the work described in this chapter was to evaluate αIIb integrin 
subunit expression in K562 cells treated with PMA (Phorbol 12-myristate 13-
acetate), a putative inducer of integrin expression. The obtained results were 
valuable in order to develop a functional assay model for testing the effect of 
dual β3 antagonism in cancer, and screening novel dual integrin antagonists. 
The aim was addressed by the following experiments 
 Investigate by immunofluorescence and flow cytometry, the effect of PMA on 
the expression of the αIIb and αv integrin subunits in K562 and DU145 cells. 
 Determine, using flow cytometry, the optimal concentration of PMA for 
increasing the expression of αIIb subunit in K562 cells.    
  Evaluate the effect of the selected concentration of PMA on the expression 
of αIIb integrin subunit in K562 cells by Western blot.  
  Investigate, using the MTT assay, the effect of PMA on K562 cell survival.  
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3.3 Materials and methods 
3.3.1 Materials 
 
Human tumour cell lines K562 and DU145 were maintained as described in 
section 2.2.2.1. All reagents if not specified, were obtained from Sigma-Aldrich 
(Poole, UK). Primary antibodies and secondary antibodies used in 
immunofluorescence and flow cytometry are as listed in Chapter 2, Table 2. 
Primary antibodies and secondary antibodies used in Western blotting are 
summarised in Table 5
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Table 5: Primary antibodies and related secondary antibodies used in Western blot experiments 
Primary antibody Company Secondary antibodies 
Anti-β3 (B-7), monoclonal 
mouse antibody 
Santa Cruz 
Biotechnology  
Polyclonal rabbit anti mouse immunoglobulins 
horseradish peroxidase (P0260, Dako Cytomation, 
Glostrup, Denmark) 
Western dot 625 fluorescence based anti-mouse 
secondary antibody  
(Life technologies) 
Anti-αv (Q-20), polyclonal 
rabbit antibody 
Santa Cruz 
Biotechnology  
Polyclonal goat anti-rabbit immunoglobulins 
horseradish peroxidase (P0260, Dako Cytomation, 
Glostrup, Denmark)  
Western dot 625 fluorescence based anti-rabbit 
secondary antibody  
(Life technologies) 
Anti-αllb (Anti-CD41 
antibody [EPR4330]), 
monoclonal rabbit antibody 
Abcam (Cambridge, 
UK)  
Polyclonal goat anti-rabbit immunoglobulins 
horseradish peroxidase  
Western dot 625 fluorescence based anti-rabbit 
secondary antibody 
(Life technologies) 
Anti–β actin (A1978), 
Monoclonal mouse antibody 
Sigma-Aldrich, Poole, 
UK  
Polyclonal rabbit anti -mouse, immunoglobulins 
horseradish peroxidase 
Western dot 625 fluorescence based anti-mouse 
secondary antibody 
(Life technologies) 
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3.3.2 Methods 
3.3.2.1 Induction of αllb integrin subunit in K562 cells by PMA using 
Immunocytochemistry 
 
K562 cells were treated with 0.04, 0.08 or 0.1 μM of PMA for 24, 48, or 72 
hours. After incubation, the expression of αllb integrin subunit was detected as 
described in Section 2.3.3.5. 
 
3.3.2.2  Induction of integrin subunits in K562 and DU145 cells by PMA. 
 
K562 cells were treated with 0.1 μM of PMA and DU-145 cells with 0.5 μM of 
PMA for 24 hours. After incubation, the expression of α5, αv, β3, and β5 integrin 
subunits was detected using primary antibodies as previously described in 
sections 2.3.3.5.1 and Table 2 (Chapter 2). 
 
3.3.2.3  Flow cytometry 
3.3.2.3.1 Optimization of induction of αv and αllb integrin subunits 
expression in K562 and DU145 cells by PMA.  
 
After determining the concentration of cells, 5X105 cells/ml of cell suspension 
was added to each well of 6-well plates at various concentrations of PMA (0.5 
μM, 1 μM, or 2 μM) for incubation of durations 24, 48 or 72 h respectively. After 
incubation, the methods as described in section 2.4.4.1.1 were used to detect 
αv and αllb integrin subunits, and following incubation, cellular expression of α5, 
β3, and β5 integrin subunits was measured. Unlabelled (without primary 
antibody) treated and untreated cells were used as controls. See section 
2.3.3.6.1 for experimental details.  
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3.3.2.4 The effect of PMA on cell viability  
 
The cells were stimulated with different concentrations of PMA (0.1 μM, 0.5 μM, 
1 μM or 2 μM), for 2, 24, and 96 h at 37 ºC. After incubation, cells were washed 
with PBS and centrifuged at 1000 rpm for 5 minutes. After each incubation 
times, cells were washed with PBS and fresh media added and then incubated 
for 96 hours. Cell survival was measured by the MTT assay (section 2.3.3.4 in 
chapter 2). 
 
3.3.2.5  Western Blotting  
 
Western Blotting of the αIIb integrin subunit was performed on whole cell 
lysates of ±PMA treated K562 cell line as described below. 
 
3.3.2.5.1 Cell Lysis 
 
Cells were collected from incubation flasks after stimulation with PMA (0.04 uM) 
for 40 hours then washed with PBS by centrifugation (1000 x g). Complete 
RIPA lysis buffer (300 μl); [100 mM Tris pH 8.8, 5 mM EDTA, 300 mM NaCl, 2% 
Triton X-100] and protease inhibitor mix (PI, Complete mini EDTA-free, Roche, 
Mannheim, Germany) and water (50 μl/ml of PI added in RIPA) were added for 
30 min on ice, after which sonication (Philip Harries Scientific Sonicator, 
Scientific Laboratory) was applied for 5 cycles of four seconds and speedial on 
10% with cooling on ice between each sample to avoid overheating. Sonicated 
cells were centrifuged at 13,000 rpm for 15 min at 4 ºC. The supernatant of the 
lysed cells was collected into new Eppendorf tubes and stored at -20 °C until 
analysed.  
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3.3.2.5.2 Bradford assay 
 
Protein concentrations in cell lysates were measured using the Bradford Assay 
(Coomassie Brilliant Blue). Bovine serum albumin (BSA) was used to calibrate 
the assay by preparing six serial dilutions of protein (2 mg/ml of BSA dissolved 
in HPLC water) from 0.0625 - 1.0 mg/ml. 50 μl from each BSA dilution was 
added to 1.5 ml of Bradford reagent. All tubes were vortexed and left to stand at 
room temperature for 15 minutes to allow the Coomassie Brilliant Blue dye to 
react with the protein. Dilutions of cell lysates were prepared in HPLC grade 
water (2.5 μl of lysate added to 47.5 μl of water) and mixed with 1.5 ml of 
Bradford reagent. 1 ml from each BSA dilution and lysate were vortexed and 
transferred to plastic cuvettes. Absorbance readings were measured at 595 nm 
using a spectrophotometer (Thermo Scientific Multiskan Spectrum, 1500, 
Thermo Fisher Scientific, Finland) and a standard curve was plotted (Figure 23). 
 
 
 
 
 
 
 
 
Figure 23: Representative calibration graph for protein concentration using the Bradford 
assay. Data points represent the mean ± SE of three determinations.  
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3.3.2.5.3 Polyacrylamide gel electrophoresis  
 
Proteins were separated using pre-cast 12% polyacrylamide SDS gels (Bio-
Rad, Hertfordshire, UK). The gel was immersed in running buffer (10X Tris-
glycine electrophoresis buffer: 25 mM Tris, 250 mM glycine pH 8.3, 0.1% SDS). 
50 μg of protein was diluted in 10 μl SDS loading buffer (Laemmli sample 
buffer, Sigma Aldrich, UK) and 10 μl distilled water, then heated at 80 °C for ten 
minutes followed by rapid cooling on ice to denature proteins. Sample (20 μl) 
was loaded into each well. PageRuler™ Plus Prestained Protein Ladder marker 
with a size range from 10 to 250 kDa (26619, Thermo Fisher Scientific Inc. 
Rockford, USA) was loaded into the first lane. The electrophoresis of proteins 
was carried out at 120 V for 1 hour. 
 
 
3.3.2.5.4 Western Blot processing  
 
Proteins were transferred from the SDS-polyacrylamide gel to nitrocellulose 
membrane (GE Healthcare Life Sciences) using transfer buffer (2.9 g glycine, 
5.8 g Tris base, 0.37 g SDS, 200 ml methanol, 800 ml water pH 8.3). Protein 
transfer was run at 100 volts for 1 to 2 hours. After transfer, membranes were 
immersed in Ponceau S solution (1 g Ponceau S plus 50 ml acetic acid, made 
up to 1 L with distilled water) for 3 minutes to confirm protein transfer then 
washed with distilled water in order to de-stain the membrane. 
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3.3.2.5.5 Immunoblotting of nitrocellulose membrane  
 
The nitrocellulose membranes were blocked with either 3% non-fat dried milk in 
TBST or 5% BSA in PBS for one hour at room temperature, followed by 
application of primary antibody. The membrane was then washed with TBST or 
PBS (3 washes for 10 minutes each) followed by application of secondary 
antibodies (HRP secondary antibody or Western blot 625 fluorescence based 
secondary antibody) as specified in Table 5. 
Membranes were developed using either the enhanced chemiluminescent 
system (Roche) method or the transilluminator system depending on the 
secondary antibody type. For the chemiluminescent system, the ECL plus 
Western blotting detection system (NEL104, Perkin Elmer LAS) reagents A and 
B were mixed in a 1:1 ratio and applied to the membrane for one minute, then 
the detection reagent was discarded, and the membrane placed in an X-ray film 
cassette (Amersham hyperfilmTM ECL, GE Healthcare) before being developed 
in an Ilford Developer for 2 minutes and Ilford fixer solution for another 2 
minutes in the dark.  
The same membrane was washed with PBST (3 X 5 minutes) and re-probed 
with primary and secondary antibodies that detect β-actin protein. For the 
transilluminator system, the membrane was placed in the transilluminator in 
which the proteins side of the membrane faces the UV light for image 
development. The results were analysed by ImageJ Software (National 
Institutes of Health, U.S.A) which was utilised to quantify each blot by dividing 
the protein signal intensity by the signal of β actin control. 
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3.4 Results 
3.4.1 Effect of PMA on the expression of αIIb in K562 cells. 
 
K562 cells treated with different concentrations of PMA (0.04 μM, 0.08 μM or 
0.1 μM) were investigated at different incubation times (24, 40 and 72 hours) for 
αIIb subunit expression using the αIIb antibody EPR4330. At all concentrations 
of PMA used the expression of αIIb increased with time (Figure 24). 
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Figure 24: Effect of time of incubation and PMA concentration on expression of αllb subunit in K562 cells. Blue-fluorescent DAPI is nuclear staining 
and the red colour represents αllb expression detected by a fluorophore TRITC. White arrows point to membrane expression of αllb in higher magnification 
image of cells. Bar length = 50 μm at 40X objective lens.         
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3.4.2 Effect of PMA on the expression of αv, α5, β3 and β5 integrin 
subunits in K562 and DU145 cells.  
 
The expression of αv, α5, and β3 and β5 integrin subunits in K562 cells 
treated with PMA after 24 hours incubation was higher than in untreated 
cells (Figure 25).  
DU-145 cells treated with PMA were also investigated for the 
expression of αv, αllb, α5, β3 and β5 integrin subunits. No difference 
was detected in the level of αv, α5, αllb, and β3 and β5 integrin subunit 
expression in DU145 cells which had been treated with PMA compared 
to untreated cells (Figure 26). 
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Figure 25: Effect of PMA treatment on αv, α5, and β3 and β5 expression in K562 cells. K562 
cells were treated with PMA (0.1 μM) and incubated for 24 hrs. The expression of αv, α5, β3 and 
β5 integrin subunits was detected by immunofluorescence with Q20 anti-αv, C9 anti-α5, B7 anti-
β3, and ab15459 anti-β5 integrin antibodies. Bar Length = 50 μm. Blue-fluorescent DAPI is 
nuclear staining and colours (green and red) represent integrin expression detected by a 
fluorophore (TRITC or FITC). 
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Figure 
26: Effect of PMA treatment on αv, α5, β3 and β5 expression in DU145 cells. DU145 cells 
were treated with PMA (0.5 μM) and incubated for 24 hrs. The expression of αv, α5, β3 and β5 
integrin subunits was detected by immunofluorescence with Q20 anti-αv, C9 anti-α5, B7 anti-β3, 
and ab15459 anti-β5 integrin antibodies. Bar Length = 50 μm. Blue-fluorescent DAPI is nuclear 
staining and green colour represents integrin expression detected by a fluorophore FITC.   
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3.4.3 Quantification of the effect of PMA concentrations and incubation 
times on αv and αIIb integrin subunit expression by flow cytometry. 
 
The expression of αv and αIIb integrin subunit in K562 cell lines stimulated with 
1 nM, 2 nM and 5 nM of PMA for 2 and 24 hours was quantified using FACS. 
The expression of αv and αllb in PMA treated cells were not changed compared 
to untreated cells after 2 hours. The mean fluorescence intensities for αv in 
treated cells showed no observed difference compared to untreated cells but 
αllb was not clear (Figure 27). However, the expression of αv in PMA treated 
cells for 24 hours increased with increasing PMA concentration (Appendix V). 
The expression of αllb in cells treated with PMA for 24 hours was slightly 
shifted, see figure 28 (showing a double peak in the histogram, see Appendix 
VI).   
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Figure 27: Effect of PMA concentration on expression of αv in K562 cells. 
Cells were pre-treated with PMA for 2 or 24 hours prior to analysis (see section 3.2.2.2.1 for 
experimental detail). Mean fluorescence intensity of anti αv (using primary antibody B-7).  
** p>0.01.  
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Figure 28: Effect of PMA concentration on expression of αllb in K562 cells. 
Cells were pre-treated with PMA for 2 or 24 hours prior to analysis (see section 3.2.2.2.1 for 
experimental detail).  Mean fluorescence intensity of anti αllb (using EPR4330 primary antibody).  
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The effect of PMA on integrin expression was further evaluated using 1000-fold 
increased concentrations of PMA. To this effect K562 and DU-145 cells were 
treated with 0.5 μM, 1 μM or 2 μM of PMA for 24 hours, 48 hours h or 72 hours 
respectively. The cells were then harvested and labelled with anti-αv and anti-
αIIb antibodies and presence of both integrin subunits assessed by FACS 
analysis.  
 
In K562 cells, all concentrations of PMA used produced an increase in αIIb 
integrin expression although there was no clear dose response relationship with 
PMA concentration or time of PMA exposure. 2 μM of PMA for 24 hours 
produced the largest increase in the expression of αv integrin (Figure 29). The 
largest shift for αllb was obtained with 0.5 μM of PMA for 48 hours (Figure 30). 
For FACS data of K562 cells, see Appendix VII. 
 
 In DU-145 cells, treatment with 0.5 μM of PMA for 24 hours gave the highest 
shift from control and the highest mean fluorescence intensity for the expression 
of αv (Figure 31), whereas treatment for 24 hours caused no clear shift in the 
expression of αllb but the mean fluorescence intensity with 2 μM of PMA was 
higher than control. There was no significant difference in the shift and mean 
fluorescence intensity between all three concentrations at 48 and 72 hours 
(Figure 32).  For FACS data of DU-145 cells, see Appendix VIII. 
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Figure 29: Effect of PMA concentration and treatment time on αv integrin expression in 
K562 cells. Comparison of αv expression in K562 induced by three concentrations (0.5 µM 1 
µM, 2 µM of PMA) for 24h, 48 h, and 72h.  B-7 primary antibody was utilised to detect expression 
of the αv using flow cytometry.  
 
 
 
  
  
114 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 30: Effect of PMA concentration and treatment time on αllb integrin expression in 
K562 cells. Comparison of αllb expression in K562 treated by three concentrations (0.5 µM 1 
µM, 2 µM of PMA) for 24h 48 h and 72h. EPR4330 primary antibody was utilised to detect 
expression of the αllb using flow cytometry.  
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Figure 31: Effect of PMA concentration and treatment time on αv integrin expression in 
DU145 cells. Comparison of αv expression in DU145 treated by three concentrations (0.5 µM 1 
µM, 2 µM of PMA) for 24h, 48 h and 72h.  B-7 primary antibody was utilised to detect expression 
of the αv using flow cytometry.  
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Figure 32: Effect of PMA concentration and treatment time on αllb integrin expression in 
DU145 cells. Comparison of αllb expression in DU145 treated by three concentrations (0.5 µM 1 
µM, 2 µM of PMA) for 24h, 48 h and 72h. EPR4330 primary antibody was utilised to detect 
expression of the αv using flow cytometry.  
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3.4.4 Effect of PMA on expression of α5, β3 and β5 integrin subunits: 
comparison with αIIb and αv in K562 and DU145 cells. 
  
The expression of αv, α5, αIIb, β3 and β5 integrin subunits in K562 cells 
stimulated with PMA (0.1 μM, 24 hours) compared to unstimulated cells was 
quantified. The expression of integrin subunits αv α5, αIIb, β3 and β5 was 
increased compared to untreated cells (Figure 33). For FACS data, see 
Appendix IX. 
Increasing the K562 cell exposure to a 20-fold PMA concentration (i.e. 2 μM) 
exposure also stimulated the expression of αv α5, αIIb, β3 and β5 subunits, 
compared to PMA-untreated cells. The baseline expression level of the αv 
subunit was increased by approximately 4-fold compared to untreated cells. 
(Figure 34). The expression level of αllb was also measured in K562 cells 
treated with PMA (0.04µM) at incubation times (0, 24 and 40 hours) (Figure 36). 
The expression level of αllb was highest (more than 2-fold increase) compared 
to untreated cells after 40 hours. For FACS data, see Appendix X and Appendix 
XII. 
 
DU-145 cells treated with PMA (0.5 μM, 24 h) did not show a significant 
increase in the expression of αv α5, αIIb, β3 and β5 subunits. Instead all 
subunits other than α5 showed a decrease in fluorescence intensity following 
PMA treatment (Figure 35). For FACS data of DU-145 cells, see Appendix XI.
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Figure 33: Expression of αv, αllb, α5, β3 and β5 subunits in PMA stimulated K562 cells. 
The anti-αv (Q20), anti-αllb, anti-α5, anti-β3 (B-7), and anti-β5 (C-9) antibodies were utilized to detect expression of αv, αllb, α5, β3 and β5 subunits in 
K562 cells in the presence of PMA (0.1 µM) using flow cytometry. Data are shown as mean ± standard error of 3 independent repeats. 
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Figure 34: Expression of αv, αllb, α5, β3 and β5 subunits in PMA stimulated K562 cells. 
The anti-αv (Q20), anti-αllb, anti-α5, anti-β3 (B-7), and anti-β5 (C-9) antibodies were utilised to detect expression of αv, αllb, α5, β3 and β5 subunits in 
K562 cells in the presence of 2 µM PMA and in its absence using flow cytometry. Data are shown as mean ± standard error of 3 independent repeats. * 
indicated   p <0.05, ** indicated p < 0.01
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Figure 35: Expression of αv, αllb, α5, β3 and β5 subunits in PMA stimulated DU145 cells. 
The anti-αv (Q20), anti-αllb, anti-α5, anti-β3 (B-7), and anti-β5 (C-9) antibodies were utilised to detect expression of αv, αllb, α5, β3 and β5 subunits in 
DU145 cells in the presence of 0.5 µM PMA and in its absence using flow cytometry. Data are shown as mean ± standard error of 3 independent results.
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Figure 36: Effect of time on PMA (40 nM) induced expression of αllb in K562 cells.  Analysis 
of FACS data using mean fluorescence intensity. Data are shown as mean ± standard error of 3 
independent results. * p <0.05. 
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3.4.5 Expression of αllb, αv and β3 using Western blot 
 
The expression of αllb, αv and β3 were also investigated in K562 cells treated 
with 0.04 µM PMA for 40 hours using the semi quantitative Western blot 
technique to confirm the results of the flow cytometry and to show if there is any 
difference between the membrane expressions of integrin subunits and the 
whole cell expression. The results of Western blot (Figure 37) confirmed the 
FACS analysis; Q-20 anti-αv antibody gave a band at 132 kDa in K562 
 (±PMA). The expression of αv was higher in PMA treated K562 than untreated. 
The anti-β3 antibody (B-7) gave a band at 120 kDa in K562 (± PMA) and 
showed moderate expression. There was no apparent difference between two 
bands in stimulated and unstimulated cells. The expression of αllb was present 
in stimulated cells only and αllb antibody (EPR4330) gave a band at 113 kDa.
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Figure 37: Expression of αv, αllb and β3 integrin subunits in PMA-treated K562 cells 
compared to untreated cells. Membranes were blotted with anti αv (Q20), anti αllb (EPR4330) 
and anti-β3 (B7) integrin antibodies and β-actin antibody as a loading control. Data are average 
of 2 experiments.                                                                                                                                                                                          
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3.4.6 The effect of PMA on K562 cell survival and cell morphology 
 
The effect of PMA on cell viability was determined to assist selection of a 
concentration of PMA and incubation time that would be stimulatory in term of 
integrin expression with minimal effect on cell viability. PMA concentrations in 
the range (0.04 - 2 μM) and incubation time used for subsequent stimulation of 
integrin expression were investigated (see figures 26 - 37). The data obtained 
show that PMA affected cell viability in a dose dependent manner. At an 
incubation time of 2 hours, in which no cell division would be anticipated, PMA 
(up to 0.5 µM) had no effect on cell viability but did decrease cell numbers at 
higher concentrations of PMA (1 or 2 μM). Increasing the PMA incubation time 
to 24 hours had a moderate effect on cell viability whereas, exposure to PMA at 
all concentrations for 96 hours produced a cytotoxic effect (Figure 38). 
Treatment of cells with approximately ten-fold lower concentration (0.04 µM 
PMA) for 24 and 40 hours (Figure 39) upregulated expression of αllb whilst 
producing a minimal effect on cell survival.  
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Figure 38: Effect of PMA on K562 cell viability. Cell viability versus PMA concentration at 
incubation times of 2, 24 and 96 hours. Cell viability was determined using the MTT assay as 
described in section 2.3.3.4. Data are shown is the mean ± standard error of 3 independent 
results.               
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Figure 39:  Effect of PMA (40nM) on K562 cell viability. Cells were treated with 40 nM PMA for 
24 and 40 hours. Cell viability was determined using the MTT assay as described in section 
2.3.3.4. Data are shown as mean ± standard error of 3 independent results. ** indicated p <0.01, 
*** indicated p < 0.001. 
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A significant difference in morphology and integrin expression levels was 
observed using FITC immunofluorescence (Figure 40). PMA treatment induced 
changes of cell shape; irregular cell surfaces and cell size became slightly 
larger. Expression of both subunits αv and αllb was increased. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 40: Effect of PMA treatment on αv and αllb integrin subunit expression in K562 
cells. Cells were treated with PMA (2 µM) for 24h. Cells were labelled with anti-αv (Q20) and 
anti-αllb (EPR4330) integrin antibodies for FITC immunofluorescence. Bar length = 50 μm. 
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3.5 Discussion  
 
The importance of targeting integrins as a therapeutic strategy arises from their 
overexpression in various diseases (Engebraaten et al., 2009; Sheldrake and 
Patterson, 2014). Blocking integrins has an essential function in inhibiting 
angiogenesis and cancer metastasis (Liu et al., 2009). Inhibition of both cancer 
cells and endothelial αvβ3, and platelets αIIbβ3, can promote blockade of 
tumour growth in vivo (Engebraaten et al., 2009; Trikha et al., 2002b). 
Therefore, we hypothesise of that a dual αIIbβ3/αvβ3 antagonist would have a 
direct anti-proliferative effect on dual β3 expressing models and inhibit 
angiogenesis and metastasis through targeting cancer cell interaction with 
platelet αIIbβ3 and endothelial cell αvβ3.  
 
The major purpose of this chapter was to investigate potential dual αllbβ3 and 
αvβ3 expressing functional models. The leukaemia cell line (K562) was chosen 
for investigation in order to develop functional assay models for testing dual β3 
antagonism. PMA treatment of K562 cells is known to upregulate αllbβ3 integrin 
expression (Galletti et al., 2014; Stupp et al., 2014). In order to investigate the 
utility of K562 cells as an inducible model of αIIbβ3 expression PMA treatment 
was used to stimulate protein expression on the cell surface. 
 
To determine the best conditions for αllbβ3 induction, K562 cells were treated 
with three different low concentrations (0.04 μM, 0.08 μM, and 0.1 μM) of PMA 
and different PMA incubation times to increase αIIb subunit expression which 
we then measured using immunofluorescence. An increase in the expression of 
the αIIb integrin subunit was observed; expression increased with increasing 
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time of incubation with PMA and with increasing dose. These data agree with 
previous research, which links PMA to the induced surface expression of 
integrins. That research described this to be through its activation of protein 
kinase C (PKC) that requires mitogen-activated protein kinases (MAPK) 
pathway activity for regulating the cell cycle (see Figure 8). This has an effect 
on cell surface expression of integrins (Conran and Hemming, 1998). For 
example, PMA-induced differentiation of human erythroleukaemia cells caused 
an increase in the expression of functionally active αvβ3, αllbβ3 and α5β1 which 
simultaneously considerably altered their morphology and allowed them to 
spread on ECM fibronectin and vitronectin (Ylanne et al., 1990). Very low 
concentrations (1 nM, 2 nM and 5 nM) of PMA did not induce a significant 
increase in αIIb and αv expression. 
As the upregulated expression of αllb was achieved with PMA treatment, the 
effect of PMA (0.1 μM) on αv, α5, β3, and β5 integrin subunits expression in 
K562 was investigated by using immunofluorescence and flow cytometry to 
check the localisation and quantity of integrin expression. Expression of all 
subunits detected by both techniques was increased compared to untreated 
cells particularly αv. Since a dual expressing model is desired, increased αv, 
and β3 levels is not an issue, but increased levels of α5, and β5 will need to be 
taken into account in functional assays. 
The effects of 1000-fold increase concentrations of PMA on the expression of 
αv and αllb integrin subunits in K562 and DU145 were investigated to explore 
whether the effects of PMA are cell line dependent. PMA (2 μM) led to a rapid 
increase in αv expression and upregulation in αllb expression in K562 cells. The 
expression of all other subunits (α5, β3, and β5) was also increased on PMA 
treatment. However, no significant change in integrin subunit expression on 
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treatment with PMA was detected by flow cytometry or immunofluorescence in 
DU-145 cells. This was not unexpected, since there are no literature reports of 
DU145 cells undergoing differentiation or changing integrin expression in 
response to phorbol esters. This result may suggest that K562 has upregulated 
levels of PKC isozyme, while DU145 has deregulated expression. K562 cells 
undergo differentiation in response to PMA which involves changes in integrin 
expression. Phorbol esters also affect cell signalling in DU145 cells (Stewart 
and O'Brian, 2005). 
Comparing morphological changes in PMA-stimulated K562 cells with 
unstimulated K562 cells revealed that the PMA caused phenotypic alterations, 
such as irregular cell shape and increased size. The morphological changes 
agree with the findings of other studies (Burger et al., 1992). PMA-induced 
megakaryocytic differentiation of K562 cells has been shown to be 
accompanied by alterations in cell morphology, specific markers expressing on 
the cell surface of megakaryocytes, the acquisition of adhesion properties, cell 
growth arrest, and other changes. The change in cell adhesion is associated 
with cytoskeleton alterations and integrin expression (Butler et al., 1990; Huang 
et al., 2014; Whalen et al., 1997). 
To allow the use of an adhesion assay with stimulated cell lines at the optimum 
concentration (0.04μM), evaluating the effect of PMA on cell survival was 
required. Therefore, the same concentrations that gave increased integrin 
expression above were used to screen the effect of PMA on cell survival for 
different incubation times (2, 24 & 96 hours). The absorbance values for PMA-
treated cells were lower than untreated cells. This means treatment with PMA 
inhibited the cellular growth as well as enhancing the differentiation and 
increasing adhesion. 
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 However, the MTT absorbance decrease is not necessarily a reflection of PMA 
mediated cytotoxicity because PMA is a differentiating agent then one of the 
effects of cell differentiation is cells no longer divide and undergo growth arrest. 
In this regard, PMA induces the inhibition of cell growth because of an arrest of 
the phase of G1 cell cycle and leads to a marked decrease in cdk2 activity 
(cyclin-dependent kinase 2), which is related to complete cdk2 
dephosphorylation (Asiedu et al., 1997). Furthermore, the growth inhibition for 
PMA-treated cells may be because of other proteins being activated after PKC 
activation, such as caspase-3, serine protease(s), and pro-apoptotic proteins, 
which induces apoptosis (Park et al., 2001). This may interfere with the use of 
stimulated cells in functional assays as it is difficult to measure changes in low 
absorption values. For this reason, the effect of PMA on the cell survival and 
αllb integrin subunit expression was investigated with 0.04 µM PMA which was 
used previously by Galletti et al (Galletti et al., 2014) for 0, 24 and 40 hours. I 
found that the cell density was very suitable at 0.04 µM PMA for 40 hours and, 
αllb was significantly upregulated. 
 
In conclusion, I have identified that treating K562 cells with 0.04 µM PMA for 40 
hours is appropriate to create a dual αv/αllbβ3 expressing cell line which will be 
a useful model to screen novel dual αvβ3 and αllbβ3 antagonists in the 
functional assays reported in the next chapter. 
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4 Chapter 4: Investigation of the effect of 
novel β3 integrin antagonists 
in functional cell assays 
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4.1 Introduction  
  
In the previous chapter, αllb integrin subunit expression in PMA treated K562 
cells was assessed by qualitative and quantitative analysis. The demonstration 
that αllb expression was induced suggests PMA-treated cells may be useful in 
assays to measure the effect of integrin inhibitors on cell adhesion and 
detachment. 
Cell adhesion and detachment have severe effects on the function and 
behaviour of cells. For instance, cell adhesion and detachment are involved in 
promulgating a diverse range of biological phenomena including embryonic 
development, wound healing, cancer development, progression, and 
dissemination. Therefore abnormality in cell adhesion and detachment can lead 
to consequences associated with pathophysiologies (Yoon and Mofrad, 2011) 
such as osteoporosis (Cho et al., 2006; Perinpanayagam et al., 2001), arthritis  
(Lasky et al., 1992; Szekanecz and Koch, 2000), cancer (Hirohashi and Kanai, 
2003; Huang and Ingber, 1999; Okegawa et al., 2004) and atherosclerosis  
(Serhan and Savill, 2005; Simon and Green, 2005). When cells adhere to 
components of ECM, integrins are activated; the activated integrins connect 
target ligands; the linked integrins cluster together by altering their affinity (Yoon 
and Mofrad, 2011).  
 
In general, there are two key events in cancer cell adhesion: cell attachment 
and cell detachment. Attachment events of cell adhesion focus on the 
mechanism of cell attachment to the ligand, whereas the detachment events of 
cell adhesion include load application to detach the adhered cells from the 
ligand (Khalili and Ahmad, 2015). 
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In the development and validation of cell functional assays to explore the effect 
of integrin antagonist, cRGDfV, a cyclic RGD peptide which is a known αvβ3/β5 
integrin antagonist, and GR144053, a small molecule αllbβ3 antagonist, were 
used as positive controls.  
 
This chapter describes the validation and use of adhesion and detachment 
assays to evaluate potential novel β3 integrin subunit antagonists synthesised 
at the Institute of Cancer Therapeutics, University of Bradford. K562 cells were 
used as an inducible model of αllb expression for investigating the inhibition of 
cellular adhesion to fibrinogen and breaking cell-ECM interactions in order to 
detach from fibrinogen. MCF-7 cells also were used in these functional assays 
as a dual β3-expressing modal. 
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4.2 Aims and objectives 
 
The aims of this chapter were to evaluate a panel of novel small molecules 
designed to antagonise the β3 integrin subunits, for their cytotoxicity and effects 
on integrin-mediated tumour cell adhesion, detachment and migration. These 
aims achieved through the following experiments:  
 
 Evaluation of the cytotoxicity of known integrin inhibitors (cRGDfV and 
GR144053) as control compounds and comparing this activity with the 
novel compounds using the MTT assay.  
 Validation of the K562 and MCF-7 cell-based integrin functional assays 
using control β3 antagonists. 
 Evaluation of the effects of novel compounds on K562 and MCF-7 cell 
adhesion and detachment. 
 Evaluation of the effects of novel compounds on K562 and MCF-7 cell 
migration using the transwell migration assay. 
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4.3 Materials and methods 
4.3.1 Materials 
 
Fibrinogen from human plasma (Fg) and Hoechst stain solution were obtained 
from Sigma-Aldrich. The Hoechst stain solution was prepared by diluting 5 μl of 
1 µg/ml of Hoechst staining into 495 µl of PBS. GR144053 was sourced from 
Tocris Bioscience and cRGDfV from Peptinova. 
A group of small molecule β3 antagonists synthesised in-house by Dr. Helen 
Sheldrake were investigated in this chapter (Table 6). The compounds were 
initially dissolved in DMSO at a concentration of 10mM or 100mM. The stock 
solutions were kept at -20ºC and working solutions were prepared in complete 
RPMI medium immediately prior to use. 
 
4.3.1.1 Cancer cell lines 
K562 and MCF-7 cancer cell lines were maintained as described in chapter 2  
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Table 6 : Molecular weights of novel antagonists. See insert card for 
structures (confidential due to intellectual property embargo). These compounds 
were synthesised by Dr. Helen Sheldrake.  
        ICT compounds Molecular weight (g/mol) 
ICT9001 305 
ICT9025 517 
ICT9026 475 
ICT9055 542 
ICT9066 345 
ICT9072 474 
ICT9073 516 
ICT9085 500 
ICT9094 557 
ICT9099 542 
ICT9101 514 
ICT9103A 600 
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4.3.2 Methods 
4.3.2.1 Cytotoxicity assay using MTT assay 
 
The cytotoxicity assay was performed in triplicate wells per drug concentration. 
180 μl cell suspension per well (2 x 104 cell/ml of K562 and 1x104 cell/ml of 
MCF-7) were plated into the required number of 96 well plates. 20 µl of the 
control compounds (GR144053 and cRGDfV): 1, 2, 5, 10, 20, 50, 100, and 200 
µM and ICT compounds: serial dilutions of each compound 0.01 to 100 µM 
were prepared using cell culture medium as a diluent. The compounds were 
added to all wells except the blank control (200 µl of RPMI medium) and 
untreated control. Control cells were treated with 0.1% DMSO with the same 
concentrations that used with drugs as seen in Appendix I. The 96 well plates 
were incubated for 4 hours at 37 °C and then centrifuged for 5 minutes at 1000 
rpm and then thus the supernatant was removed. 200 μl PBS was added to 
wash the cells and centrifuged again to remove PBS. 200 μl of fresh RPMI 
medium was added and incubated for 92 hours at 37 °C. Following incubation 
for 96 hours, cell survival was quantified using the MTT assay.  
96-hours drug exposure: after 4 hrs treatment, the plate was incubated directly 
for a further 92 hours at 37 °C. Following 96 hours incubation, cell survival was 
quantified using the MTT assay. The IC50 is defined as the compound 
concentration that is required to causes a decrease in the percentage of 
surviving cells to 50 %. The following equation was used to calculate cell 
survival as following: 
% Cell survival =   
Average of the absorbance of treated wells − blank     
Average of the absorbance of untreated wells (control) − blank
× 100 
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4.3.2.2 Adhesion assay 
4.3.2.2.1 Fibrinogen preparation  
 
2 mg/ml of fibrinogen from human plasma powder was dissolved in 1 ml of 
saline (0.9% NaCl). The fibrinogen saline solution was incubated at 37°C (warm 
water bath) without mixing for 3 – 4 hours and then filtered through a 0.2 µm 
filter using a syringe. After filtration, the fibrinogen stock solution was used 
immediately or stored for up to one week at 4°C. 
 
4.3.2.2.2 Fibrinogen adhesion assay  
 
96 well plates (treated microplate, Costar, Corning, NY) were coated with 100 
µl/well of fibrinogen (2 µg/ml or 5 µg/ml) and incubated overnight at 4°C. The 
wells were blocked with 3% BSA in PBS (100 μl/well) for 1 - 2 hrs at 37 
°C. K562 cells were stimulated with PMA (0.04 μM) and incubated for 40 hrs at 
37 C, then prepared in FCS-free medium (5X105 cells/ml) and MCF-7 cells 
were also prepared in FCS-free medium (4X105 cells/ml) and then treated with 
different concentrations of drugs for 4 hours on a rotator at room temperature. 
Control cells were treated identically apart from the absence of drugs. After the 
4 hours incubation, cells were added to the fibrinogen-coated plates and 
incubated at 37 °C for one hour. The supernatant was removed, and the wells 
washed twice with PBS to remove non-adherent cells. 180 μl of complete 
medium was added to each well and incubated overnight at 37°C. Finally, 20 μl 
of MTT was added and incubated for 4 hours at 37°C, and then measured 
spectrophotometrically by the plate reader at 540 nm. This experiment was 
repeated three times. The following equation was used to calculate cell 
adhesion as following:  
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% Adhesion  =
Average of the optical density of treated cells − blank     
Average of the optical density of untreated cells – blank
× 100 
 
 
 4.3.2.2.3 Non-adherent cell viability assay 
 
K562 cells were treated with different concentrations of ICT9055 for 0, 4 and 24 
hours. After the exposure times, cells were plated on the fibrinogen-coated 
plates and incubated at 37°C for one hour. Non-adherent cells were removed by 
washing gently twice with PBS then centrifuged at 1000 RPM for 5 minutes. The 
viability of cells was evaluated using the trypan blue assay, where 100 µL of cell 
suspension was added to100 µL of trypan blue stain and mixed gently. 10 µL of 
trypan blue-treated cell suspension was applied to the haemocytometer to 
calculate live and dead cells by the followed equations: 
% Viability =
Average number of live cells 
Average number of total cells 
× 100 
% Nonviability =
Average number of dead cells 
Average number of total cells 
× 100 
The sample of untreated and treated non-adherent cells were stained with 
Hoechst 33342 (5 μg/ml) for 5 -10 minutes at room tempreturere to indicate the 
morphology of cells, and if they had any signs of apoptosis or necrosis. The 
slides were then examined using a LEICA fluorescence microscope at 40X 
objective lens magnification and photographed.  
  
 141 
 
4.3.2.3 Fibrinogen detachment assay 
  
96 well plates (non-treated microplate, Corning) were coated with 100 µl/well of 
fibrinogen (2 µg/ml or 5 µg/ml) or coated with100 µl/well of 5% BSA in PBS as a 
blocking agent (control for non-specific adhesion). The coated plates were 
incubated overnight at 4C. K562 cells were stimulated with PMA (0.04 μM) and 
incubated for 40 hrs at 37C, then seeded in complete medium (5 X105 cells/ml) 
and incubated overnight at 37C. The next day, the cells were treated with or 
without different concentrations of drugs for a range of time points: 2, 4 & 6 
hours at 37C for detachment. After each incubation period, the supernatants 
were collected in labelled Eppendorf tubes, and the wells washed gently with 
PBS to remove non-adherent cells which were added to the suspension and 
then centrifuged at 1000 RPM for 5 minutes. The supernatant was removed and 
washed with PBS at 1000 RPM for 5 minutes. 10 µL of cells were taken and 
applied to the haemocytometer for counting. The equation below was used to 
calculate cell detachment. The remaining attached cells were measured using 
the MTT assay as described above. Half maximal effective concentrations 
(EC50) were calculated to measure a response of drug to detach 50 % of cells 
from fibrinogen.  
 
% Detachment =
Average number of treated detached cells 
Average number of untreated detached cells (control)
× 100 
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4.3.2.1.1 Analysis of integrin subunit expression in fibrinogen detachment 
assay 
 
The fibrinogen detachment assay was set up in 12 well plates. The detached 
cells were collected as described above (Section 4.2.4.3). Attached cells were 
removed using a scraper and washed with PBS at 1000 RPM for 5 minutes. 
Following this the supernatant was removed and 100 μl of 4% PFA was added. 
The suspension was kept for 5 – 10 minutes at room temperature. The 
supernatant was removed, and fixed cells were obtained. Dilution of primary 
antibodies was made in 1% BSA/PBS. 100 μl of diluted primary antibodies were 
added to each tube according to their optimal concentrations in Table 3 and 
incubated for 45 – 60 minutes at 4°C in the dark. The cells were centrifuged 
with cold PBS three times at 1000 rpm for 5 minutes. The secondary antibody 
was diluted (1:500) in 1% BSA/PBS. 100 μl of diluted secondary antibodies 
were added to each tube and incubated for at least 20 – 30 minutes at 4°C in 
the dark. The cells were centrifuged again with cold PBS three times at 1000 
rpm for 5 minutes. 1% BSA/PBS (300μl) was added to the cells and then 50μl of 
the suspension mixed with one drop of DAPI stain and applied to the slide and 
photographed by LEICA fluorescence microscope at 40X objective lens 
magnification. 
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4.3.2.2  Transwell migration assay (Boyden chamber assay) 
 
The Transwell migration assay is a common alternative approach to scratch 
assays. A diagram of the assay is shown in Figure 41. The transwell insert has 
a polycarbonate membrane with pore size 8 μm (Corning® Costar® Transwell® 
cell culture inserts). When placed in the well, it divides the chamber into two 
compartments. 150 μl of cell suspension treated with different concentrations of 
compounds were seeded in serum-free medium in the top compartment so they 
can migrate directly through the pores towards a chemoattractant (10% FBS) in 
the bottom reservoir. After 24 hours of incubation at 37 °C, the cell suspension 
was removed from the insert of the top compartment and the rest of cells were 
washed with PBS and wiped off with a cotton swab. Cells on the lower side of 
the membrane were fixed with 70% ethanol for 2 minutes and left to air dry. The 
membrane was cut off using a scalpel and placed on a microscopic slide upside 
down with DAPI staining. Images were taken using LEICA fluorescence 
microscope at 20X objective lens magnification, and the cells were counted 
using Image J software as shown in Figure 42. Cell migration was calculated as 
following:  
  
% Migration =
Average number of treated cells migrating through membrane
Average number of untreated cells migrating through membrane
× 100 
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Figure 41: Diagram of Transwell migration assay. Cells are added to the upper chamber and 
then migrate through the porous membrane and adhere to the bottom surface of the membrane in 
response to the chemoattractant added to the lower chamber. This diagram was modified from 
(Strazielle et al., 2016).  
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Outlines of counted migrated cells
Fluorescence image   
Clipboard (blue)  
Binary image   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 42: Analysis of Transwell migration assay using ImageJ. The fluorescence images 
were analysed through Image J and images converted to binary for Image J recognition then cells 
were counted using Image J.  
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4.3.2.3  Statistical analysis  
 
Student’s t-test (two tailed) was utilised for statistical analysis of functional 
assay using Excel software. The results considered statistically significant for p 
< 0.05 and highly significant for p < 0.01. CompuSyn version 1.0 (Combosyn 
Inc) was sed to calculate the combination index (CI) in drug combinations. CI<1, 
CI=1 and CI>1 indicate synergistic, additive, and antagonistic effects, 
respectively. 
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4.4 Results  
4.4.1 Cytotoxicity of GR144053 and cRGDfV against K562 cells  
 
The MTT assay was utilised to measure the cytotoxicity of GR144053 and 
cRGDfV against K562 with or without PMA and MCF-7 cells at concentrations 
of 0, 1, 2, 5, 10, 50, 100, and 200 μM for two different drug exposure times; 4 
hours of drug exposure and 96 hours of drug exposure (Figure 43 and Figure 
44). Both drugs were non-toxic to K562 and MCF-7 cells except at the highest 
concentrations (50, 100 and 200 μM to K562 cells and 100 and 200 μM to MCF-
7 cells for 96 hours) which killed 40-50% of cells. Therefore, the antagonists 
could be utilised in the functional assays at lower concentrations. 
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Figure 43: Evaluation of the cytotoxicity of GR144053 and cRGDfV on K562 cells using the 
MTT assay. Cells (± 0.04 µM PMA) were exposed to the drugs for 4 hrs and 96 hrs. 
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Figure 44: Measurement of the cytotoxicity of GR144053 and cRGDfV on MCF-7 cells using 
the MTT assay. Cells were exposed to the drugs for 4 hrs and 96 hrs.  
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4.4.2  Evaluation of the cytotoxicity of potential novel β3 integrin 
antagonists 
The MTT assay was used to assess the cytotoxicity of potential novel β3 
integrin antagonists against K562 and MCF-7 cells over a range of different 
concentrations (0.01, 0.1, 1, 10 & 100 μM) for 4 and 96 hours of drug exposure. 
As shown in Figure 45A and B, Figure 46 A and B and Figure 47 A and B most 
of tested ICT compounds were non-toxic to K562 and MCF-7 within the range of 
concentrations tested for 4 hours of drug exposure; at 96 hours: ICT9094 and 
ICT9099 proved toxic in all cell lines. ICT9025 was toxic and ICT9101 had a 
moderate effect in K562 + PMA. ICT9066, ICT9072 and ICT9073 at higher 
concentrations had a toxic effect on MCF-7 cells only. IC50 values are shown in 
Table 7. 
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Table 7: IC50 values for new small molecule integrin antagonists in the 
MTT cytotoxicity assay for 96 hours. 
ICT 
compounds 
K562 
IC50 ± SD 
(μM) 
K562 (+PMA) 
IC50 ± SD (μM) 
MCF-7 
IC50 ± SD (μM) 
ICT9001 > 100 > 100 > 100 
ICT9025 > 100 68.1 ± 8.6 > 100 
ICT9026 > 100 > 100 > 100 
ICT9055 > 100 > 100 > 100 
ICT9066 > 100 > 100 81 ± 26.5 
ICT9085 > 100 > 100 > 100 
ICT9072 > 100 > 100 74.1 ± 21.7 
ICT9073 > 100 > 100 65.9 ± 8.3 
ICT9094 21.9 ± 8.4 6.5 ± 3.1 23.2 ± 7.1 
ICT9099 51.4 ± 9.3 42.7 ± 0.2 55.9 ±12.7 
ICT9101 > 100 75.7 ± 3.4 > 100 
ICT9103A > 100 > 100 > 100 
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Figure 45 A: Measurement of the cytotoxicity of the first part of new small molecule integrin antagonist’s panel for 4 h of drug exposure in K562 
cells. Cells were pre-treated with 0.04 μM PMA for 40 h (red line) or not treated with PMA (blue line). Data are shown as mean ± standard deviation of 3 
independent results. 
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Figure 45 B: Measurement of the cytotoxicity of the second part of new small molecule integrin antagonist’s panel for 4 h of drug exposure in 
K562 cells. Cells were pre-treated with 0.04 μM PMA for 40 h (red line) or not treated with PMA (blue line). Data are shown as mean ± standard deviation 
of 3 independent results. 
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Figure 46 A: Measurement of the cytotoxicity of the first part of new small molecule integrin antagonist’s panel for 96 h of drug exposure in K562 
cells. Cells were pre-treated with 0.04μM PMA for 40 h (red line) or not treated with PMA (blue line). Data are shown as mean ± standard deviation of 3 
independent results. 
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Figure 46 B: Measurement of the cytotoxicity of the second part of new small molecule integrin antagonist’s panel for 96 h of drug exposure in 
K562 cells. Cells were pre-treated with 0.04μM PMA for 40 h (red line) or not treated with PMA (blue line). Data are shown as mean ± standard deviation of 3 
independent results. 
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Figure 47 A: Measurement of the cytotoxicity of the first part of potential novel β3 integrin antagonist’s panel in MCF-7 cells. Cells were treated with 
drug for 4 (blue lines) and 96 (red lines) hrs. Data are shown as mean ± standard deviation of 3 independent results. 
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Figure 47 B: Measurement of the cytotoxicity of the second part of potential novel β3 integrin antagonist’s panel in MCF-7 cells. Cells were treated 
with drug for 4 (blue lines) and 96 (red lines) hrs. Data are shown as mean ± standard deviation of 3 independent results.
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4.4.3 Fibrinogen adhesion assay 
 
The ability of K562 cells to adhere to fibrinogen in the presence and absence of 
PMA was investigated to determine whether PMA induced functionally active 
integrins and therefore whether the cell line could be used for an adhesion 
assay. The ability of MCF-7 cells to adhere to fibrinogen was determined. 
 
4.4.3.1 Initial investigation of K562 cell binding to fibrinogen 
 
Adhesion assay methods depend on the ability of integrin receptors on the cell 
surface to interact with extracellular matrix proteins on a coated plate. The 
adhesion of three different concentrations, 1X104, 5X104 and 1X105 K562 
cells/ml, to two different concentrations of fibrinogen (2 and 5 μg/ml) was 
determined in the presence of PMA and absence (2 μM). Three different 
adhesion conditions were used: at 37°C for 4 hours, room temperature for 4 
hours and no incubation. K562 cells treated with PMA showed greater adhesion 
than untreated cells. The optimum conditions for K562 cells (±PMA) to adhere 
to 2 μg/ml of fibrinogen in a 96-well plate were 37 °C for 4 hrs (Figure 48). 
However, the absorbance values of K562 cells in the presence of PMA (2 μM) 
were lower than desired. 
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Figure 48: Optimization of K562 cell binding to fibrinogen. K562 (± 2 μM PMA) cells were 
applied to plates coated with 2 and 5 μg/ml of fibrinogen and adhered cells quantified either 
immediately (blue lines), after 4 hours at room temperature (red lines) or after 4 hours at 37 °C 
(green lines). Results shown are the mean ± SE of 3 independent experiments.   
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4.4.3.2  Optimisation of K562 cell binding to fibrinogen  
 
The best cell binding was observed with cells incubated at 37 °C for 4 hours 
with 2 μg/ml of fibrinogen but the number of bound cells was low. To optimise 
the cell number, six different concentrations of cells (5 X104 - 5 X105 cell/ml) 
treated with 0.04 μM PMA (ideal dose was described in Chapter3) or untreated 
in the FCS-free medium were used. The results, as shown in Figure 49, indicate 
treatment with PMA increased cell binding to fibrinogen 500,000 cells/ml gave 
the greatest absorption value, therefore this was chosen as the best cell density 
for further experiments.  
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Figure 49: K562 cell binding to fibrinogen. K562 cells (± 0.04μM PMA) were allowed to adhere 
to a plate coated with 2 µg/ml of fibrinogen at 37 °C for 4 hours. Results shown are the mean ± 
standard error of 3 independent experiments. 
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4.4.3.3  Evaluation of MCF-7 cell binding to fibrinogen 
 
The ability of MCF-7 cells to adhere to two different concentrations of fibrinogen 
(2 and 5 μg/ml) was investigated. To optimise the cell number, six different 
concentrations of cells (5 X104 – 5 X105 cell/ml) in FCS-free medium were used. 
Cell adhesion was higher on 5 μg/mL fibrinogen than 2 μg/mL fibrinogen. The 
highest absorbance was seen with 400,000 cells/ml (Figure 50).  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 50: Optimisation of MCF-7 cell binding to fibrinogen. MCF-7 cells were allowed to 
adhere to a plate coated with 5 µg/ml of fibrinogen at 37 °C for 4 hours. Data are shown as mean 
± standard error of 3 independent results. 
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4.4.3.4  Validation of the fibrinogen adhesion assay using cRGDfV and 
GR144053 
 
In order to validate the fibrinogen adhesion assay for using with novel 
compounds which are expected to inhibit adhesion, the response of the cells to 
the positive controls cRGDfV and GR144053 was evaluated. Controls were 
used singly and in combination at different concentrations. There was an 
apparent inhibitory effect of combined drugs on the ability of K562 (±PMA) and 
MCF-7 cells to adhere to fibrinogen in a dose dependent manner whereas 
cRGDfV alone had a moderate effect and GR144053 had lower effect (Figure 
51 and Figure 52). Adhesion was partially reliant on the β3 integrins in 
untreated K562 cells, and more dependent in PMA-treated cells, where 20 µM 
of combined antagonists almost completely blocked cell adhesion. In addition, 
adhesion was inhibited more than 50% in MCF-7 cells treated with 50 µM 
combined antagonists. The specific interaction between cRGDfV and 
GR144053 on these cell lines was evaluated by the combination index (CI) 
analysis where CI<1 indicates a synergistic effect. The results of all 
concentrations from each compound used (5, 10 and 20 μM with K562 and 5, 
10, 20 and 50 μM with MCF-7) gave the synergistic effect. CI values for actual 
experimental points can be seen in Table 8, and IC50 values in Table 9. 
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Figure 51: Effects of GR144053 and cRGDfV on K562 adhesion to fibrinogen. K562 cells 
(±0.04µM PMA) were treated with the compounds for 4 h. Values are the average of 3 
independent experiments and error bars are SE. P values: * p<0.05 and ** p<0.01.     
  
0
20
40
60
80
100
A
d
h
e
s
io
n
 %
Concentration (µM)
cRGDfV
+PMA
-PMA
*
*
*
*
*
0
20
40
60
80
100
A
d
h
e
s
io
n
 %
Concentration (µM)
GR144053
+PMA
-PMA
*
*
*
*
*
0
20
40
60
80
100
A
d
h
e
s
io
n
 %
+PMA
-PMA
**
*
*
*
*
*
**
GR144053 and cRGDfV
Concentration (µM)
 165 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 52: Effects of GR144053 and cRGDfV on MCF-7 adhesion to fibrinogen. MCF-7 cells 
were treated with the compounds for 4 h. Values are the average of 3 independent experiments 
and error bars are SE. P values: * P<0.05, **P.0.01 and ***P>0.001.       
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Table 8: Combination index (CI) values for the effect of GR144053 and 
cRGDfV on adhesion to fibrinogen. CI < 0.1 very strong synergism, 0.1 - 0.3 
strong synergism, 0.3 - 0.7 synergism, 0.7 - 0.85 moderate synergism, 0.85 - 
0.90 slight synergism, and 0.90 -1.10 additive.  
Type of Cell Total Dose CI Value Interpretation 
K
5
6
2
 w
it
h
 P
M
A
 
 
5.0 0.33 Synergism 
10.0 0.34 Synergism 
20.0 0.34 Synergism 
K
5
6
2
 w
it
h
o
u
t 
P
M
A
 5.0 0.25 Strong synergism 
10.0 0.42 Synergism 
20.0 0.51 Synergism 
M
C
F
-7
 
5.0 0.46 Synergism 
10.0 0.62 Synergism 
20.0 0.42 Synergism 
50.0 0.16 Strong synergism 
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4.4.3.5 Effects of potential β3 integrin antagonists on K562 (±PMA) cell 
adhesion. 
 
The compounds were tested at a range (0.1, 1.0, 10 and 100 µM) of 
nontoxic concentrations in the fibrinogen adhesion assay. The compounds 
developed in house have been tested using in K562 cells with and without 
PMA. Initial screening concentrations were selected based on their 
cytotoxicity results for 96 hours. In the adhesion assay, the K562 cells were 
treated for 4 hours only. Consequently, as the exposure time was shorter 
than it was expected that these concentrations would not have a cytotoxic 
effect. The compounds tested inhibited cell adhesion to fibrinogen at 
different concentrations (0.1, 1.0, 10 and 100 µM). ICT9055 showed the 
highest effect of inhibiting PMA treated K562 cell adhesion at the lowest 
concentration while ICT9072 and ICT9073 had lower effects at the same 
concentration compared to untreated cells. IC50 values were calculated for 
ICT9055, ICT9072 and ICT9073 and are given in Table 9. Compared to 
cRGDfV (anti-αvβ3) and GR144053 (anti-αIIbβ3) controls, in the presence 
of PMA (66 ± 3%, P<0.001), the ICT9055 (77 ± 4.2%) had a higher effect 
than the combined control, while ICT9072 (63 ± 3.9%) and ICT9073 (59 ± 
1.92%) had a slightly lower effect than combined control. In the absence of 
PMA, all three compounds had a highest showed greater anti-adhesive 
activity than the positive control (40 ± 5%, P<0.01) (Figure 53). ICT9026 (40 
±12%), ICT9094 (42 ± 7%), ICT9099 (51 ± 4%), ICT9101 (42 ±11%), and 
ICT9103A (49.5 ± 5%) were moderately effective at inhibiting PMA treated 
K562 cell adhesion at 10 μM, but these compounds showed lower anti-
adhesive activity than the combined controls (Figures 54 A and B). A 
summary of the effect of all the β3 integrin antagonists on the adhesion of 
 168 
 
K562±PMA at 10 μM is shown in Figure 55. ICT9055 (77± 4.2%) had a 
higher effect than the combined control, while ICT9072 (63 ± 3.9%) and 
ICT9073 (59 ± 1.9%) had a lower effect than combined control. In the 
absence of PMA, all three compounds had a higher effect than the positive 
control (40 ± 5%, P<0.01). 
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Figure 53: Effect of small molecule integrin antagonists on K562 cell adhesion to fibrinogen. (A) Representative images the fibrinogen adhesion assay 
with K562 cells treated with the indicated concentrations of ICT9055 for 4 hours compared to untreated cells. (B) Quantification of anti-adhesive effects of 
ICT9055, ICT9072 and ICT9073 on K562 cells with (red lines) and without (blue lines) 0.04µM PMA * p <0.05, ** p < 0.01, *** p < 0.001. 
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Figure 54 A: Effect of small molecule integrin antagonists on K562 cell adhesion to fibrinogen. Quantification of anti-adhesive effects of ICT9001, 
ICT9025, ICT9026, ICT9066, ICT9085 and ICT9094 on K562 cells with (red lines) and without (blue lines) 0.04µM PMA. * p <0.05, ** p < 0.01. 
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Figure 54 B: Effect of small molecule integrin antagonists on K562 cell adhesion to 
fibrinogen. Quantification of anti-adhesive effects of ICT9099, ICT9101 and ICT9103A on K562 
cells with (red lines) and without (blue lines) 0.04µM PMA. * p <0.05, ** p < 0.01. 
30
50
70
90
0.1 1 10
A
dh
es
io
n 
%
Concentrations µM
+PMA
- PMA
*
**
**
**
**
ICT9099
**
30
50
70
90
0.1 1 10
A
dh
es
io
n%
Concentrations μM
- PMA
+PMA
*
*
*
*
*
*
ICT9101
30
50
70
90
0.1 1 10
A
dh
es
io
n%
Concentrations μM
- PMA
+PMA
**
*
**
**
*
ICT90103A
 172 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 55: Inhibition of K562 cell adhesion to fibrinogen by ICT compounds. Cells pre-treated with 0.04 μM PMA (red bars) or not treated with PMA 
(blue bars) were treated with 10 μM compound for 4 hours. % adhesion is normalised compared to cells not treated by ICT compounds. * p <0.05, ** p 
<0.01 and *** p <0.0001. 
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4.4.3.6 Effects of novel integrin antagonists on MCF-7 cell adhesion. 
 
 
The compounds were also tested in MCF-7 cells according to the same 
procedure. IC50 values are given in Table 9. ICT9055, ICT9072 and ICT9073 
significantly reduced the adhesion of the MCF-7 cells to fibrinogen at the lowest 
concentration, while other ICT compounds had smaller effects at the same 
concentration (Figure 56 and Figures 57 A and B). Compared to the positive 
control (61 ± 2.2%), ICT9055 (68 ± 6.3%) at 10 μM was more potent, whereas 
ICT9072 (55.7 ± 4%), ICT9073 (50 ± 4.5%) at 1 μM and ICT9099 (57.5 ± 5.8%) 
at 10 μM were less potent. The rest of the ICT compounds at 10 μM were less 
potent (< 40%) than control (59 ± 7.9%). 
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Figure 56: Effect of small molecule integrin antagonists on MCF-7 cell adhesion to fibrinogen. (A) Representative images the fibrinogen adhesion assay 
with MCF-7 cells treated with the indicated concentrations of ICT9055 for 4 hours. (B) Quantification of anti-adhesive effects of ICT9055, ICT9072 and ICT9073 
on MCF-7 cells. * p <0.05, ** p <0.01.  
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Figure 57 A: Effect of small molecule integrin antagonists MCF-7 cell adhesion to fibrinogen. Quantification of anti-adhesive effects of ICT9001, 
ICT9025, ICT9076, ICT9066, ICT9085 and ICT9094 on MCF-7 cells compared to untreated cells. * p <0.05, ** p < 0.01.  
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Figure 57 B: Effect of small molecule integrin antagonists MCF-7 cell adhesion to 
fibrinogen. Quantification of anti-adhesive effects of ICT9099, ICT9101 and ICT9103A on MCF-7 
cells compared to untreated cells. * p <0.05.  
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Table 9: IC50 values for inhibition of cell adhesion by β3 integrin 
antagonists. 
ICT 
compounds 
K562-PMA 
IC50 ± SD (μM) 
K562 +PMA 
IC50 ± SD (μM) 
MCF7 
IC50 ± SD (μM) 
ICT9001 >100 84.66 ± 24 >100 
ICT9025 > 100 > 100 > 100 
ICT9026 > 100 > 100 > 100 
ICT9055 9.3 ± 0.75 0.96 ± 0.1 0. 43 ± 0.34 
ICT9066 > 100 > 100 > 100 
ICT9085 > 100 > 100 > 100 
ICT9072 79.7 ±17.7 6.6 ± 4 0.71 ± 0.2 
ICT9073 98 ± 3.6 13.7 ± 7.97 0.86 ± 0.2 
ICT9094 > 100 > 100 > 100 
ICT9099 > 100 8.58 ± 1.3 2.6 ± 2.3 
ICT9101 > 100 > 100 > 100 
ICT9103A > 100 8.64 ± 1.9 > 100 
cRGDfV 20 12.6 ± 6.4 50 
GR144053 > 20 14.1 ± 5.2 > 50 
GR144053 and 
cRGDfV 
17.7 ± 3.2 5.9 ±1 24.4 ± 4.8 
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4.4.3.6.1 Effect of ICT9055 on the viability of non-adherent cells.  
 
To further investigate the mechanism of action of ICT compounds on cancer cell 
lines, the most active compound, ICT9055, was selected for use in a viability 
assay. The viability of non-adherent cells collected during adhesion assays was 
determined using the trypan blue exclusion test. The results showed no 
apparent effect on the K562 cells (±PMA) after 4 hours of treatment. However, 
at 24 hours, cell viability was reduced by both ICT9055 and control compounds. 
The viability of MCF-7 cells was decreased after both 4 and 24 hours. Hoechst 
staining was used to determine whether the cell death in this assay was 
associated with apoptotic changes by IF. Cells with signs of apoptosis 
(fragmented nuclei) were observed (Figure 58 A and B and Figure 59 A and B). 
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Figure 58 A: Viability of K562 non-adherent cells upon ICT9055 treatment.  Nuclei staining with Hoechst in K562 (±PMA) non-adherent cells treated 
with ICT9055 showing signs of apoptotic morphology (white arrows). Scale bar = 50μm.
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 180 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 58 B: Viability of K562 non-adherent cells upon ICT9055 treatment. (A) Viability of 
K562 (±PMA) cells treated with ICT9055 for 4 hrs determined using the trypan blue assay. (B) 
Viability of K562 (±PMA) cells treated with ICT9055 for 24 hrs determined using the trypan blue 
assay. * P<0.05. 
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Figure 59 A: Viability of MCF-7 non-adherent cells upon ICT9055 treatment using the trypan blue assay.  Nuclei staining with Hoechst in MCF-7 
non-adherent cells treated with ICT9055 showing signs of apoptotic morphology (white arrows). Scale bar = 50μm.  
Untreated cells ICT9055 (4h) ICT9055 (24h)
MCF-7
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Figure 59 B: Viability of MCF-7 non-adherent cells upon ICT9055 treatment using the 
trypan blue assay. (A) MCF-7 cells treated with ICT9055 for 4 hrs determined using the trypan 
blue assay. (B) Viability of MCF-7 cells treated with ICT9055 for 24 hrs determined using the 
trypan blue assay. * p<0.05.  
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4.4.4 Validation of the fibrinogen detachment assay using cRGDfV and 
GR144053 
 
The detachment of K562 and MCF-7 cells from fibrinogen induced by integrin 
antagonists was first investigated using cRGDfV and GR144053 singly and in 
combination. Combination of the control compounds caused a larger amount of 
cell detachment than single compounds. Inhibition of β3 function caused partial 
detachment of untreated K562 cells and greater detachment of PMA-treated 
cells, where 40 µM combined antagonists had more effect than single 
compounds (Figure 60). Inhibition of β3 function also caused partial detachment 
of MCF-7 cells, with 50 µM combined antagonists having a greater effect than 
single compounds (Figure 61). Combination index analysis showed the two 
compounds had a strongly synergistic effect at all concentrations tested (Table 
10). 
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Table 10: Combination index values for cRGDfV/GR144053-induced 
detachment from fibrinogen. CI < 0.1 very strong synergism, 0.1 - 0.3 strong 
synergism 0.3 - 0.7 synergism, 0.7 - 0.85 moderate synergism, 0.85 - 0.90 slight 
synergism, and 0.90 -1.10 additive  
Type of Cells 
Total Dose 
(μM) 
CI Value Interpretation   
K
5
6
2
 w
it
h
 P
M
A
 
5.0 0.20 Strong synergism 
10.0 0.12 Strong synergism 
20.0 0.17 Strong synergism 
40.0 0.16 Strong synergism 
K
5
6
2
 w
it
h
o
u
t 
P
M
A
 5.0 
0.18 Strong synergism 
10.0 0.13 Strong synergism 
20.0 0.17 Strong synergism 
40.0 0.19 Strong synergism 
M
C
F
-7
 
5.0 0.34         Synergism 
10.0 0.26 Strong synergism 
20.0 0.30 Strong synergism 
50.0 0.44 Synergism 
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Figure 60: Effects of cRGDfV and GR144053 on K562 cells detachment. Cells (± 0.04μM PMA) were treated with the stated concentration of 
compounds for 6 h, then number of detached cells quantified by counting with haemocytometer. (A) Number of detached cells (B) Number of remaining 
attached cells. Values are the average of 3 independent experiments and error bars are SE. * p<0.05
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Figure 61: Effects of cRGDfV and GR144053 on MCF-7 cells detachment. Cells were treated 
with the stated concentration of compounds for 6 hours, then number of detached cells quantified 
by counting with haemocytometer. (A) Number of detached cells (B) Number of remaining 
attached cells. Values are the average of 3 independent experiments and error bars are SE. *p 
<0.05, ** p<0.01 and *** p<0.001. 
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Subsequently, a time course of cell detachment was performed (Figure 62 and 
Figure 63). Detachment determinations were performed after 2, 4 and 6 hour’s 
incubation with cRGDfV and GR144053 singly and in combination at 50 μM. As 
anticipated, a time-dependent increase in the percentage of detached cells was 
shown which was accompanied by a corresponding decrease in the percentage 
of remaining attached cells in both cell lines. Combined antagonists had a 
greater effect than single compounds. Doses of 40 μM and 50 μM of the 
combined controls for 6 hours were selected for use in K562 and MCF-7 
respectively as comparators with ICT compounds. 
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Figure 62: Effects of cRGDfV and GR144053 on K562 cell adhesion. Cells (± 0.04μM PMA) 
were treated with the stated concentration of compounds for 2, 4 and 6 hours, then number of 
detached cells quantified by counting with haemocytometer. (A) Number of detached cells (B) 
Number of remaining attached cells. Values are the average of 3 independent experiments and 
error bars are SE. * p <0.05. ** p < 0.01 and *** p < 0.001.  
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Figure 63: Effects of cRGDfV and GR144053 on MCF-7 cell adhesion. Cells (± 0.04μM PMA) 
were treated with the stated concentration of compounds for 2, 4 and 6 hours, then number of 
detached cells quantified by counting with haemocytometer. (A) Number of detached cells (B) 
Number of remaining attached cells. Values are the average of 3 independent experiments and 
error bars are SE. * p <0.05 ** p < 0.01 and *** p < 0.001.  
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4.4.4.1 Effects of novel β3 integrin antagonists on cell detachment 
 
Detachment determinations were performed after 2, 4 and 6 hour’s incubations 
with different concentrations (0.1, 1, and 10 μM) of ICT9055 evaluated by 
counting with haemocytometer (Figure 64 and Figure 65). ICT9055 showed the 
highest effect of detaching PMA treated K562 cells from fibrinogen compared to 
untreated cells in a time and dose dependent manner. 
 
ICT9055, ICT9072, ICT9073 and ICT9099 were selected for further 
investigation in the detachment assay as they had been demonstrated (sections 
4.4.3.5 and 4.4.3.6) to give significant inhibition of the adhesion of K562 cells 
±PMA and MCF-7 cells to fibrinogen. The selected cells were plated on 
fibrinogen coated wells and treated with different concentrations (0.1, 1 and 10 
μM) of the compounds for 6 hours. The detached cells from the fibrinogen-
coated plates were counted. The number of cells remaining on the plates 
decreased with increasing compound concentration, whereas the number of the 
detached cells increased with increasing compound concentration (Figure 66). 
The most successful compound at causing K562 cell detachment at 10 μM was 
ICT9055 then ICT9072, ICT9099 and ICT9073 respectively. Positive control (49 
± 0.5%, P<0.01 without PMA and 66 + 3.6%, P<0.05 with PMA) was less 
effective at causing cell detachment than all tested compound except ICT9073 
(±PMA) and ICT9099 (+PMA), which were a slightly less effective. EC50 are 
given in Table 11. 
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Figure 64: Effects of ICT9055 on K562 cell adhesion. Cells (± 0.04 μM PMA) were treated with 
the stated concentration of compound for 2, 4 and 6 hours, then number of detached cells 
quantified by counting with haemocytometer. (A) Number of detached cells (B) Number of 
remaining attached cells. Values are the average of 3 independent experiments and error bars 
are SE. * p <0.05. ** p < 0.01, *** p < 0.001.  
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Figure 65: Effects of ICT9055 on MCF-7 cell adhesion. Cells were treated with the stated 
concentration of compound for 2, 4 and 6 hours, then number of detached cells quantified by 
counting with haemocytometer. (A) Number of detached cells (B) Number of remaining attached 
cells. Values are the average of 3 independent experiments and error bars are SE. * p <0.05 ** p 
< 0.01 and *** p < 0.001.
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Figure 66: Induction of K562 detachment from fibrinogen by ICT compounds. Cells (± 0.4 μM PMA) were treated with the stated concentration of compound for 6 
h, then number of detached cells quantified by counting with haemocytometer. (A) Number of detached cells (B) Number of remaining attached cells. Values are the 
average of 3 independent experiments and error bars are SE. * p <0.05. ** p < 0.01 and *** p < 0.001. 
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Table 11: EC50 values for cell detachment caused by ICT compounds, 
GR144053 and cRGDfV. 
Compounds 
K562 (- PMA) 
EC50 ± SD (μM) 
K562(+PMA) 
EC50 ± SD (μM) 
MCF-7 
EC50 ± SD (μM) 
ICT9055 0.8 ± 0.1 0.1 1. 8 1 ± 1.1 
ICT9072 9.1 ± 0.7 0.47 ± 0.08 3.4 ± 3.8 
ICT9073 > 10 4.4 ± 1.9 > 10 
ICT9099 8.5 ± 2 2.3 ± 0.4 > 10 
CRGDfV > 40 > 40 25.42 ± 5.5 
GR144053 > 40 > 40 > 50 
GR144053 and 
cRGDfV 
30.4 ± 2.2 9.1 ± 1.3 11.88 ± 2 
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4.4.4.1.1 Characterisation of αv, αllb and β3 integrin subunit expression in 
detached and attached PMA-treated K562 cells.  
 
Analysis of αv, αllb and β3 integrin subunit expression after 6 hours of exposure 
to ICT9055 showed no alterations in expression in detached K562 cells 
compared to untreated cells. In contrast, attached cells showed lower 
expression of αv, αllb and β3 integrin subunits than untreated cells and 
detached cells (Figure 67). ICT9055 caused significant detachment of PMA-
treated K562 cells from fibrinogen coated plates, which suggests it is able to 
disrupt binding to αllbβ3 and αvβ3. However, reduced expression levels of αv, 
αllb and β3 integrin subunits were observed in cells which remained attached to 
fibrinogen-coated plates in the presence of ICT9055. These findings may be 
explained by the existence of subpopulations of PMA induced K562 cells which 
attach to fibrinogen via other integrins such as α5β1; a clear expression of α5 
was previously shown in K562 cells (Figure 25, Figure 33 and Figure 34). 
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Figure 67: Expression of αv, αllb and β3 integrin subunits in K562 cells treated with 
ICT9055. (A) The expression of integrin subunits in detached cells and (B) the expression of 
integrin subunits in attached cells compared to untreated cells (UTC) using immunofluorescence 
with Q20 anti-αv, EPR4330 anti-αIIb, and B7 anti-β3. Scale bar = 50 μm. Blue-fluorescent DAPI 
is nuclear staining and green colour represents integrins expression detected by a green 
fluorophor. White arrows point to positive labelling of αv, αIIb, β3 integrin subunits in the detached 
and attached cells. 
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4.4.4.2 Effects of novel β3 integrin antagonists on MCF-7 cell detachment 
 
ICT9055, ICT9072, ICT9073 and ICT9099 were also investigated on 
detachment and remaining attachment of MCF-7 cells. The cells were plated on 
fibrinogen coated wells and treated with different concentrations (0.1, 1 and 10 
μM) of the compounds for 6 hours. The detached cells from the fibrinogen-
coated plates were counted. As with K562 cells, a dose dependent increase in 
cell detachment was observed, and ICT9055 was the most effective compound 
identified (Figure 68). EC50 are given in Table 11. 
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Figure 68: Induction of MCF-7 cells from fibrinogen by ICT compounds. Cells were treated with the stated concentration of compound for 6 h, then number of 
detached cells quantified by counting with haemocytometer. (A) Number of detached cells (B) Number of remaining attached cells. Values are the average of 3 
independent experiments and error bars are SE. * p <0.05 ** p < 0.01, *** p < 0.001.
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4.4.5  Transwell migration assays 
 
The ability of K562 and MCF-7 cells to migrate through a porous membrane 
was investigated in order to determine whether models are fit for measuring 
inhibition of migration. 
 
4.4.5.1 Cell migration  
 
Cell migration depends on the ability of cells to move from one area to another 
in response to a chemoattractant. The transwell migration assay was optimised 
using different concentrations of FCS as a chemoattractant. The best results 
were obtained with unstimulated K562 and MCF-7 cells.  K562 cells treated with 
PMA were unable to migrate through the pores successfully (Figure 69 and 
Figure 70)
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Figure 69: Optimisation of chemoattractant concentration for K562 cell migration through 
a transwell membrane. 5 X 105 cells were seeded in the upper chamber of a transwell insert and 
allowed to migrate towards FBS for 24 hours. (A) Representative images of the migrated cells 
visualised with. Scale bar = 100 μm (B) Quantification of cell migration in response to different 
concentrations of FBS. * p <0.05. 
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Figure 70: Optimisation of chemoattractant concentration for MCF-7 cell migration through 
a transwell membrane. 4 X 105 cells were seeded in the upper chamber of a traswell insert and 
allowed to migrate towards FBS for 24 hours. (A) Representative images of the migrated cells 
visualised with. Scale bar = 100 μm (B) Quantification of cell migration in response to different 
concentrations of FBS. * p <0.05. 
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4.4.5.2 Validation of the transwell migration assay using cRGDfV and 
GR144053 
 
Different concentrations of cRGDfV and GR44053 were used singly and in 
combination for 24 hours in the transwell migration assay to confirm migration 
was β3 integrin dependent and provide a baseline to compare new antagonists 
(Figure 71 A and B and Figure 72 A and B). The ability of combined compounds 
to inhibit migration of K562 and MCF-7 cells through the membrane of the 
chamber was higher than single compounds and combination index analysis 
indicated the interaction was synergistic at all doses tested (Table 12). 
GR144053 alone had little effect, indicating migration is not αIIbβ3 dependent. 
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Figure 71 A: The effect of cRGDfV and GR144053 on K562 cell migration.  Representative images of the bottom surface of a transwell plate are 
shownfor each compound. Scale bar = 100 μm at 20X objective lens. 
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Figure 71 B: The effect of cRGDfV and GR144053 on K562 cell migration.  Quantification of 
reduction in migration; results presented are an average of 3 random microscopic fields (20X) 
from 3 independent experiments error bars are SE.  * p <0.05, ** p <0.01 and *** p <0.001.
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Figure 72 A: The effect of cRGDfV and GR144053 on MCF-7 cell migration. (A) Representative images of the bottom surface of a transwell plate are shown 
for each compound. Scale bar = 100 μm at 20X objective lens.
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Figure 72 B: The effect of cRGDfV and GR144053 on MCF-7 cell migration. Quantification of 
reduction in migration; results presented are an average of 3 random microscopic fields (20X) from 3 
independent experiments and error bars are SE. * p <0.05, ** p <0.01 and *** p <0.001. 
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Table 12: Combination index values of GR144053 and cRGDfV on 
transwell migration. CI < 0.1 very strong synergism, 0.1 - 0.3 strong synergism 
0.3 - 0.7 synergism, 0.7- 0.85 moderate synergism, 0.85 - 0.90 slight synergism, 
and 0.90 -1.10 additive. 
 
 
 
 
 
 
 
 
Type of 
Cells 
Total Dose 
(μM) 
CI Value Interpretation 
K
5
6
2
 
5.0 0.35 Synergism 
10.0 0.29 Strong synergism 
20.0 0.32 Synergism 
40.0 0.23 Strong synergism 
  M
C
F
-7
 
  
5.0 0.28 Strong synergism 
10.0 0.24 Strong synergism 
20.0 0.27 Strong synergism 
50.0 0.34 Synergism 
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4.4.5.3 Characterisation of the anti-migratory effect of novel β3 integrin 
antagonists 
 
To investigate whether ICT9055, ICT9072 and ICT9073 are able to block the 
migration of K562 and MCF-7 cells, I performed in vitro migration assays using 
transwell chambers in vitro. ICT9055 produced a greater effect than ICT9072 
and ICT9073 at all concentrations tested. ICT9055 and ICT9072 had a higher 
effect than the combination of anti-αvβ3 and anti-αIIbβ3 controls (55.5% + 4.7 in 
MCF-7 cells and 45.5% + 3.3 in K562 cells, P<0.01) while ICT9073 was less 
effective (Figure 73 A and B and Figure 74 A and B). IC50 values are given in 
Table 13. 
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Figure 73 A: The effect of ICT compounds on K562 cell migration.  Representative images of the bottom surface of a transwell plate are shown for each ICT 
compound. Scale bar= 100 μm at 20X objective lens.   
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Figure 73 B: The effect of ICT compounds on K562 cell migration. Quantification of reduction 
in migration; results presented are an average of 3 random microscopic fields (20X) from 3 
independent experiments and error bars are SE. * p <0.05, ** p <0.01, *** p <0.001.
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Figure 74 A: Effect of ICT compounds on MCF-7 cell migration.  Representative images of the bottom surface of a transwell plate are shown for each ICT 
compound. Scale bar = 100 μm at 20X objective lens. 
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Figure 74 B: Effect of ICT compounds on MCF-7 cell migration. Quantification of reduction in 
migration; results presented are an average of 3 random microscopic fields (20X) from 3 
independent experiments and error bars are SE. * p <0.05, ** p <0.01, *** p <0.001. 
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Table 13: IC50 values for β3 integrin antagonists in inhibition of cell 
migration. 
Compound 
K562 
IC50 ± SD (μM) 
MCF-7 
IC50 ± SD (μM) 
ICT9055 7.3 ± 1.7 1.08 ± 0.96 
ICT9072 48.9 ± 8 3.4 ±   2.3 
ICT9073 78.6 ± 10.1 8.4 ±1.2 
CRGDfV > 50 39.7 ± 10.1 
GR144053 > 50 > 50 
GR144053 and 
cRGDfV 30.5 ± 5.6 14.8 ± 9.5 
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4.5 Discussion   
 
The metastatic cascade of tumour cells includes sequential multi-steps: 
detaching from the primary tumour, migrating to distant sites and attaching to 
the tumoural niche (Hanahan and Weinberg, 2011). During the steps of 
metastasis formation, the capability of cells to interact with ECM proteins 
through integrins provides the traction necessary for regulating both adhesion 
and migration processes. Consequently, blocking tumour cells binding to the 
ECM is an important strategy to prevent their spreading (Desgrosellier and 
Cheresh, 2010). 
In the previous chapters the β3 integrin expressing cancer cell lines, K562 and 
MCF-7 were characterised and selected to use in the functional assays. In this 
chapter, these selected models were validated using known β3 antagonists 
cRGDfV and GR144053 as positive controls. The purpose of these validations 
was to demonstrate that the models are suitable for assessing inhibition of cell 
adhesion; induction of cell detachment and anti-migration properties in that the 
models were responsive to β3. The validated models were then used to 
investigate the effect of novel small molecule β3 integrin antagonists.  
Subsequently, the novel small molecule β3 integrin antagonists were evaluated 
for their relative cytotoxicity before they were used in the functional assays, in 
order to determine the safe dose of the antagonists that would show effects 
through blocking β3 integrin function in mediating cell adhesion and migration 
rather than inducing cytotoxicity. Firstly, the cytotoxicity of αllbβ3 antagonist 
(GR144053) and αvβ3/β5 antagonist (cRGDfV) against K562 cells (in the 
presence of PMA and its absence), and MCF-7 cells was investigated utilising 
the MTT assay, to determine concentrations that could be used in the functional 
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assays without causing cell killing. cRGDfV and GR144053 had no toxic effects 
on the K562 cell lines (±PMA) and MCF-7 compared to their control except at 
higher doses.  
As seen in Table 7, different anti β3 integrin antagonists had different cytotoxic 
effects. ICT9001, ICT9026, ICT9055 and ICT9103A were not toxic to K562 and 
MCF-7 cells. ICT9066, ICT9072 and ICT9073 had a cytotoxic effect on MCF-7 
only, and ICT9025 and ICT9101 were cytotoxic to K562 in the presence of 
PMA. ICT9094 and ICT9099 showed the cytotoxic effect with all tested cell 
lines. Previous studies have also found cytotoxic effects of αvβ3 antagonists are 
highly variable within a library (Dayam et al., 2006). 
The cell adhesion assay is an important method in cell biology because cellular 
adhesion is a contributing factor in many diseases, including inflammatory 
diseases, tumour progression, and metastasis. These cellular responses are 
based on the attachment of adhesion receptors to existing extracellular matrix 
proteins or another cell’s surface, and also cellular adhesion is essential for the 
growth and survival of the cell (Soloviev et al., 2007). Therefore, a cell adhesion 
assay is often utilised to evaluate the metastatic ability of cancer cells and also 
provides a low-cost method for screening integrin antagonists.    
In order to identify models of cellular adhesion, the concentration of K562 cells 
binding to fibrinogen was optimised with and without PMA. PMA stimulation of 
K562 cells increased adhesion on fibrinogen compared to unstimulated cells, 
indicating that the integrin receptors induced by PMA treatment were 
functionally competent. 
Likewise, cell detachment is fundamental to several phenomena of cellular 
dynamic such as cell migration (Geiger et al., 2001a, b; Ridley et al., 2003). 
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Cheng et al.(2016) found that blocking the activity of αvβ3 and αvβ5 integrin 
induced the detachment of all three papillary thyroid cancer cell lines. In 
endothelial cells, inhibiting integrin activity usually results in cell detachment and 
leads to a form of programmed cell death called anoikis. 
Further, cellular adhesion and detachment were validated with controls singly 
and in combination. K562 cells (with and without PMA) were treated with 
different concentrations of GR144053 and cRGDfV to measure the antagonists’ 
ability to inhibit the adherence of cells to fibrinogen and to break the established 
binding interactions between the targeted integrin receptors and fibrinogen.  
The inhibitory and detaching effects were greater in PMA-stimulated cells than 
in unstimulated. These data showed that the known β3 antagonists, GR144053 
and cRGDfV, decrease cellular adhesion to fibrinogen in the adhesion assay 
and increase cellular detachment from fibrinogen in the detachment assay. 
Adhesion and detachment were partially dependent on the β3 integrins in 
untreated cells and more dependent in PMA-treated cells, where 20 μM and 40 
μM combined antagonists respectively in adhesion and detachment assays 
almost completely blocked cell adhesion and induced cell detachment with the 
synergistic effects in the analysis of combination index (CI<1). The importance 
of synergistic effects arises through pharmacokinetic and/or pharmacodynamics 
interactions that occur between two or more agents which result in an effect 
greater than the sum of individual effects. The pharmacodynamic synergy refers 
to two or more compounds that work on the same biological targets or receptors 
that lead to induced therapeutic results through their positive interactions (Zhou 
et al., 2016a). Synergistic effects also arise from working on the targets that 
have different modes of action. For instance, the combination of cilengitide and 
temozolomide gave synergistic antiproliferative effects against endothelial and 
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malignant melanoma cells in vitro and enhanced a statistically significant 
decrease in melanoma growth in vivo, thereby providing  novel insights for the 
utilisation of integrin inhibitors not only in an adjuvant therapy to inhibit tumour 
spreading but also to improve the efficiency of chemotherapy (Tentori et al., 
2008). In MCF-7 cells, 50 μM combined antagonists reduced cell adhesion to 
fibrinogen and induced cell detachment with a synergistic effect. These data 
indicate that blocking of integrin by either GR144053 or cRGDfV particularly 
with PMA treated K562 incompletely inhibits integrin function, through acting on 
either αllbβ3 or αvβ3, whereas the combination improves β3 integrin receptors’ 
occupation by covering both targets, which can inhibit adhesion completely or 
completely induce detachment. The present data suggest that targeting αllβ3 
alone is insufficient to inhibit cell adhesion, whereas targeting αvβ3 and αllbβ3 
integrins has a greater effect on cancer cell interactions with a biologically 
relevant extracellular matrix derived ligand, such as fibrinogen in these 
particular dual expression models. This result corresponds with the finding of 
Gomes et al.(2004) which identified cooperation between αIIbβ3 and αvβ3 in 
breast adenocarcinoma cells’ adhesion to ECM under flow conditions. The 
αIIbβ3 antagonist lamifiban (Ro 44-9883) reduced adhesion of cancer cells to 
ECM while the αvβ3 antagonist (SB-273005) did not affect cancer cell adhesion 
to the ECM. However, the combination of both antagonists (SB-273005 and Ro 
44-9883) had a synergistic effect on adhesion compared to the effects of single 
antagonists. 
 
The effect of the novel β3 integrin antagonists was investigated using the 
fibrinogen adhesion assay. GR144053 and cRGDfV were included as combined 
control integrin antagonists. The data obtained showed that different 
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antagonists had different effects on inhibition of K562 (±PMA) and MCF-7. 
ICT9055 which contains the tetrahydronaphthyridine (THN) αv-binding 
functional group was an effective inhibitor of PMA treated K562 cell adhesion 
and showed a 10-fold difference in the effect between untreated and PMA 
treated K562. ICT9055 was, therefore, the most effective functional antagonist 
with no toxic effect on PMA treated K562 cells, which had upregulated integrin 
expression. ICT9055 also was significantly more potent at inhibiting MCF-7 
attachment to fibrinogen compared to the combined control. 
ICT9094 also contains the THN group, and a longer β3 binding group. It has 
cytotoxic effect on all tested cells and had minor effect on adhesion. ICT9101 
has a very similar structure and similar efficacy. 
Many of the tested compounds are methyl esters which are expected to be 
rapidly hydrolysed by cell esterases, releasing active carboxylic acids. ICT9099 
contains a tert-butyl ester group which is a non-physiologial group and sterically 
hindered so might not be hydrolysed by cells. ICT9099 effectively inhibited 
K562 and MCF-7 cells’ adhesion in vitro, which suggests the tert-butyl ester is 
being hydrolysed releasing ICT9103A.  
The positive effect on K562 (±PMA) and MCF-7 was seen with the compounds 
ICT9072 and ICT9073. The carboxylic acids ICT9001 and ICT9103A were 
effective inhibitors of K562 cell adhesion in the presence of PMA only, which it 
suggests they act on the upregulated integrins. The effect of ICT9001 is 
surprising as it does not contain an exosite binding group so would be expected 
to have lower affinity for β3 integrins than other compounds. The other 
compounds including ICT9025, ICT9026, ICT9066, ICT9085, and ICT9101 
showed a minor effect compared to ICT9055 on all tested cells. ICT9066 has 
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the THN αv binding group, which is generally more active than the αv binding 
group found in ICT9001, and like ICT9001 has no exosite binding group. These 
results indicate that the observed activity of compounds is not dependent on 
one particular functional group and it is difficult to identify SAR or predict activity 
in this chemical library.  
Further analysis during the fibrinogen adhesion assay found ICT9055 
demonstrated time-dependent effects on cellular viability of non-adherent K562 
cells. The viability of non-adherent cells declined with increasing time (Figure 
59) indicating that the effects of ICT9055 might be associated with an initial loss 
of cellular attachment followed by cell death. However, the viability of non-
adherent MCF-7 cells was reduced with short and long exposure times. The 
analysis of non-adherent cells with Hoechst staining revealed a time-dependent 
increase in the number of cells displaying apoptotic morphology. Results 
presented herein demonstrate that the compounds’ effects on cellular viability 
depend on the cell lines as MCF-7 was more affected than K562. This in 
agreement with Frisch and Ruoslahti., (1997) who confirm that the loss of 
integrin-mediated cell–matrix interaction can enhance programmed cell death of 
some cell types such as mammary epithelial cells. Other cell lines might be 
more resistant to a drug than others; insensitivity to loss of normal cell-matrix 
interactions is a feature of cancer progression, promoting migration and 
invasion (He et al., 2010). 
Additionally, the data obtained from the cell detachment assay showed that β3 
integrin antagonists induced a statistically significant concentration and time 
dependent increase in the detachment of cells. Similar data have been obtained  
with other αvβ3 small molecule antagonists (Christenheit et al., 2016). However, 
in cell-free systems, integrin antagonists have been found to be unable to 
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reverse pre-existing integrin-matrix interactions. For example, RGD-based 
inhibitor such as cilengitide was unable to induce cell detachment. A non-
reversible complex formed very rapidly that did not depend on the integrin leg 
regions or the time-dependent formation of a high-affinity state of the integrin, 
Compared to RGD-based inhibitor, Ca2+ (but not Mg2+) caused on increased 
detachment rate of integrin-fibronectin complexes (Mould et al., 2014). 
Humphries et al.(2015) have suggested this may be a reason for the failure of 
RGD-based competitive antagonists in the clinic. These results suggest there 
are significant differences between the effect of RGD-mimetic antagonists in 
cell-free and cell-based systems so the inability to reverse binding interactions 
may not be a problem in vivo.  
Using the detachment assay, analysis of αv, αllb and β3 integrin subunit 
expression in attached and detached cells showed no changes in integrin 
expression in detached cells compared to control cells. In contrast, attached 
cells showed lower expression of αv, αllb and β3 integrin subunit than in 
untreated control or treated detached cells. Most probably these observations 
may be explained by a fraction of PMA treated K562 cells with low expression 
of the integrins targeted by ICT9055 binding to fibrinogen via integrin α5β1 as a 
clear expression of α5 was observed in the presence of PMA.  
In addition to investigating the effects of novel β3 antagonists on the adhesion 
and detachment of the cells in vitro, it was important to study their effect on 
other features that characterise cancer spreading such as cell migration. The 
determination of the migratory and invasive potential and activity of cancer cells 
is essential for offering novel clinical strategies in cancer prognosis, diagnosis 
and drug development, since the acquisition of a migratory phenotype is 
needed for metastatic spreading. A wide range of assays are available to 
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evaluate the migratory or invasive potential of cells in vitro. These assays range 
from cheap and simple ones to expensive ones (Justus et al., 2014) such as the 
scratch assay, the cell-exclusion zone assay and the transwell migration assay. 
The advantages of the transwell migration assay are the availability of different 
cell culture inserts and sizes, a short path length medium/chemokine gradient 
between the upper and lower culture medium reservoir and the relative ease of 
the experimental setup. Therefore, this assay is commonly used to evaluate cell 
migration (Justus et al., 2014). The transwell migration assay was used in this 
work since the selected cell lines were not suitable for the scratch assay; K562 
cells are suspension cells while MCF-7 cells did not completely close a scratch 
after 72 hours (Appendix ll). 
The transwell migration assay was optimised for use with K562 and MCF-7 
cells. MCF-7 and K562 cells with and without PMA were investigated using 
different concentrations of FBS as chemoattractant to evaluate the ability of the 
cells to migrate through pores of the membrane. PMA stimulation of K562 cells 
reduced migration through the pores compared to unstimulated cells (K562 and 
MCF-7). Zhou et al., (2016) demonstrated that K562 cells treated with PMA 
showed increased strength of binding to other cells, which was attributed to 
increased E-cadherin expression, and decreased migration in a transwell assay 
due to increased traction forces.  
Anti-migratory effects were shown with all β3 antagonists investigated. 
cRGDfV had a greater effect than GR144053 when used singly, 
indicating migration of K562 and MCF-7 cells is more dependent on 
αvβ3 than αIIbβ3. cRGDfV and GR144053 shows synergistic effects in 
the analysis of combination index when used together at all 
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concentrations tested. ICT9055, ICT9072 and ICT9073 suppressed 
migration of K562 and MCF-7 cells in a dose-dependent manner. 
ICT9055 and ICT9072 were more potent, but ICT9073 was less potent. 
No SAR is apparent here.  
To sum up, these findings (Table 14, Appendix III) demonstrate the 
ability of novel small molecule β3 integrin antagonists to inhibit cell 
adhesion and migratory potential effectively, both of which are critical 
factors for infiltration of remote tissues and cancer spreading in vivo. 
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Chapter 5: General discussion, conclusion 
and future work 
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4.6  General discussion 
 
Metastasis depends on the regulation of some specific cellular properties, 
amongst them cell survival/programmed cell death, cell migration/invasion and 
cell proliferation. These processes are partially regulated by cell attachment and 
detachment, which require the involvement of integrin receptors. Integrins are 
also recognised as being important for mediating cell migration in tumours 
(Felding-Habermann et al., 2001; Huttenlocher and Horwitz, 2011), in addition 
to interactions of tumour cell and tumour cell-platelet binding (Weber et al., 
2016), functions which are essential for immune evasion and metastasis 
(Yacobovich et al., 2016). 
The expression of selected integrins is upregulated, often dramatically, during 
human cancers and inflammatory diseases (Raab-Westphal et al., 2017). 
Therefore, due to their involvement in these process have become popular 
targets in the battle against metastasis (Ganguly et al., 2013).  
Small molecule drugs are popular as antagonists as they have better stability 
and are less costly to manufacture than antibodies (Millard et al., 2011). For 
example, pharmacokinetics of small molecules are often better than antibodies 
in vivo; half-life, typically less than 5 hours and attractive plasma protein binding 
and daily dosing. Antibodies may have half-lives of many weeks and require 
monthly dosing and no renal filtration. They are also subject to target mediated 
clearance (Carter, 2006; Hatley et al., 2017; Vugmeyster et al., 2012). 
Integrin targeted therapies are employed in two strategies: blockade of integrin 
function; and the utilisation of integrin expression patterns to facilitate drug 
delivery (Currier et al., 2016). Blockade of integrin function has so far been the 
main therapeutic strategy that has reached the clinic (Raab-Westphal et al., 
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2017), although it has not been successfully used to treat cancers. Notably, 
selective integrin ligands have been widely utilised to target tumours with high 
integrin expression as inhibitors of cancer angiogenesis (Desgrosellier and 
Cheresh, 2010; Kapp et al., 2017). 
Inhibition of β3 integrins (platelet αIIbβ3 and endothelial and cancer cell-αvβ3) 
has an important role preventing tumour angiogenesis and cancer metastasis 
(Gay and Felding-Habermann, 2011). Accordingly, we hypothesise that dual β3 
antagonists will have superior efficacy in a dual β3 integrin expressing model by 
reducing proliferation, as well as preventing angiogenesis and metastasis 
through targeting dual expressing cancer cell interaction with platelet αIIbβ3 and 
endothelial cells αvβ3. 
In this thesis, the overall aim was to evaluate the effect of ICT compounds on 
the inhibition of human tumour cell adhesion and migration; and induction of cell 
detachment utilising functional assays. The main objectives of the work were to 
develop models that can be used for evaluation of novel β3 integrin antagonists 
by detecting expression of integrin subunits particularly αIIb, αv and β3 in 
human cancer cell lines. 
Initially, the expression of αv, αIIb, α5, β3 and β5 integrin subunits was 
investigated in the panel of human cancer cell lines (K562, DU145, PC-3, 
LNCap, MCF-7, M14, MeWo, UACC-62 and HT-29) using IF and FACS 
(Chapter 2). Since FACS analysis is quantitative and sensitive measurements, it 
can be used to investigate even weak expression (Goodman and Picard, 2012; 
Nolan and Sklar, 1998). However, FACS does not evaluate the location of 
protein expression, so it must still be run in comparison with IF.   
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αv, αllb and β3 integrin subunits were found to be highly expressed in MCF-7 
cells. This is in agreement with IF and FACS analysis that showed expression 
of αIIbβ3 and αvβ3 in MCF-7 (Oleksowicz et al., 1995). Therefore, MCF-7 was 
chosen as a suitable dual β3-expressing model in its native state to investigate 
novel dual αvβ3 and αllbβ antagonists in the functional assays.  
Integrin expression in the leukaemia cell line K562, which has been shown to 
express αIIbβ3 when treated with PMA (Galletti et al., 2014; Stupp et al., 2010), 
was also investigated in order to develop a functional assay model for testing 
dual β3 antagonism.  
The different times of induction at different concentrations of PMA were 
investigated to explore its effect on integrin expression as discussed in Chapter 
3; 0.04 μM PMA for 40 hours was chosen as a safe concentration and time to 
induce αllb in K562 cells. PMA stimulation of K562 cells increased adhesion on 
fibrinogen compared to unstimulated controls. This suggests that the functional 
response of stimulated cells depends on integrin-mediated binding. Zhou found 
increased E-cadherin was responsible for increased adhesion in PMA-treated 
leukaemia cell lines (Zhou et al., 2016b). Therefore, known β3 antagonists, 
GR144053 and cRGDfV were used singly and in combination to validate cell 
adhesion and detachment assays, confirming the binding was β3 integrin 
mediated. Their inhibitory and detaching effects were dose dependent and 
greater in PMA-stimulated K562 cells than in unstimulated cells. Combination of 
the control compounds inhibited cellular adhesion and induced cellular 
detachment more than single compounds with a combination index CI<1, 
indicating there was a synergistic interaction between the two agents. The same 
effects were seen in MCF-7 cells. The synergy of two or more agents is a highly 
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pursued goal for developing combined drugs which lead to greater efficacy than 
monotherapy because their interaction is accompanied by a greater response in 
the tumour microenvironment. In this case, the efficacy of the combination 
indicates the two β3 integrins both contribute to cell functions and are partially 
redundant if one is inhibited, and support our hypothesis that dual antagonism is 
required for effective control of dual integrin expressing tumours.  
After establishing the fibrinogen adhesion assay response to controls, novel β3 
integrin antagonists were screened. From investigating a panel of 12 small 
molecules, ICT9055 was not toxic and had the greatest effect in inhibition of 
K562 (±PMA) and MCF-7 cell adhesion compared to the combined controls. 
Other compounds had different cytotoxicity such as ICT9072 and ICT9073 
which were toxic to MCF-7 cells but not toxic to K562 cells. The difference in the 
cytotoxic effect of some integrin antagonists on some tumour cells is a common 
observation. For example, the effects of cilengitide were investigated against 
the three papillary thyroid cancer cell lines (BCPAP, TPC1, and K1). These data 
showed a moderate effect on cell viability of BCPAP and K1 cells but cilengitide 
was toxic in TPC1 cells which had the highest expression of the target integrins 
(Cheng et al., 2016).  
Cheng et al., (2016) suggested that integrin antagonists may be most useful in 
subgroups of patients with high integrin expressing tumours. The toxicity results 
in this study are more likely to result from idiosyncratic or off target effects of 
particular compounds, and may suggest that these compounds are also pro-
apoptotic. 
ICT9072, ICT9073 and ICT9099 reduced the adhesion of K562 cells treated 
with PMA more than untreated controls. ICT9001 and ICT9103A reduced 
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adhesion only in the presence of PMA suggesting they are acting specifically on 
the upregulated integrins rather than those expressed on untreated cells.  
In addition, the viability of non-adherent K562 cells (±PMA) and MCF-7 treated 
with ICT9055 during the adhesion assay was investigated and showed that 
ICT9055 affected cell survival in a time-dependent manner. When K562 cells 
were treated with ICT9055, no difference in the number of viable cells was 
detected within 4 hours, but the number of viable K562 cells had decreased by 
24 hours. The number of viable MCF-7 cells declined with both short and long 
times of exposure. The effects of ICT9055 may be related to the initial loss of 
cell adhesion leading later to cell death, with different cell lines being more 
sensitive to loss of adhesion. The proteins of the pro-apoptotic BH3 family are 
essential players within the intrinsic pathway of the anoikis programme (Bouillet 
and Strasser, 2002). Bid and Bim are members of the BH3-only protein family 
which are activated following cells detachment from ECM and stimulate the 
assembly of Bax–Bak oligomers within the outer mitochondrial membrane 
(Taylor et al., 2008). Bim is isolated in the dynein cytoskeletal complexes until 
loss of cell adhesion promotes a release of Bim from these complexes and 
leads to its translocation to the mitochondria (Cheng et al., 2001; Paoli et al., 
2013). Loss of cell adhesion also results in accumulating of Bim, during the 
prevention of its proteasomal degradation caused by an ERK and PI3K/Akt-
mediated phosphorylation of Bim, elicited upon engagement of integrin (Le Gall 
et al., 2000; Paoli et al., 2013; Qi et al., 2006). 
Hoechst staining of K562 and MCF-7 indicated apoptosis was taking place. As 
noted by Hook and Schagat., (2012) the same compound may induce 
programmed cell death in one cell type but not in other cells, and the time of 
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drug exposure required to induce a response which also may change with cell 
type.  
The effect of compounds on cellular detachment was investigated, as Mould et 
al., (2014) had postulated that RGD-mimetic antagonists were ineffective due to 
their inability to detach integrins from their ligands, demonstrated with 
Cilengitide and cycloGRGDSP. Amino acid residues involved in integrin-
fibronectin binding become masked in the ligand-occupied state which prevents 
binding competitive antagonists. As a result of location of the epitopes of some 
function-blocking anti-integrin mAbs close to the ligand-binding pocket, it follows 
that the epitopes of these mAbs may become protected in the ligand-occupied 
state. mAbs could fail to cause dissociation of integrin-fibronectin interactions 
(Mould et al., 2016). 
ICT9055, ICT9072, ICT9073, and ICT9099 were chosen to investigate their 
effect on cellular detachment as they significantly inhibited the adhesion of 
K562 ±PMA and MCF-7 to fibrinogen. ICT9055 had a greater effect in inducing 
cell detachment than other tested compounds.  
The findings of this current study are consistent with those of Oliveira-Ferrer et 
al., (2008) who demonstrated that cilengitide causes cellular detachment, 
disassembly of the cytoskeleton and induction of a cell death programme in 
glioma and endothelial cells thereby clarifying the activity of integrin inhibitors in 
gliomas. Earlier data suggested that cilengitide also enhances cellular 
detachment from the ECM proteins vitronectin and tenascin present in the brain 
(Taga et al., 2002).  
The expression of αv, αllb and β3 integrin subunits was analysed in detached 
and attached PMA treated K562 cells resulting from treatment with ICT9055 for 
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6 hours to investigate a possible mechanism of action. The observation showed 
no changes in integrin expression in detached cells compared to control 
untreated cells. In contrast, attached cells showed reduced expression of αv, 
αllb and β3 integrin subunit compared to the untreated control and or treated 
detached cells. These data may be explained by the attached cell binding to 
fibrinogen using another integrin which is not targeted by ICT9055, such as 
α5β1.  
After investigating the library of ICT compounds in adhesion and detachment 
assays, it was important to study their impact on other biological functions such 
as cell migration. Cell migration is a fundamental cellular behaviour that not only 
contributes to developing homeostasis but also to cancer metastasis. Because 
of its relevance to numerous aspects of human health, many approaches have 
been developed to measure cell migration (Glenn et al., 2016). Integrins 
regulate complex molecular processes including the interaction between the 
ECM and cell receptors, and the signal integration that modulates cell 
phenotype and migration rate (Friedl and Wolf, 2003; Madrazo et al., 2017). The 
expression of integrin αvβ3 has been revealed to have a significant effect on the 
invasive and migratory potential of various cell types (Christenheit et al., 2016; 
Hynes, 2003).  
The anti-migratory effects of the novel integrin antagonists comprising ICT9055, 
ICT9072 and ICT9073 in comparison with combined controls were evaluated in 
K562 and MCF-7 cells using a transwell migration assay. ICT9055, ICT9072 
and ICT9073 inhibit migration of K562 and MCF-7 cells in a dose-dependent 
manner. ICT9055 and ICT9072 had greatest efficacy but ICT9073 had a lesser 
impact than combined cRGDfV/GR144053. 
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Small molecule RGD-mimetic antagonists have been shown to inhibit migration 
and adhesion of U251 and U373 human glioblastoma cell lines via modulation 
of a FAK-dependent pathway (Russo et al., 2013). FAK is the connection 
between downstream signalling transduction pathways and integrins and 
activates the PI3K/AKT and ERK pathways implicated in cell migration and 
proliferation (Schaller, 2010). Treatment of endothelial and glioma cells with 
cilengitide for a short period causes inhibition of the FAK/Src/AKT-dependent 
pathway but did not impact on ERK activation in human umbilical vein 
endothelial cells (Oliveira-Ferrer et al., 2008). Cells treated with a small 
molecule integrin antagonist 1a-RGD showed a significant decrease of FAK 
phosphorylation but no obvious effect on phosphorylation of AKT and ERK was 
observed, suggesting other receptor systems (possibly including other integrins) 
can activate the AKT and ERK dependent pathways after αvβ3 inhibition 
(Russo et al., 2013).  
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4.7 Conclusion  
  
In conclusion, this thesis validates the use of αvβ3 and αllbβ3 integrin 
expressing models using both naturally and induced expression for functional 
assays which have been utilised to evaluate a group of novel small molecule β3 
integrin antagonists. The findings presented here show the importance of the 
RGD binding integrin expression in cancer cell adhesion, detachment and 
migration. Of note, ICT9055 resulted in significant inhibition of cell adhesion and 
migration and significant induction of cell detachment.  
 
4.8 Future work 
 
The future experiments could be achieved in the short, medium and long term 
are described below.  
  
4.8.1 Short-term work 
 
Apoptosis assessment by a quantitative in vitro assay (Annexin V apoptosis 
detection assay) should be utilised to confirm our qualitative analysis, and a 
wider range of cell lines used to rule out line specific effects when selecting 
compounds for progression. It may also be worthwhile to investigate whether 
pro-apoptotic BH3 family proteins are involved in cell detachment and apoptosis 
caused by ICT compounds. For example, ICT9049 had cytotoxic effects on 
selected cells in this work, therefore, we need to determine whether ICT9094 is 
more effective in pro-apoptotic cells expressing β3 integrins, or whether this 
antagonist has cytotoxic effects, using tumour and healthy cells. 
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Further research is necessary to determine whether the adherent cells are a 
subpopulation with naturally low expression of the β3 integrins, or whether 
treatment with the antagonist decreases expression of its target. This should be 
followed by investigating the effect of ICT9055 on the subpopulation by 
characterising their integrin expression.    
In further work, it may be worthwhile to look the impacts of integrin antagonists 
on cell signalling pathways, such as the FAK and ERK pathways, to explore the 
mechanism that facilitates cell migration, as well as exploring combinations of 
integrin antagonists with other pathway inhibitors. For example, Inhibition of αv 
integrins and Src has been shown to be more effective than integrin antagonism 
alone (Jia et al., 2013). 
In this work the effect of novel compounds was investigated by a 2D migration 
assay (a transwell migration assay). Although it has advantages, as described 
earlier in Chapter 4, investigating the effect of ICT compounds using a 3D 
migration assay would give further understanding in a situation more closely 
mimicking the tumour in vivo. 
Another aspect that should be considered is evaluating the effect of ICT 
compounds on angiogenesis, utilising an in vitro matrigel-based angiogenic 
assay. 
 
4.8.2 Medium term work 
 
Investigating the effect of selected antagonists on xenograft models in mice 
would be a next step. Developing a model for in vivo analysis of anti-metastatic 
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effects would be the next stage for the evaluation of integrin antagonists. This 
would additionally allow assessment of possible side effects of treatment, and 
also synergistic effects when in combination with other treatments. Further 
steps would include assessment of pharmacokinetics, off-target effects, safety 
and toxicology. 
 
4.8.3 Long term work 
 
Ultimately, the final goal would be assessment of a candidate inhibitor in a 
phase I clinical trial in cancer patients. There are many factors would need to be 
taken into consideration that could be the effect on the sensitivity of integrin 
antagonist. For example, Glut3-addicted glioblastoma tumours are extremely 
sensitive to drugs targeting αvβ3 (Cosset et al., 2017). 
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Appendix I: Cytotoxicity effect of dimethyl sulfoxide (DMSO).  
 
The MTT assay was used to assess the cytotoxicity of DMSO against K562 
(±PMA) and MCF-7 cells over a range of different concentrations (0.01, 0.1, 1, 
10 & 100 μM) for 96 hours.  
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Appendix II: Analysis of Scratch assay of MCF-7 
 
Migration of MCF-7 cell lines was assessed by the scratch assay. 1x105 
cells/ml were seeded into 24-well plates and incubated at 37 °C for 24 hours. 
After 24, 48 and 72 hours, the appearance of the monolayer was examined 
visually. The scratch was not healed after 72 hours due to slow wound closure, 
meaning MCF-7 could not be used in this migration assay.  
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Appendix III: Histogram analysis of αv, αIIb, α5, β3 and β5 integrin subunit expression (coloured 
histograms) compared to negative control cells (purple histograms) in K562, DU145, PC-3, LNCap and 
MCF-7 cells using FACS. 
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Appendix IV: Histogram analysis of αIIb and β3 integrin subunit expression (green histograms) compared to negative 
control cells (purple histograms) in M14, MeWo, UACC-62 and HT-29 cells using FACS. 
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Appendix V: Histograms analysis of effect of PMA concentration on expression of αv in K562 cells 
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Appendix VI: Histograms analysis of effect of PMA concentration on expression of αllb in K562 cells 
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Appendix VII:   Histograms of αv and αllb integrin subunit expression in 
K562 induced by three concentrations (0.5 µM 1 µM, 2 µM of PMA) for 24h 
(A), 48 h (B), and 72h (C).  
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Appendix VIII: Histograms of αv and αllb integrin subunit expression. in 
DU145 induced by three concentrations (0.5 µM 1 µM, 2 µM of PMA) for 
24h (A), 48 h (B), and 72h (C).   
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Appendix IX: Histograms of αv, αllb, α5, β3 and β5 subunits expression in PMA (0.1µM) stimulated K562 cells.   
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Appendix X: Histograms of αv, αllb, α5, β3 and β5 subunits expression in PMA (2 µM) stimulated K562 cells   
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Appendix XI: Histograms of αv, αllb, α5, β3 and β5 subunits expression in PMA (0.5µM) stimulated Du145 cells 
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Appendix XII; Histograms analysis of αllb expression in K562 treated 
with 0.04 µM PMA for different times 
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Appendix XIII: Table 14: Summary of the effect of ICT compounds on the functional assays. NT: Not Tested  
 
 
 
 
 
 
 
 
 
 
 
 
 
Adhesion Detachment Migration Adhesion Detachment Migration Adhesion Detachment Migration Adhesion Detachment Migration Adhesion Detachment Migration Adhesion Detachment Migration
ICT9001
0.1μM
1 μM
10 μM
100 μM
9 + 0.3  
28 + 6
34 + 6.9
44 + 3.4 
NT NT
P<0.05
P<0.01
P<0.01
P<0.01
NT NT
16 + 4.8
30 + 3.0
38 + 4.7
53 + 6.4  
NT NT
P<0.05
P<0.01
P<0.01
P<0.01
NT NT
15 + 4.9
20 + 2.9  
32 + 5.0
NT NT
P<0.05
P<0.01
P<0.01
NT NT
ICT9025
0.1 μM 
1 μM 
10 μM
16% + 7
22 + 6.4
29 + 3.3 
NT NT
P>0.05
P>0.05
P<0.05
NT NT
21 + 10
27 + 8.2
36 + 5.9
NT NT
P=0.05
P<0.05
P<0.01
NT NT
15 +  5.3
20 + 2.6
25 + 5.4
NT NT
P<0.05
P<0.01
P<0.05
NT NT
ICT9026
0.1 μM
1 μM
10 μM
100 μM
15 + 8.4
20 + 8.9
26 + 8.0
NT NT
P>0.05
P>0.05
P<0.05
NT NT
19 + 2.0
28 + 6.2
40 + 12.3
NT NT
P<0.1
P<0.05
P<0.05
NT NT
 
18 + 5.6
26 + 3.0  
31 + 1.6.8
33  + 6.5 
NT NT
P<0.05
P<0.01
P<0.05
P<0.05
NT NT
ICT9055
0.01 μM
0.1 μM
1 μM
10 μM 
100 μM
25 + 4.4 
31 + 1.6 
51 + 1.0  
57 + 2.9
 
42% + 3.2
53% + 3.0  
67% + 2.8
 
26 + 4.0
41 + 4.5  
53 + 1.3
69 + 6.5 
P<0.05
P<0.001
P<0.001
P<0.001
P<0.01
P<0.01
P<0.01
P<0.01
P<0.01
P<0.001
P<0.01
33 + 3.7
51 + 1.2
65 +  2.2 
77 + 4.2
54 + 3.5
70 + 2.5
81 +1.5
NT
P<0.01
P<0.001
P<0.001
P<0.001
P<0.01
P<0.01
P<0.01
NT
31 + 8.0 
45 + 4.4   
58 + 5.0   
68 + 6.3
 
42 + 2.0   
48 + 4.0   
68 + 2.4
36 + 10.5   
54 + 5.0   
70 + 5.8
P<0.05
P<0.01
P<0.01
P<0.01
P<0.05
P<0.05
P<0.05
P<0.05
P<0.01
P<0.01
ICT9066
0.1 μM
1 μM
10 μM
100 μM
18 + 6.4
23 + 9.6
30 + 9.7 
33 + 5.9
NT NT
P<0.05
P=0.05
P<0.05
P=0.01
NT NT
21 + 4.6
29 + 3.9
34 + 2.2
39 + 5.7  
NT NT
P<0.05
P<0.01
P<0.01
P<0.01
NT NT
16 + 7.6
24 + 3.0 
38 + 9.9  
NT NT
P>0.05
P<0.01
P<0.05
NT NT
ICT9085
0.1 μM
1 μM
10 μM
100 μM
14 + 3.0
19 + 4.5
25 + 2.8
31 + 2.3 
NT NT
P>0.05
P<0.05
P<0.01
P<0.001
NT NT
23 + 11.4
28 + 11.9
38 + 10
46 +13  
NT NT
P>0.05
P= 0.05
P<0.05
P<0.05
NT NT
18 + 4.8
21 + 6.4
37 + 8.3 
NT NT
P>0.05
P>0.05
P>0.05
NT NT
ICT9072
0.01 μM
0.1 μM
1 μM
10 μM 
100 μM
16 + 3.7
27 + 2.2
38  + 4.4
55 + 4.9
34 +  1.6
43 + 3.7
51 + 1.4
20 + 4.8
34 + 2.8
45  + 3
57 + 1.5
P<0.05
P<0.01
P<0.01
P<0.01
P<0.05
P<0.05
P<0.05
P<0.05
P<0.01
P<0.01
P<0.001
28 + 2.7
45 + 4 
52 + 2.7 
63 +3.9
41 + 2.8
64 + 3.5
74 + 4.5
NT
P<0.01
P<0.01
P<0.001
P<0.01
P<0.05
P<0.05
P>0.05
NT
27 + 6.0
40 + 2.0  
56 + 4.0
  
17 + 1.8
24 + 2.4  
44 + 2.3
25 + 8.8   
47 + 8.6   
63 + 5.0
P<0.05
P<0.001
P<0.01
P<0.001
P<0.001
P<0.05
P<0.05
P<0.01
P<0.01
ICT9073
0.01 μM
0.1 μM
1 μM
10 μM
100 μM
10 + 5
16 + 3.7
34 + 3.5
50+ 1.3
27 + 1.7
34 + 4.8
46 + 10
18 + 3.6
32 + 2.5
43 + 4.7
51 + 0.6
P>0.05
P<0.05
P<0.01
P<0.001
P<0.05
P<0.05
P>0.05
P>0.05
P<0.01
P<0.01
P<0.0001
20 + 1.6
35 + 5 
50 + 1.8 
59 + 1.9
33 + 2.4
44 + 5
59 + 3
NT
P<0.01
P<0.01
P<0.001
P<0.001
P<0.05
P<0.05
P<0.05
NT
22 +3.3
33 + 3.6 
50 + 4.5 
28 + 2.5
48 + 2.0  
61 + 8.3
18 + 8.5
32 + 5.0  
53 + 2.0 
P<0.1
P<0.05
P<0.05
P<0.001
P<0.001
P<0.001
P>0.05
P<0.01
P<0.001
ICT9094
0.1 μM
1 μM
10 μM
9 + 6.8
21 + 1.9
31 + 5.2
NT NT
P>0.05
P<0.01
P<0.01
NT NT
18 + 4.8
30 + 3.9
42 + 6.9 
NT NT
P<0.05
P<0.01
P<0.01
NT NT 26 + 5.5
 33 + 2.9 
NT NT P<0.05
P<0.05
NT NT
ICT9099
0.1 μM
1 μM
10 μM
18 + 1.6
34  +  2.5
51  + 4
27 + 2.7
35 + 4
51 + 3.5 NT
P<0.01
P<0.01
P<0.01
P<0.001
P<0.01
P<0.01
NT
18 + 1.6 
34 + 2.5
51 + 4 
37 +3.8
48 + 1.5
63 + 4
NT
P>0.05
P<0.01
P<0.01
P>0.01
P<0.001
P<0.01
NT
32  + 2.0
42 + 4.6
58 + 5.8  
19 + 4.3
32 + 5.2
42 + 3.4  
NT
P<0.05
P<0.05
P<0.05
P<0.05
P<0.05
P<0.05
NT
ICT9101
0.1 μM
1 μM
10 μM
100 μM
11 + 1.8
17 + 5.7
28 + 7
NT NT
P<0.01
P<0.05
P<0.05
NT
NT
17 + 3.9
34 + 7.9
42 + 10.5
NT NT
P<0.05
P<0.05
P<0.05
NT NT
8 + 4.5
20 + 2.8 
26 + 6.6  
30 + 9.7 
NT NT
P>0.05
P>0.05
P>0.05
P>0.05
NT NT
ICT9103A
0.1 μM
1 μM
10 μM
14 + 6.9
24 + 7.5
34 + 5.9 NT NT
P>0.05
P<0.05
P<0.01 NT
NT
23 + 6.9
38 + 3
50 + 5 
NT NT
P<0.05
P<0.01
P<0.01
NT NT
13 + 3.7
26 + 2.8 
37 + 3.3 
NT NT
P<0.05
P<0.05
P<0.05
NT NT
MCF-7
Percentage of the effect Level of significance
K562 -PMA K562 +PMA
Percentage of the effect Level of significance Percentage of the effect Level of significanceThe 
compound
Concentration
